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Abstract

INVESTIGATIONS OF NOVEL MECHANISMS OF ACTION FOR ANTI-BACTERIAL
AND ANTI-CANCER AGENT DEVELOPMENT
By Jenson Verghese, Ph.D.

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2014.
Major Director: Keith C. Ellis
Assistant Professor, Department of Medicinal Chemistry

The development of drugs and therapeutic agents for combating infections and human
malignancies continues to be a forefront area in both academic and industrial research.
This is driven by the rapid emergence of multi-drug resistant bacterial strains and
accumulating mutations in cancer targets that is quickly rendering our current arsenal of
drugs ineffective for these therapies. Unless new drugs with novel mechanisms of action

are identified and developed at a faster pace, we face a losing battle in managing these
diseases.
The first part of this work concerns with the natural product Simocyclinone D8 (SD8).
Simocyclinone D8 is an angucyclinone antibiotic that inhibits DNA gyrase with a novel
mechanism of action that has been termed competitive inhibition. Simocyclinone D8 was
found to inhibit the growth of both Gram-(+ve) and Gram-(–ve) organisms and also inhibit
a fluoroquinolone resistant mutant of DNA gyrase. Inspired by the structure and novel
mechanism of action that SD8 displays, we synthesized analogues based on the cocrystal structure of SD8 with DNA gyrase. These compounds were found to inhibit DNA
gyrase, albeit by a different mechanism of action than that of SD8. We also conducted
studies towards the total chemical synthesis of SD8 and made three out of the four
fragments in SD8 in decent yields.
The second part of this work is focused on the development of a substrate-competitive
covalent inhibitor for protein kinase B (AKT). AKT is a valid target for cancer research
with two compounds currently in late stage clinical trials. Developing substratecompetitive inhibitors for kinases is a novel approach in targeting them, with very few
examples in the literature. This mechanism has been postulated to overcome common
resistance mutations that cancer targets harbor. A major drawback in this approach is the
low binding affinity for peptide substrates by kinases. We circumvented this problem of
affinity by utilizing a covalent mode of binding and synthesized a potent non-peptide
active-site directed irreversible compound that inhibits AKT. Further studies on this
compound are underway and are expected to yield a compound that can be used as a
therapeutic agent or as a probe for AKT.
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CHAPTER 1: FLAVONE BASED ANALOGUES INSPIRED BY SIMOCYCLINONE D8
(SD8)
1.1: Critical need for New Anti-Bacterial agents
The discovery of anti-bacterial agents has been one of the most significant scientific
achievements of the past century. Their influence has not only revolutionized the
treatment of infectious diseases, but also many advanced surgical procedures would not
have been possible without them. However, bacterial resistance has evolved to every
anti-bacterial that has been commercially introduced and most pharmaceutical
companies have already exited this area of drug discovery1.
The introduction and discovery of anti-bacterials is the most prototypical incident in the
archives of medicinal chemistry research. It could be argued that the discovery of the first
synthetic anti-bacterial agent, Salvarsan (Arsphenamine), by Paul Ehrlich in 1909 was
the first documented instance of lead optimization by systematic chemical modifications
for biological activity. In fact, the term “magic bullet” was first introduced in drug discovery.
Salvarsan was discovered form the lead Atoxyl (Arsanilic acid) and was used for the
treatment of syphilis and was the world’s first blockbuster drug until the discovery of
penicillin and sulfonamides. These compounds heralded a new era in medicine, where
the concept of the “magic bullet” came closer to reality2.

1

Currently there are many anti-bacterial agents that have been introduced to the market.
Broadly they can be classified into synthetic and natural scaffolds. The synthetic scaffolds
consist of the sulfonamides, diaminopyridines, quinolones and oxazaolidinones and the
natural scaffolds consist of β-lactams, tetracyclines, macrolides, aminoglycosides and
glyco and lipo peptides. However, these compounds target a very limited number of
clinically relevant targets: DNA gyrase and topoisomerase IV, ribosomal function
inhibition and inhibition of cell wall biosynthesis. Most compounds currently in the pipeline
of pharmaceutical companies are derivatives of the above mentioned chemical scaffolds,
but there already exists microbes with underlying resistance mechanisms in clinical
settings that have built resistance to all these chemical classes. Derivatizing these already
existing chemical scaffolds might temporarily improve efficacy of the drug, but the binding
interaction with the target remains unchanged; hence, development of resistance to the
scaffold is just a matter of time3.
Drug resistance is mostly seen in gram-positive and gram-negative organisms, both in
hospital and community based settings. The majority of these organisms that cause
infections and are effectively resistant to most of the current drugs have been collectively
termed as the “ESKAPE” pathogens (Enterococcus faecium, Staphylococcus aureus,
Klebsiella

pneumonia,

Acinetobacter baumanii,

Pseudomonas aeruginosa

and

Enterobacter species). In addition to these, there are reports of increasing infection and
death rates in hospitals due to methicillin-resistant S. aureus (MRSA), vancomycinresistant E. faecium (VRE) and fluoroquinolone-resistant P. aeruginosa. Due to the
increasing immunocompromised patient population consisting of geriatrics, patients
undergoing surgery, chemotherapy and neonatal units, infections due to these antibiotic

2

resistant pathogens are rising rapidly and are of significant concern in the medical
community4.
There are various factors that lead to the slow development of anti-bacterials. The overall
time line, success rate and investment required to launch a novel broad-spectrum
antibacterial is staggering as compared to other therapeutic areas. Scientifically, it is also
an exhaustive challenge considering that bacterial cells are quite different from human
cells, so the general rules used in drug discovery for e.g. Lipinsky’s “rule of 5” does not
translate into antibiotics.
The advent of the genomic era in the 1990’s followed by the complete sequencing of the
Haemophilus influenza genome changed the focus of drug discovery from chemical
modification of already existing molecules to discovery of newer targets and molecules in
the pharmaceutical industry. High throughput screens (HTS) were run with isolated
enzyme or protein targets and whole cells, but these did not translate well into lead
molecules. Most molecules that progressed into the lead optimization stage did not make
it through Phase 1 testing. The difficulties were attributed to less diversity in compound
libraries screened, multiple pathogens that have to be inhibited by a broad-spectrum
compound, both Gram-positive and Gram-negative species with different molecular
targets, membrane permeabilities, metabolic pathways and an acceptable and
convenient pharmacokinetic and dynamic profile. After the failure of this earlier genomic
based approach for anti-bacterial drug discovery, the current approach in industry has
been shifting to a renewed focus on novel chemical scaffolds, concentrating on already
validated targets, exploring new binding modes and including more diversity in chemical
screens5.
3

There is a critical and unmet need for the development of newer anti-bacterials. This is
driven by the emergence of bacterial strains that have the capacity to mutate over a time
period of hours compared to the years required to develop antibiotics, rendering our
current arsenal of antibiotics ineffective. The discovery of anti-bacterials was one of the
biggest discoveries in medicine, but unless newer anti-bacterials are developed at a faster
pace, we face a losing battle.
1.2: DNA-Gyrase as a drug target.
DNA Topoisomerases are enzymes that change the topology of DNA in both prokaryotic
and eukaryotic cells. They catalyze changes in the topology of DNA at various steps in
the replication cycle. The helical intertwined nature of DNA presents a problem during
replication and transcription, where DNA gets overwound ahead of the replication fork.
To overcome this tension, topoisomerases either bind to one strand or both strands of
DNA and nick the phosphate backbone. This process removes supercoils of DNA and
after the process, the DNA strand is resealed, so these enzymes remove catenanes and
knots in DNA. Topoisomerases are classified into type I and type II based on whether
they catalyze the transient breakage of one strand or both strands of DNA 6.
DNA gyrase is a type II topoisomerase that can also introduce negative supercoils in
DNA. It is the only known topoisomerase enzyme that can generate negative supercoils
as well as relax positive and negative DNA supercoils; however, generating negative
supercoils appears to be the primary function of gyrase in the cell. The enzyme uses the
hydrolysis of ATP to carry out this process. Prokaryotic DNA gyrase consists of two
subunits A and B. In the active enzyme, these associate to form an A2B2 complex. The
E. coli gyrase has a molecular weight of 97 and 90 KDa for its A and B subunits,
4

respectively. The A subunit interacts with DNA and has the active site tyrosine that
catalyzes the DNA cleavage. The B subunit consists of the ATP binding site and catalyzes
the ATPase activity.
DNA gyrase is an important anti-bacterial drug target due to its important function in the
cell. The mechanism by which the enzyme supercoils DNA is complex and multistep and
this offers an avenue for its inhibition at various steps in the process. A model called the
“two – gate mechanism” has been proposed for how gyrase supercoils DNA and is
supported by structural and biochemical data7, 8. DNA gyrase consists of three interfaces
that interact with DNA, and they can either exist in an open or closed conformations
(Figure 1). The “N–gate” is the N–terminal domain of GyrB, “DNA gate” is the GyrA–
GyrB–DNA interface that cleaves DNA and the “C–gate” is the C–terminal area of coils
where DNA exits the enzyme. The supercoiling reaction progresses in the following
fashion: the first step (step 1, Figure 1) involves DNA (named as the G-segment)
association with the unliganded enzyme at the GyrA and GyrB interface that is between
the TOPRIM domain of GyrB and the N–terminal domain of GyrA dimer. This leads to
conformational changes and the formation of the DNA gate (step 2, Figure 1), following
which about 130 base pairs of DNA wrap around the enzyme in a right handed supercoil.
Wrapping of DNA around the C–terminal domain of gyrase facilitates the T–segment of
DNA (the segment that will be passed through the cleaved DNA) to reach the N gate and
is placed over the G segment (the segment that forms the DNA gate, step 3, Figure 1).
ATP binding dimerizes GyrB allowing the trapping of the T segment and cleaving the G
segment at the DNA gate (step 4, Figure 1). The cleavage site in double stranded DNA
occurs 4 base pairs apart and results in the G segment covalently attaching itself to the

5

GyrA subunit of DNA gyrase. The T segment is passed through the DNA gate and the
cleaved G segment and finally through the exit gate. The translocation of the T segment
is allowed by the rotation of GyrB, due to the hydrolysis of one molecule of ATP. The next
step is the religation of the G segment, which introduces two negative supercoils in DNA
(step 5, Figure 1). The hydrolysis of a second molecule of ATP opens the N-gate and the
enzyme is ready for the next supercoiling cycle and resets to step 2. One gyrase cycle
introduces two negative supercoils into DNA at the expense of two ATP molecules. The
supercoiling reaction is a complex cycle and the exact order and mechanism of the steps
are not unambiguously known, however due to the multiple number of steps, there exists
enough opportunity for disruption of this cycle with inhibitors.

6

Figure 1: Model for the catalytic reaction of topoisomerase II. ATPase domain is shown
in yellow, domain in red forms the DNA gate and the domain in blue has the catalytic
tyrosines9.
There are multiple points of intervention in the supercoiling cycle that inhibitors act on i.e.
DNA binding, DNA cleavage, strand passage and ATP hydrolysis. There are two main
mechanisms by which inhibitors act on DNA gyrase. The first one involves the inhibition
of the enzymatic activity of gyrase and the second is the stabilization of the covalent
enzyme DNA adduct or otherwise known as gyrase poisoning.
1.3: Quinolones
The origin of Quinolones can be traced to the discovery of nalidixic acid, a by–product
formed during the preparation of chloroquine (an anti–malarial). Systematic chemical
modifications lead to the discovery of the fluoroquinolones: norfloxacin, ciprofloxacin,
7

levofloxacin and gemifloxacin (Figure 2). These compounds have been significantly used
as broad spectrum antibiotics in the treatment of both Gram positive and Gram negative
infections10.

Figure 2: Structure of Quinolones
Based on the type of organism and the quinolone, topo IV has also been indicated as a
target in addition to gyrase. Bacteria harbor resistance genes to fluoroquinolones and the
site of point mutations that give quinolone resistance is called the quinolone resistance–
determining regions or QRDR. Fluoroquinolone resistance has been reported in
pneumonia, influenza, MDR/XDR tuberculosis and respiratory tract diseases.
Quinolones stabilize the covalent gyrase DNA complex, where DNA gyrase is covalently
bound to the 5’ ends of the cleaved DNA. Crystal structures of the fusion protein involving
C–terminal of GyrB with the N–terminal of GyrA, show that the DNA gate is in the closed
conformation, suggesting that opening of this gate is not required for quinolone binding.
The aromatic rings of the quinolone are found to be stacked against the DNA bases at

8

the site of cleavage. This interaction can cause a misalignment of DNA on either side of
where cleavage happens and difficulty in joining the broken DNA11.
Quinolones in vivo display both bacteriostatic and bactericidal activities. The quinolone–
gyrase (or quinolone–topo IV) complex formed can stall the replication fork and lead to a
bacteriostatic effect. The bactericidal effect mechanistically happens through two distinct
pathways; first one dependent on protein synthesis and the second on in its absence,
which depends on the particular type of quinolone. The ultimate consequence of a
quinolone–stabilized gyrase (or topo IV) complex with DNA is cell death that occurs
through chromosome fragmentation, induction of SOS response and eventually cell
fragmentation that could involve reactive oxygen species.
It has been hypothesized that the mode of action that the quinolones employ for gyrase
(or topo IV) inhibition is the most effective. Relatively only a low occupancy of inhibitor
bound to the target is required to cause enough chromosome fragmentation for cell death
to occur.
1.4 Aminocoumarins
The aminocoumarins are characterized by their 3-amino–4,7-dihydroxycoumarin ring.
Further substitutions on the ring or groups attached to the amine or phenol make up the
diversity in this class of compounds. The prototypical aminocoumarins: novobiocin and
clorobiocin (Figure 3) were extracted from Streptomyces species. These compounds
were used once to treat methicillin resistant S. aureus (MRSA), but they have been
withdrawn from clinical use because of their toxicity and poor pharmacokinetic
parameters12.
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Figure 3: Structure of Novobiocin and Clorobiocin
Aminocoumarins bind tightly to the B subunit of DNA gyrase and they work
mechanistically by inhibiting the catalytic activity of DNA gyrase. They compete with ATP
for binding to the GyrB domain; hence, the ATPase reaction of gyrase is inhibited. Their
binding site overlaps the ATP binding site in GyrB that is a 24–KDa amino–terminal
subdomain in GyrB and is named as the aminocoumarin binding site. This binding
prevents ATP binding to the site and thus inhibits the supercoiling reaction from
proceeding13.
Naturally occurring resistance to the aminocoumarins has been observed in DNA gyrase
and these involve mutations in the aminocoumarin binding site (Arg136 and Gly164, E.
coli numbering). However, due to the proximity of this site to the ATP binding site, these
mutants show a loss in enzymatic activity due to impaired ATPase activity.
In vitro aminocoumarins are potent inhibitors of DNA gyrase, but they display poor activity
against Gram negative bacteria. Additionally, their mammalian toxicity and poor
bioavailability have precluded their use clinically and they have been most commonly
used to study the ATP–binding site of DNA gyrase.
1.5: New Bacterial Topoisomerase Inhibitors (NBTIs)
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NBTIs are a new class of synthetic anti-bacterials, which have a non-quinolone scaffold
but bind to topoisomerase II class of enzymes in a similar fashion as that of the
quinolones. They have a mechanism of action distinct from that of the quinolones and
currently are being pursued by the pharmaceutical industry because they are not affected
by mutations that affect fluoroquinolone binding14.
One of the most studied compounds is the quinolone based drug candidate NXL101,
licensed by Novexel (Figure 4). NXL101 displayed a preference for inhibition of topo IV
over DNA gyrase in E. coli and displayed the opposite trend when it came to S. aureus.
This preference in targets was the opposite to that displayed by fluoroquinolones. NXL101
displays the ability to inhibit mutant forms of gyrase that are resistant to fluoroquinolones
and the mutations that render the drug ineffective were found to be outside the QRDR
domain region in DNA gyrase. One of the mutations that confers fluoroquinolone
resistance is Ser84 in GyrA (S. aureus numbering), whereas for NXL101 was Asp83 (S.
aureus numbering), which highlight the differences in binding of NXL101 as compared to
fluoroquinolones. Nonetheless, the lack of co–crystal structures of DNA gyrase with
NBTIs has made determination of the precise binding site impossible. However, in 2009,
the development of NXL101 was discontinued due to QT prolongation in Phase I
studies15.
In 2010, GSK reported the crystal structure of the compound GSK299423 (Figure 4) with
DNA and S. aureus gyrase. They isolated the precleaved complex of mutant S. aureus
gyrase (Tyr123 to Phe) and observed that the cyano–quinoline region of the compound
intercalates DNA, midway between the two gyrase active sites and arrests the complex
before the double strand is cleaved. The compound does not directly inhibit the DNA
11

cleavage and religation process like quinolones do, but it stabilizes the pre-cleavage
complex and prevents strand separation. This binding site is distinct from the
fluoroquinolone binding site and the compound was active against MRSA and
fluoroquinolone resistant strains. But no further studies on this compound have been
reported16.

Figure 4: Structures of NXL101 and GSK299423
1.6 Simocyclinone D8 (SD8)
Simocyclinone D8 is an antibiotic that belongs to the family of angucyclinones. It was first
reported in 2000 by Fiedler et al. after they isolated it from Streptomyces antibioticus Tu
604017. Screening of metabolites from the novel Streptomyces strain that was isolated
from a soil sample in Argentina, lead to the discovery of SD8. Simocyclinone D8 was
found to have antibiotic activity against Gram positive bacteria (S. aureus, Bacillus brevis,
Bacillus subtilis and Streptomyces viridochromogenes) and cytostatic effect on tumor
cells lines, but no significant activity against Gram negative organisms (E. coli). The
authors also optimized the fermentation conditions and reported that various partially
substituted analogues of SD8 can be obtained by varying the carbohydrate source in the
medium18. The SD8 molecule consists of three subunits: an aminocoumarin similar to
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that present in novobiocin and clorobiocin, a tetraene linker that is present in the
veterinary antibiotic fumagillin and an angucyclinone, which is comprised of an olivose
sugar bound by a C–glycosidic bond to a highly substituted benz[a]anthracene system
(Figure 5)19. This angucyclinone system is very similar to that present in the natural
product aquayamycin. The biosynthetic gene cluster of SD8 was cloned by Heide et al.
in 200220. The authors reported that the gene cluster consists of several genes with high
similarity to that of the aminocoumarin class of antiobitics, however in contrast with the
aminocoumarins, the SD8 gene cluster doesn’t have an obvious resistance gene,
hindering the identification of a possible target. They also proposed a biosynthetic
pathway of how SD8 is synthesized in the microorganism 21.

Figure 5: Structure of SD8
The first report that garnered attention for SD8 in the scientific community was published
by Maxwell et al. in 200519. The authors test the compound for inhibition of DNA gyrase
because of its chemical similarity to the aminocoumarin antibiotics. They found that SD8
inhibits gyrase supercoiling reaction with an IC50 of 0.1 µM as compared to novobiocin
with an IC50 of 0.25 µM and 0.7 µM for ciprofloxacin. SD8 also inhibited the DNA relaxation
activity of gyrase with an IC50 of 0.5 to 1.0 µM. To determine the possible mode of binding,
they tested whether the observed inhibition was dependent on ATP and report that SD8
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does not compete with ATP unlike novobiocin. Assaying SD8 with a ciprofloxacin resistant
DNA gyrase (Ser83 to Trp) for supercoiling activity increased the IC50 10-fold, whereas
for ciprofloxacin increased 30-fold. This established that SD8 does not share the same
binding site on DNA gyrase as novobiocin and there might be an overlap of binding
regions with quinolones. SD8 also did not form linear DNA from supercoiled DNA in the
presence of gyrase and it also abolished DNA–DNA gyrase cleavage complex formation
in the presence of ciprofloxacin, suggesting that it had a distinct mechanism of action
from the quinolones by inhibiting the enzyme prior to DNA cleavage.
Binding studies by SPR indicated that SD8 prevented DNA from binding to gyrase, while
isothermal calorimetric studies showed that SD8 bound to the GyrA subunit in a ratio of
1:1. This mechanism of inhibition has been termed as catalytic and SD8 is the first and
only molecule reported to date as a catalytic inhibitor of DNA gyrase.
In 2009 the first co-crystal structure of SD8 was reported with the N-terminal domain of
GyrA (GyrA59) at 2.6 Å resolution (Figure 6)22. This crystal structure also assigned the
absolute stereochemistry of SD8. The crystal structure reveals a homotetramer of two
A59 dimers cross-linked by four molecules of SD8. Each GyrA subunit has two distinct
pockets for the aminocoumarin and the polyketide moieties. The tetraene subunit, about
10 Å long, displays no interaction with the enzyme and holds the two binding moiety’s
apart. The stoichiometry remain consistent (1:1), as reported earlier by the ITC studies.

14

Figure 6: GyrA59 dimer with two molecules of SD8. The catalytic Tyr122 on both
subunits are labeled (PDB ID: 2Y3P).
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Figure 7: Residues interacting with SD8 in GyrA59 structure (PDB ID: 2Y3P).
Also, the SD8 molecule can be modeled in a bent conformation that bridges between the
aminocoumarin and polyketide binding pockets within the same subunit. This could place
the tetraene linker possibly interacting with the α-helix 4 of GyrA. Nanoelectrospray
ionization mass spectrometry experiments reveal that the most probable binding
conformation is a single SD8 molecule bound to the aminocoumarin and polyketide
pockets within the same subunit. SD8 at high concentration causes tetramerization of
GyrA by bridging the homodimers, but at pharmaceutically relevant concentrations, the
dimeric form of GyrA exist bound to one or two SD8 molecules.
Analysis of the crystal structure reveals some interesting observations for both the
pockets. The aminocoumarin and polyketide both bind in separate pockets and the
tetraene linker and olivose sugar are not seen interacting with any residues. In the
aminocoumarin pocket there is a halogen bond between the 8-position chlorine on the
16

coumarin ring with the carbonyl oxygen of Gly170. In the polyketide pocket, Arg121 and
Tyr122 in the active site interact via water molecules to a Mg2+ that is bound to the diols
on the polyketide fragment. On a similar basis His80 makes a water-mediated interaction
with the second Mg2+ ion that coordinates to the angular diols on the polyketide ring. His80
also π stacks with the phenol on the angucyclinone. The tetra-substituted epoxide on the
angucyclinone ring interacts with the guanidine group on the side chain of Arg32 (Figure
7).
Mutations in the aminocoumarin and polyketide pockets result in significant abrogation of
supercoiling activity. Also, QRDR mutations in the α-helix 4 region of GyrA result in
resistance to SD8, despite none of these amino acids making direct contact with SD8. It
might be possible that mutating the residues in the α-helix 4 might impede the
conformation of the linker and affect bridging of the aminocoumarin and polyketide
binding sites.
Further mass spectrometry studies with GyrA and SD8 reveal that the binding is a function
of both aminocoumarin and polyketide groups on SD8, and comparison with free
aminocoumarin and polyketide groups reveal that the polyketide fragment binds with five
times more affinity than the aminocoumarin fragment, but these individual fragment
interactions are much weaker than bifunctional SD8 23. Furthermore, binding of SD8
induces a strong allosteric cooperativity between the two binding sites, where occupancy
in the first pocket strongly promotes binding in the second pocket. A >20-fold increase in
affinity of binding the aminocoumarin subunit is seen after binding of the first polyketide
unit. Edwards et al. report that the only binding mode supported by this data is that where
both binding sites on a single monomer are bound by a single molecule of SD8. Based
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on the binding constants of aminocoumarin and polyketide fragments, they hypothesize
that: polyketide fragment binds first, increasing the local concentration of the
aminocoumarin fragment followed by its binding. This bent over conformation of SD8
induces a strain in the tetraene linker that results in small structural changes in GyrA,
which then results in the positive cooperativity upon binding of SD8.
In 2010, protein melting studies were reported to characterize the interaction of SD8 with
DNA gyrase24. The circular dichorism profile of DNA gyrase indicates that both the A2B2
heterodimer and individual subunits (GyrA and GyrB) were established in presence of
SD8 at various temperatures. For the GyrA subunit, as expected, a compound mediated
shift of Tm was recorded and by plotting Tm vs SD8 concentrations, a cooperative
conformational change was noticed. Unexpectedly, however binding of SD8 with the
GyrB47 domain induced a change in Tm. The GyrB47 domain is also involved in DNA
binding and the GyrA site displays much higher affinity than that of the GyrB domain. SD8
also changed the proteolytic pattern of GyrB digestion by trypsin, which also indicates a
binding site on GyrB.
In 2014, a new crystal structure of SD8 was published with GyrA55 at 2.05 Å resolution
(Figure 8)25. This 55 kDa fragment lacks the crucial residues that stabilize the tetrameric
state of GyrA, hence obtaining a better picture of SD8 binding in physiological
concentrations. The conformation of bound SD8 in this structure is different from that in
the earlier reported crystal structure. The polyketide moiety binds at the interface of the
two GyrA monomers, displaying interactions with 5 residues, out of which Asp87 and
Met120 are from the adjacent monomer. The aminocoumarin pocket is the same as
earlier, but the orientation of the AC moiety in the pocket is different. The tetraene in this
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structure is distant from the α-helix and does not interact with it, although it is seen to
have hydrophobic interactions with Val44 and His78. No Mg2+ ions were found in the
polyketide pocket (Figure 9).

Figure 8: GyrA55 dimer with SD8 (displayed as spheres) bound in “bent-over”
conformation (PDB ID: 4CKL).
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The report also reevaluates the mutation data that was published in the original GyrA59SD8 paper and the crystal structure explains all the observed data for GyrA mutants. Also
to validate the intra-dimer binding mode of SD8 in the GyrA55-SD8 complex, three
mutants were made: Met120 to Pro (PK pocket), Lys42 to Ala (AC pocket) and Ala84 to
Arg (α-helix 4). The first two resulted in 60- and 50-fold increases in resistance to SD8,
but the Ala84 to Arg mutant showed very little increase in resistance to SD8. The authors
explain this by asserting that the Arg84 side chain adopting a conformation that does not
impinge on the SD8 binding site. Based on this recent crystal structure, they also
hypothesize a mechanism by which SD8 blocks DNA binding to gyrase: SD8 positions
itself on the dimer interface and “staples” the dimer closed and preventing the DNA gate
from opening for strand passage and also interfering with the conformational changes
required in the DNA gate for DNA binding. The interaction of Asp87 and Gly81 with SD8
will prevent movement of α-helix 4, interaction of Met120 and SD8 will prevent the loop
having the catalytic tyrosine (Tyr122) from orienting itself with DNA, and binding of Arg91
on α-helix 4 with the AC will prevent it from stabilizing the GyrA-DNA complex.
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Figure 9: Residues interacting with SD8 in GyrA55 structure (PDB ID: 4CKL).
ITC studies of SD8 with GyrA and GyrB43 (N-terminal GyrB) and GyrB47 (C-terminal
GyrB), yielded a substantially higher affinity of SD8 for GyrA over GyrB (1000 fold). The
authors conclude that GyrA is the primary target for SD8 and the interaction with GyrB is
an in vitro artifact manifested in the absence of GyrA.
Because most gyrase inhibitors also inhibit topo IV, SD8 was tested for its in vitro and in
vivo profiles of enzyme inhibition26. The in vitro activity was accessed by determining the
sensitivity of E. coli and S. aureus type II topoisomerases to SD8 and in vivo activity was
studied using microarray analysis for cellular responses. The IC50 (supercoiling assay) for
E. coli gyrase (Gram -ve) and S. aureus gyrase (Gram +ve) were 0.41 µM and 1.45 µM,
respectively, whereas for E. coli topo IV and S. aureus topo IV they were 270 µM and
14.5 µM respectively. These results show that SD8 is much more selective for DNA
gyrase as compared to topo IV. Transcriptional responses of E. coli to SD8 treatment are
similar to the profile of gyrase inhibition; i.e., upregulation of gyrase genes and
downregulation of the topo I gene. SD8 treatment does not induce an SOS response,
unlike the response to quinolones. The compound also displayed an enhanced activity
against E. coli cells that lacked the AcrB multidrug efflux pump, thus explaining why, in
spite of SD8 being a potent inhibitor for DNA gyrase, it displays no activity against Gram
negative bacterium. Because SD8 was initially reported as possessing cytostatic activity
against tumor cells, it was tested against malignant mesothelioma (MM) and non-small
cell cancer (NSCLC) cell lines and displayed an IC50 ranging from 75-125 µM27. Further
assays revealed that the target in human cancer cells was human topo II with an IC 50 of
100 µM. Later, it was found that SD8 can also inhibit human topo I with an IC50 of 60 ± 15
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µM. Hence, SD8 is a dual catalytic inhibitor of human topo I and II28. Although the affinity
of SD8 for these enzymes is low and the concentrations required for growth inhibition are
not feasible in vivo, further structural modification might allow for analogues that display
better anti-cancer activity.
A recent publication also demonstrated that SD8 was highly active against E. coli clinical
isolates and also moderately effective against K. Pneumoniae. The authors explain this
unexpected result because earlier laboratory E. coli isolates were used for testing, and
these lab strains have reduced cellular uptake of the antibiotic in comparison to clinically
present strains29.
1.7: Rationale for the work
DNA gyrase is a validated drug target for developing anti-bacterials. Currently, the only
drugs in the market that target DNA gyrase are the quinolones. The quinolones have
enjoyed widespread success since their introduction and are widely used in the clinic
because of their broad-spectrum activity. However, due to the prevalent use of quinolone
antibiotics, resistance to them has already emerged in community and clinical settings 3033.

To counter the threat of these fluoroquinolone-resistant infections, compounds that

inhibit DNA gyrase by a mechanism of action other than the quinolones is required.
The natural product simocyclinone D8 is one such compound that potently inhibits DNA
gyrase (IC50 = 0.4 µM, supercoiling activity) by a different mechanism of action than the
quinolones. Unlike quinolones, which stabilize the cleavage complex formation of DNA
gyrase with DNA, SD8 acts as a competitive inhibitor for DNA, by binding to the GyrA
domain of DNA gyrase and effectively blocking the catalytic apparatus. The mode of
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inhibition of DNA gyrase by SD8 has been termed catalytic inhibition and SD8 is the only
reported compound to exhibit such a mechanism. Also, SD8 inhibits a ciprofloxacin
resistant mutant, demonstrating that this novel mechanism can be used to combat
fluoroquinolone resistance19. SD8 was also been shown to be active against Gram
positive and Gram negative bacteria in clinically relevant concentrations. Taken together,
all of this data show that the competitive inhibition mechanism of SD8 is a valid mode of
action that can be used to develop new anti-bacterials and SD8 can be used as an ideal
lead for further compound development.
The SD8 molecule has three subunits: an aminocoumarin, a tetraene linker and an
olivose sugar bound to a highly substituted benz[a]anthracene system by a C-glycosidic
linkage (Figure 5).
The GyrA59-SD8 crystal structure reveal that GyrA has 2 separate binding pockets that
can accommodate the AC and the PK moieties. The tetraene linker and the olivose sugar
do not make any contacts with the enzyme. Based on the report published by Maxwell et
al.22, the only known structure activity relationships for SD8 and reported analogues are
as follows: Simocyclinone D8 (SD8, compound 1) has an IC50 of 0.4 µM, Simocyclinone
D4 (SD4, compound 2), which is a biosynthetic intermediate of SD8 and does not have
the chlorine on the coumarin ring, has an IC50 of 1.6 µM. Simocyclinone C4 (SC4,
compound 3); an intermediate from the biosynthesis of SD8 that lacks the aminocoumarin
and the tetraene linker has an IC50 of 70 µM and MGD8N2A (compound 4), a
semisynthetic intermediate obtained from the hydrolysis of SD8 and lacks the angucyclic
polyketide fragment, has an IC50 of 50 µM (Figure 10). This data underscores the
importance that both the fragments of SD8 are required for optimal activity.
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Figure 10: Structures of SD8, SD4, SC4 and MGD8N2A
The goal is to design simplified analogues of SD8 as antibacterial agents where in the
simplest pharmacophore (extracted from the GyrA59-SD8) would be two binding
elements separated by a linker (Figure 11). In the crystal structure, the tetraene linker
and the olivose sugar do not seem to make any potential interactions with the enzyme,
merely serving as a bridge to place the AC and PK moieties in their respective pockets.

Figure 11: Simplest pharmacophore extracted from GyrA59-SD8
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We decided to use a flavone moiety as a suitable replacement for the aminocoumarin.
Flavones have previously been used as isosteric replacements for coumarins in Hsp90
inhibitors34. The 2-phenyl ring of the flavone could potentially occupy a hydrophobic cleft
formed by Leu98, Gly170 and Tyr266 that lie beside the AC binding site and potentially
create more hydrophobic interactions (Figure 12).
For the flavone, we chose to use quercetin because of its commercial availability, and for
the ease of synthesis of the linker, we chose a flexible linker comprised of pimelic acid
and glycine. The linker length of 15 Å was chosen based on the modeled binding
geometry of SD8 in the GyrA59 crystal structure. Also in the recent GyrA55-SD8 crystal,
where SD8 was crystallized in its “bent over conformation”, the distance from the residue
that interacts with the carbonyl oxygen of the amide (His45, AC fragment) to the residue
that interacts with the phenol (His80, PK fragment) is ~15 Å (Figure 13).

Figure 12: Binding pocket for the SD8 coumarin on GyrA59 (PDB ID: 2Y3P). The
angucyclinone aglycone has been omitted for clarity22.
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Figure 13: Distance for the linker chosen (PDB ID: 4CKL)25.
To potentially create interactions in the PK binding site, we chose to couple substituted
anilines to the linker. We envisioned that the aromatic ring of the anilines can π-stack with
the His80, located 15 Å away. This has been proved to be a critical residue by
crystallography and mutation studies. Based on the interactions of the highlighted diol
with Tyr122 and Arg121 through a Mg2+ ion and water, we decided to substitute the metaand para- positions of the aniline. Because the hydrogen bond distances are long in the
GyrA59-SD8 structure, we decided to extend the diol and use a more acidic substituent
(carboxylic acid). To probe the space available at the para- position of the aniline, we
decided to use a range of substituents from hydrogen to isopropyl group. To probe the
electronics of the aromatic ring, we used a para chloro and a para methoxy substituent
(Figure 14).
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Figure 14: Design of quercetin-pimelic acid-glycine linked aniline analogues
Our aims in designing these analogues were to find simpler compounds that could bind
to the AC and PK pockets of GyrA and also to determine a synthetically accessible
scaffold that could potentially bind to the PK pocket, thus obviating the need to make
structurally complex analogues of the SD8 angucyclinone.
1.8: Synthesis of flavone-based analogues of SD8
To begin our work, we protected commercially available quercetin 5 with benzyl bromide
in DMF, using potassium carbonate as a base to give tribenzyl quercetin 6 in 50% yield.
Pimelic acid 7 was selectively protected as the mono-tertbutyl ester by a standard peptide
coupling protocol using tert-butanol, N-(3-dimethylaminopropyl)-N’-(ethylcarbodiimide)
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hydrochloride

(EDCI)

and

4-(dimethylamino)pyridine

(DMAP) as the base in chloroform to obtain the mono protected tert-butyl ester of pimelic
acid 8 in 44% yield (Figure 15).

Figure 15: Synthesis of 6 and 8
Tribenzyl quercetin 6 was esterified using the acid 8 and the peptide coupling reagent
EDCI in THF, with stoichiometric amounts of Hunig’s base and catalytic DMAP in THF to
obtain the ester 9 in quantitative yield. The tert-butyl ester was removed using
trifluoroacetic acid (TFA) in DCM with triethylsilane as a cation scavenger to afford the
compound 10 in 76% yield (Figure 16).
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Figure 16: Synthesis of compound 10
Suitably protected anilines 11a – 11j were coupled to N-phthaloyl-glycine acid chloride in
THF with triethylamine as the base under reflux conditions. The obtained aniline-glycinephthalimide compounds were sufficiently pure to be used for the next step. The
phthalimide protecting groups were removed using hydrazine hydrate in ethanol under
reflux conditions. The deprotected primary amines 12a – 12j were purified on silica and
were obtained in 60-80% overall yields (Figure 17).
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Figure 17: Synthesis of compounds 12a to 12j
These obtained compounds 12a – 12j were coupled to the acid 10 using standard peptide
coupling procedures with EDCI as the coupling reagent, 1-hydroxybenzotriazole as the
promoter and N-methyl morpholine as the base in DMF to offer the amides 13a – 13j in
77 to 95% yield (Figure 18).
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Figure 18: Preparation of compounds 13a to 13-j
From the obtained amides, the aniline protecting groups were initially removed, followed
by removal of the benzyl ethers. The silyl protecting groups were removed using
tetrabutylammonium fluoride in THF, which gave the alcohols in moderate yields (69%
for compound 14b and 65% for compound 14h, Figure 19). Tert-butyl ester was removed
using TFA and the cation scavenger triethylsilane in DCM to give the carboxylic acid 15c
in quantitative yield (Figure 20). The acetonide protecting group was removed using HCl
in THF, obtaining the diol 14i (Figure 21) in 36% yield. The benzyl ethers were removed
by hydrogenation using hydrogen at 1 psi (balloon pressure) and palladium on charcoal
as the catalyst to obtain the benzyl deprotected quercetin derivatives 15a – 15j in yields
ranging from 33% - 57% (Figure 19 – Figure 22).
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Figure 19: Synthesis of compounds 15b and 15h
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Figure 20: Synthesis of compound 15c

Figure 21: Synthesis of compound 15i

Figure 22: Preparation of compounds 15a, 15d-g, 15j
As a control compound, we prepared a flavone based analog 15k without the aniline
fragment. Tribenzyl-quercetin 6 was esterified with mono-methyl sebacic acid, to give the
ester 14k. The ester was hydrogenated to obtain quercetin-sebacic acid methyl ester
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analog 15k (Figure 23). This compound lacks the aromatic ring that would bind to the PK
pocket.

Figure 23: Synthesis of compound 15k

1.9: Biological activity of flavone-based analogues
To assess the ability of the flavone analogues to inhibit E. coli DNA gyrase we performed
a supercoiling activity assay26. Briefly, the assay uses the relaxed plasmid PBR 322 and
E. coli gyrase. The DNA gyrase supercoils the plasmid DNA, which is shown as a band
of topoisomers into the supercoiled form that moves faster on the gel. Upon addition of
the compound, if gyrase is inhibited, the amount of supercoiled plasmid is reduced. The
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assay was performed in the presence of varying concentrations of these flavone
analogues and the 50% inhibitory concentration (IC50) was determined (Table 1).
Compounds 15d – 15g and 15j were not soluble in the assay medium, so we could not
determine any further data from these compounds.
Table 1: Activity of compounds against E. coli DNA gyrase
Compound

Supercoiling assay
IC50 (µM)

15a

48.6 ± 0.8

15h

84.7 ± 5.5

15b

>200

15c

>200

15i

>200

15k

>200

SD8

0.41

Next, to determine whether these compounds inhibit E. coli DNA gyrase by a catalytic
mechanism similar to SD8, they were tested for their ability to disrupt binding of DNA
gyrase to DNA by surface Plasmon resonance (SPR)19. Neither compounds was active
in this assay nor was disruption of the DNA –enzyme interaction observed (Figure 24).
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Figure 24: Sensogram of compound 15a
To further investigate the mechanism of how these compounds inhibited DNA gyrase, we
tested the effect of these compounds on the DNA cleavage activity of E. coli DNA gyrase
(Table 2)26. Topoisomerases cause changes in DNA topology by cleaving and religating
strands. When quinolones inhibit this religation process, they form linear DNA that makes
covalent complexes with the enzyme. Formation of linear DNA is quantified to determine
whether the compound works as a topoisomerase poison.
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Table 2: DNA cleavage assay for compounds
Compound

DNA cleavage
(Fold – stimulation)

15a

7.8

15h

5.0

15b

3.0

15c

1.8

15i

1.9

15k

>1

SD8

>1

So, determining that these compounds inhibit DNA gyrase, but with a mechanism different
than that of SD8, we tested them against human Topo II27, 28. We first evaluated the effect
of these compounds on the decatenation activity of human Topo II and also on the DNA
cleavage activity of Human Topo II (Table 3).
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Table 3: Effect of flavone analogues on Human topo II
Compound

Decatenation assay

DNA Cleavage

IC50 (µM)

(Fold – Stimulation)

15a

149 ± 3.2

2.7

15h

>200

2.4

15b

>200

2.1

15c

>200

<1

15i

78.9 ± 1.4

<1

15k

>200

<1

SD8

100

Since quercetin can intercalate into DNA35, 36 and the compounds 15a, 15h and 15b have
the quercetin moiety in them, we decided to examine if these compounds can intercalate
into DNA by using a DNA unwinding assay. We also used quercetin as a control, to
compare the level of intercalation that occurs (Figure 25). If the compound intercalated
into DNA (in this case plasmid PBR 322), after treatment with gyrase, it forms relaxed or
underwound DNA that converts into supercoiled DNA. The presence of supercoiled DNA
indicates DNA intercalation has happened. The extent of intercalation of a compound can
be measured as the level of negative supercoils introduced into the covalently closed,
relaxed circular substrate DNA37.
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Figure 25: (A) Intercalation of compounds 15a – 15k. (B) Intercalation of compound
15a as compared to intercalation by quercetin
1.10: Conclusions and Discussion
Based on the structure and competitive mechanism of action of SD8 against DNA
gyrase19, we designed and synthesized ten flavone based analogues. We prepared
compounds using the flavone quercetin as the AC binding element and various
substituted anilines to bind to the PK pocket of DNA gyrase linked by a flexible glycinepimelic acid linker in modest yields.
Initially, we tested the ability of these flavone-based compounds to inhibit E. coli DNA
gyrase supercoiling by a supercoiling activity assay. Compounds 15a and 15h displayed
39

modest inhibitory effects on the supercoiling activity of gyrase with IC50 values of 48.6 ±
0.8 µM and 84.7 ± 5.5 µM, respectively, but the other compounds were not active (i.e.,
IC50 values greater than 200 µM). The activities of these compounds for DNA gyrase were
significantly lower than that of SD8 (IC50 = 0.41 µM) and quercetin alone (IC50 value of
0.14 µM), but similar to that of the coumarin-linker subunit of SD8 (MGD8N2A, IC50 = 50
µM). Compound 15k, the flavone-based analog most similar to MGD8N2A was inactive,
suggesting that the aniline fragment is required for activity against DNA gyrase.
To determine the mechanism of DNA gyrase inhibition by these compounds we
performed an SPR assay. SD8 binds to DNA gyrase and inhibits the catalytic activity of
the enzyme by preventing DNA from binding to the enzyme and this mechanism has been
termed catalytic inhibition. SPR has been used to analyze this disruption of DNA binding
to the enzyme by SD819. Neither compound 15a nor 15h was active in this assay and no
disruption of DNA-enzyme interaction was observed. This data suggested that the
observed inhibition of DNA gyrase by the flavone analogues 15a and 15h were by a
different mechanism than that of SD8.
Quinolones inhibit DNA gyrase by stabilizing the enzyme-DNA cleavage complex, thereby
preventing religation and exit of DNA from the enzyme 11. To investigate whether the
flavone analogues inhibited E. coli DNA gyrase by a similar mechanism, we carried out a
DNA cleavage assay. All compounds except 15k modestly stimulated gyrase-catalyzed
cleavage, with compounds 15a and 15h displaying the highest levels of stimulation (7.8fold and 5.0-fold stimulation in generation of linear DNA at 200 µM, respectively). The
extent of generation of linear DNA by compounds 15a and 15h tallies up with their
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inhibition of supercoiling activity for E. coli gyrase. This suggests that compounds 15a
and 15h inhibit the activity of DNA gyrase by poisoning it.
SD8 was found to be a dual inhibitor of human topo II and topo I28. Human topoisomerase
inhibitors are used for cancer chemotherapy. To determine the potential toxicity of these
compounds, we screened them against human topo II. Initially, the effect of these
compounds on the decatenation activity of human topo II was assessed and it was found
that compounds 15a and 15i exhibited modest activities with IC50 values of 149 ± 3.2 µM
and 78.9 ± 1.4 µM. It is interesting to note that compound 15a inhibited both E. coli DNA
gyrase and human Topo II, whereas compound 15i inhibited only human topo II and
compound 15h inhibited only E. coli DNA gyrase. To determine the mechanism of action
of these compounds on human topo II, we assessed their activity on DNA cleavage by
human topo II. Similar to the results obtained for E. coli DNA gyrase, compounds 15a and
15h displayed the highest level of poisoning activity against human Topo II, although the
extent of DNA cleavage stimulation for Topo II were lower than that of E. coli DNA gyrase.
Hence, the compounds 15a and 15h appear to inhibit the activity of topoisomerases by
poisoning, as quercetin does. But, interestingly, compound 15i exhibited modest inhibition
of human topo II without poisoning it, suggesting a different mode of action for compound
15i.
Since quercetin35, 36 and also quinolones38 can intercalate into DNA, we tested the DNA
intercalation ability of these flavone based analogues by a DNA unwinding assay. Some
of these compounds were found to intercalate into DNA and their levels of intercalation
varied. Compound 15a displayed the highest level of intercalation and the level of
intercalation was similar to that of quercetin. Compound 15h displayed a modest level of
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intercalation but the level of intercalation of other compounds were limited. Compounds
15a and 15h displayed the highest level of poisoning activity among these compounds
against both E. coli gyrase and human Topo II, indicating that these compounds might
inhibit topoisomerases by their ability to intercalate into DNA.
In conclusion, we prepared flavone-based analogues inspired by the natural product
simocyclinone D8. While two of these compounds do inhibit DNA gyrase, they do not act
as catalytic inhibitors as SD8 does. The flavone based analogues 15a and 15h were
determined to be topoisomerase poisons and DNA intercalators.
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CHAPTER 2: SYNTHETIC STUDIES TOWARDS THE TOTAL SYNTHESIS OF
SIMOCYCLINONE D8 (SD8)
2.1 Introduction
Natural products have long been a source for antibiotics and it is reasonable to expect
new natural products to serve as promising leads for new antibiotic drug discovery. An
overwhelming majority (69%) of antibacterial drugs FDA approved between 1981 and
2006 were either natural products or developed from natural products39. Antibacterial drug
discovery from natural products has been more fruitful as compared from small molecule
libraries because of the chemical diversity natural products afford and also due to their
different physiochemical properties as compared to small molecules40.
The fluoroquinolones are broad spectrum antibiotics that are able to treat both Gram-(+)
and Gram-(-) infections6. They are the only class of drugs used clinically that inhibit DNA
gyrase. However, mutations in DNA gyrase that confer resistance to the fluoroquinolone
drugs like ciprofloxacin have emerged both in clinic and community settings.
Fluoroquinolone resistance has been reported in pneumonia, influenza, MDR/XDR
tuberculosis and pseudomonas respiratory infections. To counter this threat from
fluoroquinolone-resistant bacterial strains, compounds that can inhibit drug-resistant DNA
gyrase mutants must be developed30-32. One potential source of compounds that can
inhibit fluoroquinolone-resistant mutants are compounds that can inhibit DNA gyrase by
a novel mechanism.
SD8 is one such natural compound that inhibits DNA gyrase by a novel mechanism of
action as compared to the fluoroquinolones. SD8 inhibits DNA binding to the enzyme and
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has been termed competitive inhibition compared to fluoroquinolones that trap the DNADNA gyrase complex. SD8 was shown to inhibit both wild-type and a ciprofloxacinresistant mutant in a supercoiling assay proving that the competitive mechanism of action
can be exploited to overcome fluoroquinolone resistant mutants19, 22.
The structure of SD8 is highly modular, consisting of three subunits: an aminocoumarin,
tetraene linker and an angucyclinone aglycone comprised of an olivose sugar bound to a
highly substituted benz[a]anthracene system by a C-glycosidic bond. SD8 belongs to the
angucyclinone

family

of

natural

products,

which

are

characterized

by

the

benz[a]anthracene ring system and its angular A ring. Angucyclines are categorized along
with tetracyclines and anthracyclines as antibiotics with a carbotetracyclic skeleton. SD8
is further categorized as belonging to the aquayamycin sub-type of angucyclinones. This
sub-type is defined by molecules that incorporate both a C-glycoside and angular, tertiary
diols at C4a and C12b in the aglycone (Figure 26)41-43. The structure is highly modular
and this will be exploited while designing synthetic routes towards its total synthesis.

Figure 26: Structure of Angucycline antibiotics and Aquayamycin subtype Angucyclines
2.2: Review of literature
2.2.1: Prior synthetic efforts towards the Angucyclinone fragment
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Various synthetic strategies have been reported for the synthesis of angucyclinone
antibiotics, that either form the B, C or D rings as the key step. Most commonly reported
methodologies for the key ring formation include Hauser cycloaddition, radical cyclization,
Friedel-Craft cyclization, Michael addition and biomimetic reactions41, 42.
The only reported total synthesis of an aquayamycin-type angucyclinone is of
aquayamycin itself44. The study reported in 2000, uses a Hauser annulation between the
3-(phenylsulfonyl) phthalide fragment 16 and the optically active cyclohexanone fragment
17 to construct the BCD ring fragment (Figure 27). This synthesis uses a Lewis acid
catalyzed C-glycosidation to install the olivose sugar in fragment 16. The stereochemistry
of the angular C4a alcohol was derived using enzymatic resolution by Candida antartica
lipase of a racemic tertiary alcohol in the preparation of the fragment 17. The
stereochemistry at C4a is used to control the stereochemistry of the C12b alcohol during
construction of the A ring by pinacol coupling44-46. This report provides precedent for
construction of the A ring and control of stereochemistry while installing the angular diols.

Figure 27: Total synthesis of Aquayamycin
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Little synthetic work has been done on angucyclinones having epoxides. Sulikowski has
reported an epoxidation on a benz[a]anthracene ring system in work towards the
synthesis of angucycline SF 2315B (Figure 28)47. The epoxide of compound 22 was
installed using radical oxidation by oxygenating a solution of the quinone 21 in THF in the
presence of tetrabutylammonium fluoride and it was reported that only the α-epoxide is
formed due to steric hindrance on the β-face by the A ring. This breaks the conjugated
quinone system, and Sulikowski then performs a chelation-controlled syn-reduction of the
C12 quinone ketone of 23 using tetramethylammonium triacetoxyborohydride to get 24.
These conditions are chemoselective and the β-hydroxyketone can be reduced in
presence of an epoxide and a ketone. This report offers the precedent of achieving
chelation-controlled syn-reduction of a β-hydroxyketone in the presence of an epoxide
and a ketone.

Figure 28: Sulikowsky synthesis of SF 2315B
Suzuki et al. report the selective substitution of the C3’ alcohol of olivose over the C4’ in
the total synthesis of the antibiotic C104 (Figure 29)48, 49. TBS protection of the less
hindered C3’ alcohol 25 occurs more readily and is followed by the installation of the
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dienone ester at C4’ by Yamaguchi esterification to give 26. This report provides the
precedent of selective reactivity of the C3’ alcohol over the C4’ alcohol in olivose.

Figure 29: Selective reactivity of the C3’-OH over C4’-OH in the olivose sugar
2.2.2: Retrosynthetic Analysis of SD8
The structure of SD8 is highly modular, which we plan to exploit in our total synthesis.
Our first disconnection is at the olivose-tetraene bond (Figure 30). We plan to install the
coumarin-tetraene subunit 27 selectively at the C3’ of the olivose sugar of the aglycone
28 by a Yamaguchi esterification following the precedent of Suzuki48, 49.
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Figure 30: Retrosynthesis of SD8
The aglycone 28 will be prepared from the quinone 31 by a stereoselective epoxidation,
chelation-controlled reduction of the C7 ketone, Suzuki coupling to install the A ring side
chain and pinacol coupling to install the A ring. The BCD ring system 31 will be assembled
by a Hauser annulation of the isobenzofuranone 33 and the α,β-unsaturated ketone 32
will be prepared by stereoselective Rubottom-type α-hydroxylation (Figure 31).

Figure 31: Retrosynthesis of the aglycone fragment 28
Our proposed synthesis begins with the glycosidation of the sugar 34 and the
isobenzofuranone 35 (Figure 32). The sugar can be installed using a well-precedented
Lewis acid or protic acid catalyzed C-glycosylation reaction50, 51. Protection of the triol as
the tri-benzyl ether completes the synthesis of the isobenzofuranone 33.
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Figure 32: Synthesis of fragment 33
We plan to synthesize the α,β-unsaturated ketone 32 as described in Figure 33. Using
4-OTBS-cyclohex-2-en-1-one 36, which can be prepared on a large scale by multiple
chemical or enzymatic routes as reported52-55, we plan to install the hydroxymethyl at Cα’
in a non-stereoselective manner to afford 37. On this substrate, we plan to carry out an
asymmetric α-hydroxylation using Rubottom-type conditions56, which is well-precedented
in the literature using Davis’ chiral oxaziridine57, Shi epoxide catalyst/Oxone58, Mn(salen)
complexes/NaOCl59 and Sharpless Asymmetric Epoxidation (SAE)60,

61.

The silyl enol

ether is more electron rich than the olefin of the α,β-unsaturated ketone 37 and will react
preferentially under these conditions62. We expect to isolate the triol 38 after a global
deprotection using TBAF and reprotect the primary and tertiary alcohols as the acetonide
and the secondary alcohol as the TBS ether to afford the compound 32.
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Figure 33: Synthesis of the cyclohexanone fragment 32
Hauser cycloaddition of 33 and 32 under basic conditions (LiHMDS) followed by acidic
neutralization using the procedure of Hauser63 will afford the quinone 31 (Figure 34). We
plan to install the epoxide in the next step. The timing of epoxide installation (early vs.
late) was made after consideration of the stereochemical outcome of epoxidation of the
early-stage and late-stage substrates (Figure 35). We predict that epoxidation on the
early-stage substrate 31 will afford the desired β-epoxide 31’’. The protected C4a-OH
and C6-OTBS groups in this intermediate will sit in the axial positions in the half-chair
conformation, blocking the α-face and leaving the β-face sterically accessible for the
approach of mCPBA. Epoxidation of the late-stage substrate 43, wherein the A ring is
already formed, might lead to poor facial selectivity and yield because both the α- and βfaces are sterically hindered. Thus, we will install the epoxide at this earlier point in the
route. Treatment of the epoxide with TBAF will remove the C6-OTBS protecting group
and will set the stage for the next chelation-controlled syn-reduction on the substrate 39.

Figure 34: Preparation of fragment 40
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Figure 35: Epoxidation on early vs. late substrate
The C6-OH in 39 will provide the directing group for the stereoselective syn-1,3-chelationcontrolled reduction of the C7 ketone64. Several reagents have been reported to offer high
diastereoselectivity in similar systems including LiAlH(OtBu)3, DIBAL-H, LiBH4 and Luche
reduction conditions65-68. Under chelation with the metal, the β-hydroxyketone 39 will
adopt a half-chair conformation due to the stereochemistry of the C6 alcohol (Figure 36).
The hydride will be delivered axially on the β-face to afford the C7-α-alcohol. The βhydroxyketone can be reduced preferentially in the presence of the ketones at C11 and
C12b and the epoxide. Both the newly formed alcohols will be protected as the O-TBS
ethers 40 for the next step (Figure 34).
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Figure 36: Chelation-assisted syn-reduction
Acetonide 40 will be deprotected using dilute acid to afford the diol and this will be treated
with triphenylphosphine and DIAD to obtain the epoxide (Figure 37). The epoxide will be
opened with iodide to give the alkyl iodide 41. We plan to use this alkyl iodide in a Suzuki
coupling reaction using the conditions reported by Fu and Zhou 69 with the vinyl boronate
42 to obtain the extended alkyl chain in compound 43. Vinyl boronate 42 can be prepared
by hydrozirconation/methylation of a 1-alkynylboronate according to literature
procedures70. Alternatively, we can swap the coupling partners for the Suzuki reaction by
using vinyl halide and an alkyltrifluoroboronate instead. Conditions for Suzuki coupling
using alkyltrifluoroboronates and aryl halides have been reported by Molander et al.71, 72.
The alkyltrifluoroboronate can be prepared by alkylation of the enolate by iodomethyl
pinacolboronate and hydrolyzing the pinacol ester to the potassium trifluoroboronate by
using KHF2. We will prepare the vinyl iodide required for the Suzuki coupling as reported
by literature procedures73.
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Figure 37: Synthesis of compound 28
Following the extension of the side chain by Suzuki coupling, we will install the A ring
using an intramolecular pinacol coupling similar to the one used for the preparation of
aquayamycin. Hydrolysis of the ketal 43 with dilute acid will generate the aldehyde, which
will be subjected to Pedersen conditions (VCl3(THF)3 and Zn in DMF) in a chelationcontrolled pinacol coupling74. The stereochemistry of the C4a quaternary carbon will force
approach of the aldehyde from the top β-face of the C12b ketone in the chelation complex
with the metal (Figure 38). Similar to the aquayamycin total synthesis, we expect to obtain
a mixture of epimers at C1. Oxidation of the C1 alcohol will result in the desired single
diastereomer 44. Synthesis of the aglycone will be completed by removal of the three
benzyl protecting groups by catalytic hydrogenation and selective protection of the phenol
as the O-TBS ether giving 28, which will complete the synthesis of the aglycone.
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Figure 38: Pinacol coupling to form the A ring
We will make the coumarin-tetraene fragment 27 by an EDCI coupling (Figure 39). The
amide coupling with aminocoumarins using EDCI is well precedented by the work of
Blagg et al.75. The coumarin-tetraene fragment 27 will be unified with the C3’ alcohol of
olivose 28 by an ester bond using Yamaguchi coupling as described earlier. This will be
followed by a global silyl-ether deprotection using either TBAF or HF/pyridine to give SD8.

Figure 39: Final steps toward SD8
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2.3: Progress towards the total synthesis of SD8
2.3.1: Synthesis of the tetraene linker

Figure 40: Synthesis of the tetraene linker
We prepared the mono-tert butyl protected tetraene linker through multiple synthetic
routes (Figure 40). Initially, we synthesized mucodialdehyde 46 by a double Wittig76
reaction

of

glyoxal

trimer

dihydrate

44

and

the

Wittig

reagent

(triphenylphospharanylidene) acetaldehyde 45 to give the compound 46 in 64% yield.
This di-aldehyde was subjected to a mono Horner-Wardsworth-Emmons reaction with the
HWE reagent tert-Butyl diethylphosphonoacetate 47 using barium hydroxide as the base
to obtain the compound 48 in 42% yield. The yield of this reaction was unoptimized. The
mono-aldehyde 48 was subjected to an HWE reaction with diethylphosphonoacetic acid
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49 using n-BuLi as the base to obtain the tetraene-mono tert-buyl ester 50 in quantitative
yield.
The tetraene di-carboxylic acid 30 is a component of the veterinary antibiotic fumagillin B
51 that is commercially available in gram quantities as a beekeeping antibiotic. We
obtained the diacid 30 in 90% yield by base hydrolysis77 of fumagillin 51 obtained after
removal of excipients for the formulation by sodium bicarbonate wash.
We also prepared the mono-tert-butyl ester of fumagillin 52 in 60% yield using tert-butyl
bromide and caesium carbonate as the base in DMF. The fumagillol fragment was
removed using base hydrolysis to afford the compound 50 in quantitative yield.
2.3.2: Synthesis of the olivose sugar

Figure 41: Synthesis of compound 57
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Figure 42: Synthesis of compound 62
6-Deoxysugars such as D-olivose are commonly found in antibiotics produced by the
Streptomyces bacteria. The classic route reported in literature towards 2-deoxysugars
involve hydration of glycals under acidic conditions78. We chose to use the method of
O’Doherty and co-workers to prepare the olivose sugar79-81. The first step involves a
transfer hydrogenation from formic acid and triethylamine under Noyori reduction
conditions using the catalyst (R)-Ru(η6-mesitylene)-(R, R)-TsDPEN A of 53 to 54 (Figure
41). To prepare the pyran scaffold of olivose, an Achmatowicz reaction was carried out
on the furan 54 to give the dihydropyranone 55 in 45% yield. We attribute this low yield in
the initial two steps to the use of the commercially available ligand in preparation of A as
compared to the recrystallized ligand used by O’Doherty, leading to unconverted starting
material in the initial reduction. The separation of this unreacted material 53 was difficult
leading to the reduced yield in the Achmatowicz reaction.
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To separate the epimers on silica formed by the Achmatowicz reaction, the epimeric
alcohol was protected as a Boc ether, and the β-epimer was purified (1:1, α:β, 24% of β,
56). This was followed by a protecting group swap for the Boc to a benzyl using
Bis(dibenzylideneacetone)palladium(0) in 95% yield to give 57. Luche reduction on the
pyranone 57 gives a mixture of the diasteromeric alcohols 58 in 79% yield (Figure 42).
This mixture was not separated and was subjected to an allylic transposition reaction
using 2-nitrobenzenesulfonyl hydrazide (NBSH) as the nucleophile, affording the olefin
59 in 97% yield. Mechanistically, this is a Mitsonobu reaction on the allylic alcohol using
NBSH as the nucleophile, which forms the N-allylic sulfonylhydrazine derivative that at
room temperature forms the allylic diazene intermediate. The diazene intermediate is
unstable and results in the sigmatropic elimination of dinitrogen followed by the
transposition of the olefin82.
This olefin was dihydroxylated using OsO4 to give the diol 60 in 80% yield. However, the
stereochemistry of the C4’-OH obtained is opposite of what is desired (3S vs. 3R), hence
this was inverted using a Mitsonobu reaction using para-nitrobenzoic acid to afford the
compound 61. The reaction had significant amount of impurities, which could not be
removed entirely to obtain the pure product. Hence, a partially purified reaction mixture
was subjected to TBSOTf and 2,6-lutidine as the base in DCM to give the 4-OTBS ether
of D-olivose 62 in 30% yield (2 steps).
2.3.3: Synthesis of the coumarin
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Figure 43: Synthesis of the compound 68 and 71
The synthesis of 3-amino-8-chloro-4,7-dihydroxy-coumarin has not been reported in the
literature. Generally, there are two common synthetic approaches to coumarins: FriedelCrafts reaction of substituted phenols and cyclization of substituted 2-hydroxyacetophenone with base and diethylcarbonate. We used the acetophenone route to
synthesize 3-amino-4,7-dihydroxy-coumarin and explored a late stage chlorination
approach to install the 8-chloro on the ring.
Starting from 2,4-dihydroxyacetophenone 63, the 4-OH group was protected using paramethoxybenzyl chloride to afford the 4-PMB protected acetophenone 64 in 46% yield
(Figure 43). This compound was cyclized into the coumarin using sodium hydride as the
base in toluene and dimethyl carbonate as the electrophile to afford the coumarin 65 in
quantitative yield. The most commonly reported method for introducing the nitrogen at the
C3 position of the coumarin involves using concentrated nitric acid as the electrophile.
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However, we decided to install the nitrogen using the electrophilic nitrogen source
bis(Troc) azodicarboxylate83 66 to afford the compound 67 in quantitative yield. The
decision to use this reagent was taken based on the high yielding electrophilic amination
using this reagent and the ease in reaction workup and purification. Reduction of the
hydrazide to the amine was carried out using zinc and acetone in acetic acid to afford the
coumarin 68 in 46% yield. Acetone in this reaction forms the hydrazone from the
hydrazide that is reduced readily by metallic zinc under these conditions83. We see a
complete conversion of the starting material to the product by TLC and HPLC however;
recovery of the polar amino alcohol 68 is difficult. Optimization of the workup conditions
of this reaction will allow better recovery of the product.
We explored conditions for the late-stage installation of the chlorine on 4,7-dihydroxy-3nitro-coumarin 70. This compound was prepared in one step from commercially available
4-hydroxy,7-methoxy-3-nitro-coumarin 69 using dodecane thiol, KOtBu in DMF in 88%
yield. Treatment of compound 70 with chloramine-T in refluxing dioxane/water affords a
1:1 mixture of the product 71 and the starting material 70 in quantitative yield. Reduction
of the nitro group84 and TBS protection will afford the desired coumarin 29.
2.3.4: Suzuki coupling and model system
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Figure 44: Synthesis of compound 76 and 79
To prepare the A ring of the aglycone 43, we plan to install the side chain required for
formation of the A ring by Suzuki coupling of an alkyl iodide and a vinyl boronate. To
develop and optimize reaction conditions for the coupling, we decided to use the model
system having a tetralone scaffold. 6-methoxy tetralone 72 was hydroxymethylated at its
Cα position using 1H-benzotriazole-methanol under basic conditions (LiTMP) to give the
α-hydroxymethyl-

derivative85 73 in 65% yield (Figure 44). This compound was

hydroxylated at its alpha position under Rubottom conditions using m-CPBA as the
oxidant. Briefly, the di-OTBS ether derivative was made using TBSOTf and, after reaction
workup, the silanol-ether was oxidized using m-CPBA and 1,2-dichloroethane as the
solvent. Use of 1,2 DCE simplifies the workup as after oxidation the 3-chlorobenzoic acid
byproduct precipitates out of solution and after filtration the di-OTBS ether is obtained86.
The compound was stirred with TBAF in THF to get racemic (±)-74 in 65% overall yield.
To prepare the alkyl iodide, compound 74 was subjected to intramolecular Mitsonobu
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reaction conditions with tributylphosphine and DIAD to obtain the epoxide 75 in 97 yield.
The epoxide was opened with iodine and BF3(OEt)2 as the Lewis acid87 to obtain the
iodide (±)-76 in 64% yield.
We decided to swap the Suzuki coupling partners in case the reaction did not work with
the alkyl iodide. Compound 78 was prepared by a procedure reported by Molander et al..
Alkylation of 6-methoxy tetralone 72 with iodomethylpinacol boronate 77 using LiHMDS
as the base gave compound 78 in 55% yield. The potassium trifluoroboronate was
prepared by using a saturated solution of KHF2. After continuous Soxhlet extraction
overnight using acetone, compound 79 was obtained in quantitative yield71, 72.
2.3.5: Synthesis of the isobenzofuranone

Figure 45: Synthesis of the Isobenzofuranone 84
The Isobenzofuranone coupling partner for the Hauser reaction was prepared in 6 steps
from 3-hydroxybenzoic acid 80 (Figure 45). Commercially available 3-hydroxybenzoic
acid was converted to N,N-diethyl-3-methoxybenzamide 81 via the acid chloride in an
overall yield of 92% for two steps. The N,N-diethylamide was synthesized in order to
direct lithiation using s-BuLi at the ortho position. The lithium anion formed using s-BuLi
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was quenched using DMF to give the compound 82 in 67% yield. This was followed by a
protecting group swap from 3-O-methyl to 3-O-benzyl, initially deprotecting the methoxy
group using the Lewis acid BBr3 to give the phenol 82’ in 87% yield and alkylating the
phenol with benzyl bromide, using sodium hydride as the base to give the compound 83
in 76% yield. The compound was cyclized to the furan using TMSCN and catalytic KCN
and quenching with acetic acid to provide the product 84 in 68% yield.
2.3.6: Model reactions for the Olivose Sugar-Aglycone coupling (C-glycosidation)

Figure 46: Model reactions for C-glycosidation
To demonstrate the feasibility of acid catalyzed C-glycosidation, we ran the reaction using
two different conditions using 2,3,4,6-Tetra-O-benzyl-D-glucopyranose 86 as the glycosyl
donor and 1-naphthol 85 and estrone 88 as the glycosyl acceptor (Figure 46). These
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reactions were run only once and the yields were not optimized. Under these reaction
conditions, first the phenolic oxygen attacks the anomeric carbon on the glycosyl donor
forming an O-glycoside bond that rearranges to form the more stable C-glycoside. The
first reaction between 85 and 86 involved protic acid conditions, using trifluoromethane
sulfonic acid as the protic acid in DCM giving the C-glycoside 87 in 37% yield51. The
second set of conditions involved the Lewis acid TMSOTf and silver perchlorate 50 as the
promoter with 2,3,4,6-Tetra-O-benzyl-D-glucopyranose 86 as the glycosyl donor and 1naphthol 85 and estrone 88 as the glycosyl acceptor. 1-Naphthol glycoside 87 was
obtained in 32% yield and estrone glycoside 89 was obtained in 37% yield.
2.3.7: Model reactions for Coumarin-Tetraene and Tetraene-Olivose Sugar coupling

Figure 47: Model reactions for EDCI amidation and Yamaguchi reactions
To demonstrate the feasibility of the planned coupling of tetraene with the coumarin (EDCI
amidation)75 and with the Olivose sugar (Yamaguchi esterification), we have performed
the reaction on a model system with the commercially available coumarin 90, alcohol 93
and sorbic acid 91 (Figure 47).
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The amidation was done on commercially available 3-aminocoumarin 90 and sorbic acid
91 using the conditions reported by Blagg75 and coworkers to give the amide 92 in 59%
yield. Once the target aminocoumarin 29 is available, this reaction condition can be used
to synthesize the aminocoumarin-tetraene amide 27.
To demonstrate that the Yamaguchi esterification48, 49 will work on a similar substrate, we
used the alcohol 93 as a surrogate for the sugar Olivose. Yamaguchi coupling proceeds
through a mixed-anhydride intermediate. 2,4,6-trichlorobenzoyl chloride forms the mixed
anhydride with sorbic acid 91 in the presence of triethylamine. This intermediate mixedanhydride is treated with the alcohol and DMAP to form the ester. Compound 94 was
isolated in 51% yield.
2.4: Conclusion
The structure of SD8 is highly modular, consisting of four distinct fragments –
aminocoumarin, tetraene, olivose and the angucyclinone. We have proposed a synthetic
route to the highly substituted and complex angucyclinone fragment in SD8. We also have
identified and worked out synthetic routes to the aminocoumarin, tetraene and the olivose
sugar. Although none of these reactions were optimized, we have prepared these
fragments in a minimal number of steps and obtained modest overall synthetic yields
(Table 4). We have identified and worked out various fragment-linking chemistries on
model substrates like EDCI amidation for the Coumarin-tetraene fragment and
Yamaguchi esterification for the Tetraene-Olivose fragment. We have also prepared the
substrates for the Suzuki reaction for forging the A ring on model systems. Completion of
synthetic work towards the angucyclinone fragment will help identify and synthesize
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various analogues of SD8 that potentially will have better activity towards DNA gyrase
and other fluoroquinolone resistant DNA gyrase mutants.
Table 4: Fragments of SD8 prepared and overall yield
Fragment synthesized

Total Synthetic Steps

Overall yield (%)

8-chloro-4,7-dihydroxy-3-

2

69

2

80

D-Olivose

9

59

7-(benzyloxy)-3-oxo-1,33-

6

82

nitrocoumarin

(2E,4E,6E,8E)-10-(tertbutoxy)-10-oxadeca-2,4,6,8tetraenoic acid

dihydroisobenzofuran-1carbonitrile
(Isobenzofuranone)
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CHAPTER 3: DESIGN AND SYNTHESIS OF A SUBSTRATE-COMPETITIVE
COVALENT INHIBITOR FOR PROTEIN KINASE B (AKT)
3.1: Introduction
3.1.1: AGC Kinases
Phosphorylation is an important reversible covalent modification that regulates the
function of proteins in cells. Enzymes that carry out phosphorylation in cells are called
protein kinases. They transfer a phosphate group from ATP to their substrates by mostly
attaching them to Serine (76-90%), Threonine (10-20%) or Tyrosine (0.05-4%) residues.
Other residues found to be less frequently phosphorylated are histidine, aspartic acid and
glutamic acid88. Protein kinases are classified into 8 major groups: AGC (PKA, PKG,
PKC), CAMK (Ca-Calmodulin dependent protein kinases), CMGC (CDK, MAPK, GSK3,
CLK), TK (Tyrosine Kinases), TKL (Tyrosine Kinase Like Kinases), STE (homologs of
yeast kinases), RGC (Receptor Guanylate Cylases) and CK1 (Casein Kinase 1)89.
AGC kinases belong to the subgroup of Ser/Thr protein kinases that by sequence
alignments were found to have a similar catalytic kinase domain as cAMP-dependant
protein kinase 1. The AGC family has 60 out of the 518 protein kinases identified.
Structurally, most of them consist of the kinase core and other functional domains that
mediate membrane or substrate interaction90.

67

A common structural feature seen in AGC kinases is a bilobal kinase fold that consists of
an amino-terminal small lobe (N-lobe) and a carboxy-terminal large lobe (C-lobe)
sandwiching one molecule of ATP. Activation in many AGC kinases requires
phosphorylation of two highly conserved regulatory motifs: the activation segment (Tloop) and the hydrophobic motif. The activation segment is found in the C-lobe, beside
the ATP binding site, and is connected to the N-lobe by an αC helix. Phosphorylation in
this activation segment leads to conformational changes in the αC helix that are required
for the catalytic activity of the enzyme. The αC helix also forms a part of the hydrophobic
pocket in the N-lobe and is necessary for regulatory interactions of the N-lobe with the
hydrophobic motif. The hydrophobic motif extends from the tail of the C-lobe, wraps
around the N-lobe, and inserts into the hydrophobic motif pocket, thus stabilizing the
active conformation of the αC helix. The turn motif is located at the C-terminal end, before
the hydrophobic motif, and consists of a phosphorylation site required for full kinase
activity. A groove near the active site of the kinase is involved in substrate binding and
the sequence specificity is determined by residues forming this site. The structures of
activated AGC kinases are quite similar, but those of inactive AGC kinases have revealed
a range of conformations indicating that the domains are highly flexible and disordered.
Phosphorylation locks the kinase in an ordered conformation required for its activity
(Figure 48)90.
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Figure 48: AKT2 in its active conformation (PDB ID:1O6K). pThr309 and the ATP
analog are shown in stick representation. DFG-in denotes the active conformation of the
DFG motif that is ordered in the activated kinase.
3.1.2: Protein Kinase B (AKT)
AKT serine/threonine kinase (protein kinase B) is a member of the AGC kinase family
and is an important signaling molecule in eukaryotic cells. The AKT gene is the cellular
homolog of the oncogene v-AKT and was first identified in 1977 by Staal et al. and named
c-AKT91. In 1991, the AKT kinases were cloned and identified by three independent
research groups92-94. There are 3 isoforms of AKT: AKT1 (PKBα), AKT2 (PKBβ) and
AKT3 (PKBγ), all encoded by different genes. AKT1 is expressed ubiquitously throughout
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all tissues, AKT2 is expressed in insulin sensitive tissues that include the liver, skeletal
muscle and adipose tissue and AKT3 is mostly expressed in the brain and testes95.
The three isoforms of AKT share similar structures: a N-terminal regulatory domain that
includes a pleckstrin homology (PH) domain, a hinge region that connects the PH domain
to the kinase domain and a C-terminal region required for kinase activity. The catalytic
domain of AKT is quite similar to other PKA and PKC members (Table 5).
Table 5: Sequence Similarity (in %) between AKT isoforms96
PAIR

PH domain

LINK

Catalytic

C-terminal

region

domain

extension

AKT1/AKT2

80%

46%

90%

66%

AKT1/AKT3

84%

40%

88%

76%

AKT2/AKT3

76%

17%

87%

70%

3.1.3: Regulation of AKT
3.1.3.1: Regulation by phosphorylation
One of the ways AKT can be activated is by the receptor PDGFR (Platelet Derived Growth
Factor Receptor β) through the enzyme PI3 kinase 97. The tyrosine kinase receptor
PDGFR undergoes dimerization on activation and leads to auto-phosphorylation of its
tyrosine residues: Tyr740 and Tyr751. This recruits PI3 kinase to the plasma membrane
through the Src homology 2 (SH2) domains in their regulatory subunit and the phosphotyrosine residues on the receptor. PI3 kinase then generates D3 phosphorylated lipids by
the phosphorylation of phosphoinositides at the plasma membrane. This forms PIP2 and
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PIP3. PIP3 binds to AKT at its PH domain, which results in the translocation of AKT to
the plasma membrane. In addition to this PIP3 binding, phosphorylation of Thr308 in the
T-loop and Ser473 within the hydrophobic motif are required to fully activate the enzyme.
AKT is maintained in its inactive state by the interaction of the PH domain with the kinase
domain. Once phosphoinositides bind to the PH domain, the conformation is changed
and this allows subsequent phosphorylation events to occur90.
PDK1, a serine/threonine kinase, also contains a PH domain and a kinase domain97. The
PH domain binds to PIP3 at a higher affinity than that of AKT. Under physiological
conditions, PDK1 is present as constitutively active at the plasma membrane of nonstimulated cells. Once the concentration of PIP3 at the cell membrane increases by the
stimulation of PI3K, AKT is shuttled from the cytoplasm to the plasma membrane.
Following binding of the PH domain of AKT to PIP3, PDK1 phosphorylates Thr308 at the
kinase domain in AKT. The enzyme that phosphorylates Ser473 within the hydrophobic
motif had been elusive for a long time; in 2005 this was identified as the mTOR complex2 (mTORC2). mTORC298 directly phosphorylates Ser473 in vivo and also enhances the
phosphorylation of AKT by PDK1. Other kinases such as DNA-PK and ILK1, are also
capable of phosphorylating Ser473, but this may happen in a cell or context-dependent
manner. The mTORC2 complex consists of the kinase mTOR bound to: the mTORinteracting proteins rapamycin insensitive companion of TOR (RICTOR), SAPKinteracting protein (SIN1), mammalian lethal with SEC13 protein 8 (mLST8), protein
observed with RICTOR1 (PROTOR1) and PROTOR2. In addition to this AKT is
constitutively phosphorylated at Thr450 in its turn motif, which stabilizes it and protects
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the hydrophobic motif from dephosphorylation. Phosphorylation at the turn motif happens
soon after AKT is synthesized, but it is unclear which kinase participates in it.
Other miscellaneous ways in which AKT gets activated though PI3 kinase include
Integrin-mediated99 and B cell antigen receptor (BCR)100 mediated stimulation. When
cells get attached to fibronectin receptors in the extracellular matrix through integrin
receptors on the cell surface Focal Adhesion Kinase (FAK), a tyrosine kinase in the
cytoplasm gets activated and results in the phosphorylation of PI3 kinase. This activates
PI3 kinase and activates AKT signaling through phosphoinositides. BCRs also play a role
in activation of AKT though PI3 kinase.
AKT must be phosphorylated on both the hydrophobic motif (Ser473) and at the activation
loop (Thr308) to be fully active. Phosphorylation of only the hydrophobic motif or the
activation loop results in an enzyme with just 10% of kinase activity compared to the
doubly phosphorylated enzyme. Phosphorylation of the activation loop orders the catalytic
domain and forms the substrate and ATP binding site101.
AKT is mainly negatively regulated by dephosphorylation aided by the activity of various
phosphatases. Protein phosphatase 2A (PP2A)102 is a serine/threonine heterotrimeric
phosphatase that is present in the cytosol. It dephosphorylates Thr308 and returns AKT
to its inactive conformation in the cytosol. Dephosphorylation of Ser473 is carried out by
the PH domain leucine-rich repeat protein phosphatase (PHLPP), which belongs to a
class of protein phosphatases 2C (PP2C) family103.
PTEN (Phosphatase and Tensin Homologue deleted on chromosome 10) is a tumor
suppressor gene, also referred to as MMAC1 (Mutated in Multiple Advanced Cancer 1)
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and its mutation leading to loss of function has been implicated in many forms of cancers
such as glioblastomas, prostate cancer and melanomas. The PTEN protein consists of a
tensin-like domain and a catalytic domain similar to that of protein tyrosine phosphatases.
PTEN has been found to have lipid phosphatase activity that preferentially
dephosphorylates phosphoinositide substrates. It dephosphorylates PI(3,4,5)P3 to
PI(4,5)P2; hence, PTEN negatively regulates levels of PIP3 in cells and regulates the
AKT pathway. In addition to dephosphorylation of phosphoinositides, several reports
demonstrate dephosphorylation of FAK by PTEN, leading to inhibition of cell migration
and focal adhesion. PTEN only inhibits basal PKB activity, not affecting the pathway when
stimulated by growth factors (Figure 49)104.

Figure 49: Model of AKT regulation
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The SHIP (SH (Src homology)-2 containing Inositol 5’ Phosphatase) phosphatases are
lipid phosphatases with specific 5’ phosphatase activity105,

106.

They break down

PI(3,4,5)P3 to PI(3,4)P2, removing phosphates form the 5-position rather than the 3position. SHIP1 is present in haematopoietic cells and SHIP2 in non-haematopoietic cells.
SHIP inhibits the AKT pathway when stimulated by growth factors. Activated PI3-kinase
phosphorylates SHIP and it then translocates to the plasma membrane, leading to its
phosphatase activity. Although both PTEN and SHIP regulate the level of PIP3 in cells,
PTEN has the primary responsibility of controlling the mitogenic ability of these
phosphoinositides because it dephosphorylates at the 3’ position and this has been
demonstrated in knockout mice107, 108. Phosphorylation at the 3’ position is a necessity for
binding to the PH domain of AKT.
3.1.3.2: Redox Regulation
AKT displays an intramolecular redox sensitive disulfide bond between Cys296 and
Cys310 in its activation loop. Formation of this disulfide bond inactivates the enzyme that
has been doubly phosphorylated at Thr308 and Ser473, suggesting that AKT is a redoxregulated protein. A crystal structure of inactive AKT2 with this disulfide bond has been
reported. Formation of this disulfide bond changes the conformation of the activation loop
and sterically hinders both substrate and ATP binding. It also promotes the
dephosphorylation of Thr308 by PP2A. Under conditions of oxidative stress, AKT forms
the disulfide bond and targets the protein for inactivation by PP2A. Also this
intramolecular disulfide bond can be reduced by glutaredoxin in vitro, restoring AKT to its
active, functional conformation109.
3.1.4: Downstream substrates of AKT
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The minimal substrate sequence for AKT has been found to be R-X-R-X-X-S/T-B, where
X represents any amino acid and B represents bulky hydrophobic residues 110. A
representation of the most common downstream substrates is shown in Figure 50. These
substrates are phosphorylated by AKT leading to either their activation or inhibition.
Regulation of these substrates by AKT-mediated phosphorylation leads to the control of
various cellular processes111.

Figure 50: Substrates of AKT in the cell. AKT mediated phosphorylation of these
substrates lead to their activation (green arrow) or inhibition (red blocking arrow)
3.1.4.1: Cell survival
AKT enhances cell survival by inhibiting the function of various proteins that participate in
apoptosis: e.g. AKT phosphorylates the pro-apoptotic BH3-only protein BAD112, which is
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a member of the Bcl-2 gene family and inhibits it. When BAD is phosphorylated by AKT,
it forms a homodimer and releases Bcl-2 to inhibit cytochrome c-mediated apoptosis. AKT
also phosphorylates the transcription factors FOXO113 and p53114. Phosphorylation of
FOXO by AKT results in its exclusion from the nucleus thereby prevents transcription of
its target genes that mediate apoptosis, cell-cycle arrest and metabolic processes. AKT
promotes cell survival by phosphorylating MDM2115, an E3 ubiquitin ligase that is
responsible for degradation of p53, resulting in its translocation into the nucleus. Two
important transcriptional targets of p53 are the BH3-only proteins Puma and Noxa that
are important in p53 mediated apoptosis. AKT also phosphorylates GSK3, inhibiting the
enzyme. An important target for GSK3 is the Bcl-2 family member MCL-1, which is found
to enhance cell survival. Human pro-caspase-9 has been found to be phosphorylated by
AKT and this correlates with the decrease in protease activity of caspase-9 in vitro116.
3.1.4.2: Cell Growth
AKT plays a significant role in promoting cell growth (i.e. increase in cell mass) through
activation of mTOR complex 1 (mTORC1 or the mTOR-raptor complex)117. This complex
is regulated by both nutrients and growth factor signaling. AKT-mediated phosphorylation
inhibits TSC2 (tuberous sclerosis complex 2) function and TSC2 is a negative regulator
of mTORC1 signaling. This allows RHEb-GTP to activate mTORC1 signaling, which
initiates translation and ribosome biogenesis.
The AKT substrate PRAS40118 has also been found to be involved in mTORC1 regulation.
PRAS40 associates with mTORC1 and negatively regulates mTORC1 signaling.
Phosphorylation of PRAS40 by AKT results in its dissociation from mTORC1.
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3.1.4.3: Cell Proliferation
Phosphorylation of p27 cyclin-dependent kinase inhibitor by AKT leads to its cytosolic
sequestration and thus prevents its localization to the nucleus119. This negates its cellcycle inhibitory effects. AKT also phosphorylates the cyclin dependent kinase p21,
thereby inhibiting it120.
GSK3 phosphorylates the G1 cyclins cyclin D and cyclin E and the transcription factors
c-jun and c-myc, thus marking them for proteosomal degradation. These proteins play a
critical role in the G1-to S- phase cell-cycle transition, and their enhanced stability by the
inhibition of GSK3 by AKT increases the rate of cell proliferation. mTORC1 is a critical
regulator of cell proliferation and the phosphorylation of TSC2 and PRAS40 by AKT
regulates cell proliferation.
3.1.4.4: Angiogenesis
AKT signaling plays an important role in angiogenesis in both endothelial cells and tumor
cells. In endothelial cells the pathway is activated by vascular endothelial growth factor
(VEGF)121. The phosphorylation of the above-mentioned targets contributes to
endothelial cell survival, growth and proliferation. In addition to this, AKT phosphorylates
endothelial nitric oxide (NO) synthase (eNOS). The activated eNOS releases nitric oxide
and this results in stimulation of vasodilation, vascular remodeling and angiogenesis 122.
Also through mTORC1 dependent translation, AKT leads to the increased production of
hypoxia inducible factor α (HIF1α and HIF2α)123. This leads to expression and secretion
of VEGF and other angiogenic factors124. Also, AKT1 in endothelial cells is required for
proper endothelial cell migration.
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3.1.4.5: Cellular Metabolism
AKT signaling regulates nutrient uptake and metabolism by its action on a variety of
downstream targets. AKT acutely stimulates glucose uptake in response to insulin by
associating with glucose transporter 4 (Glut4)-containing vesicles on insulin stimulation
of adipocytes, and this leads to Glut4 translocation to the plasma membrane 125. The
protein Rab-GAP AS160126 also known as TBC1 domain family member 4 (TBC1D4) is
an important target that is phosphorylated by AKT in response to insulin. Phosphorylation
of AS160 inhibits its GAP activity, allowing Glut4 vesicle translocation. Glut1 is the main
glucose transporter in most cell types and AKT mediated activation of the mTORC1
pathway leads to increased transcription of the Glut1 gene, through HIFα-mediated
transcription.
AKT activation also alters glucose and lipid metabolism in cells. It stimulates the
association of hexokinase isoforms with the mitochondria where they more readily
phosphorylate glucose to glucose-6-phosphate. Inhibition of GSK3 by AKT activates
glycogen synthase leading to increased glycogen synthesis. AKT activation also
increases the rate of glycolysis due to its ability to promote expression of glycolytic
enzymes through HIFα. FOXO1 promotes glucose production in hepatocytes and
regulates the differentiation of cells involved in metabolic control. AKT-mediated inhibition
of FOXO1 also contributes to glucose homeostasis127.
GSK3 promotes the degradation of sterol regulatory element-binding proteins (SREBPs)
that are transcription factors, which turn on the genes involved in cholesterol and fatty
acid biosynthesis. AKT-mediated inhibition of GSK3 increases SREBP stability and
increases lipid production128.
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3.1.5: Rationale for inhibiting AKT
The hyperactivation of AKT is commonly seen in many cancers and through multiple
cellular mechanisms results in tumor cell survival and enhanced resistance to apoptosis.
The most frequent mechanism by which AKT is hyperactivated involves loss or
downregulation of the PTEN tumor suppressor104, 107, 108, 129. Various reasons for targeting
AKT for anti-cancer therapeutics are as follows;
1. Expression of PTEN in Jurkat T cells inhibited AKT activation and increased
apoptosis130. Introduction of wt-PTEN into tumor cell lines (glioblastoma, renal cell
carcinoma, breast and prostate cell) that are mutant for PTEN resulted in either
cell cycle arrest or apoptosis131,

132.

Expression of AKT protected cells from

apoptosis mediated by PTEN130.
2. Antisense AKT2 RNA expression in PANC-1 cells reduced their tumorigenicity in
nude mice133.
3. Expressing a kinase-dead (KD) AKT mutant in tumor cells expressing activated
AKT induced apoptosis. This did not affect normal cells or tumor cells with low
levels of activated AKT. On a similar note, expression of PTEN induced apoptosis
in several tumor cells that lack PTEN expression, but not in cells having wt-PTEN
or normal cells. These results suggest that inhibition of AKT signaling would not
be toxic to normal cells134.
4. In neural cells, expression of constitutively-active AKT enhances IGF-1-mediated
survival, but expression of a dominant-negative allele of AKT increased
apoptosis135.
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5. Introduction of anti-AKT-1 single chain antibodies into tumor cells resulted in
reduced phosphorylation of GSK3α/β, leading to apoptosis in three cell lines with
constitutive AKT activity, and inhibited tumor growth in a transgenic mouse
model136.
6. A peptide that binds to AKT, “AKT-in”, inhibited cellular proliferation and antiapoptosis in vitro and also tumor growth in vivo137.
7. Reintroduction of a phosphatase PHLPP (PH domain/leucine-rich repeat protein
phosphatase) that directly dephosphorylates AKT into a glioblastoma cell line
caused suppression of cell growth138.
8. Lung and breast cancer cell lines displayed inhibition of AKT signaling on treatment
with the PI-3 kinase inhibitors Wortmannin and LY 294002139, 140.
9. Studies indicate that blocking AKT activation is the key reason for the therapeutic
efficacy seen with the drugs Gleevec141, Trastuzumab142, Gefitinib104 and Tarceva.
Frequent alterations seen with the AKT pathway in human cancer include the activation
of growth factor receptors (GFRs) by ligand stimulation, or by overexpression/mutation of
the receptor, leading to upregulation of AKT signaling. Activation of oncoproteins in the
pathway like AKT itself, RAS, PI3-K, EIF4E by overexpression or activating mutations are
seen in many cancers. Loss or inactivation of tumor suppressors such as NF1, VHL,
PTEN, TSC2/1, LKB1 also contribute to deregulation of the pathway and subsequent
tumor formation. Multiple human cancers that include carcinomas, glioblastomas and
various hematological malignancies all display aberrant AKT activation97, 129, 143, 144 (Table
6)
Table 6: AKT activation in human cancers129
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Tumor type

% Tumors
with active
AKT

Glioma

~55

Thyroid carcinoma

80-100

Breast carcinoma

20-55

Small-cell lung carcinoma

~60

NSCLC

30-75

Gastric carcinoma

~80

Gastrointestinal stromal tumors

~30

Pancreatic carcinoma

30-70

Bile duct carcinoma

~85

Ovarian carcinoma

40-70

Endometrial carcinoma

>35

Prostate carcinoma

45-55

Renal cell carcinoma

~40

Anaplastic large-cell lymphoma

100

Acute myeloid leukemia

~70

Multiple myeloma

~90

Malignant mesothelioma

~65

Malignant melanoma

43-67

3.1.6: Inhibitors of AKT
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Based on the strong rationale for targeting AKT, development of inhibitors for AKT is an
active field of research in both the pharmaceutical industry and academia. Currently, there
are multiple compounds that inhibit AKT in clinical trials, with two of them in phase-2
studies (MK2206 and GSK2141795). This underscores the importance of developing
inhibitors for targeting AKT145.
AKT has multiple binding pockets where binding of inhibitors would block its downstream
effects. One of the most studied pockets is the PI(3,4,5)P3 pocket on the PH domain. The
PH domain binds to PI(3,4,5)P3 and PI(3,4)P2. The interactions are mostly charge-driven
through the D3 and D4 phosphates, with lysines and arginines in the pocket. Compounds
that block the binding of phosphoinsositides with the PH domain have been shown to
inhibit the growth of transformed cells. Their mode of inhibition will prevent AKT
translocation to the plasma membrane and subsequent activation, but compounds in this
class have problems with solubility, pharmacokinetics and potency and remain largely as
probe compounds to study kinase activity. In the kinase domain, the most studied is the
ATP binding pocket. However, given the high homology of the ATP pocket with other
kinases, it is quite difficult to design compounds that bind selectively to the ATP pocket in
AKT.
3.1.6.1: Phosphatidylinosotol Analogues
The lead compound in this class was DPI (Figure 51), which has an IC50 of 35 µM in the
HT-29 colon cancer cells146. This compound is an analogue of phosphatidyl-myo-inositol,
while members of the class lack the 3-position hydroxyl group, which was removed so
that it cannot be phosphorylated by PI-3 Kinase. Further analogues of this compound led
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to removal of the two labile ester groups to ether linkages resulting in DPIEL that has an
IC50 of 2.1 µM in the HT-29 colon cancer cell line147.
The analog PIA5 was found to have an IC50 of 4.13 µM in the H1603 cell line. Analogues
of this class of compounds inhibited phosphorylation targets downstream of AKT. They
also increased apoptosis in cells with higher levels of constitutive AKT activity148.
The compound Perifosine, KRK-0401 (licensed to Aeterna Zentaris) has an IC50 = 4.7 µM
against AKT and a GI50 = 5 µM in the PC-3 prostate carcinoma cell line. It was shown to
be active in phase-2 trials as a combination therapy in colorectal cancer and multiple
myeloma. But it has been withdrawn from phase-3 trials145, 149, 150.

Figure 51: Structures of Phosphatidylinositol analogues
3.1.6.2: ATP-Competitive Inhibitors
There is a high degree of homology in the ATP binding pocket among AKT, PKA and
PKC. Hence, compounds that bind to the ATP binding site in AKT have to be tested for
PKA and PKC binding as a measure of selectivity.
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High-throughput screening of the Abbott compound collection led to the identification of
3,5-disubstituted pyridine analogues that bind to the ATP binding pocket of AKT and these
compounds have been classified as ATP-competitive, reversible pan-AKT kinase
inhibitors that inhibit AKT activity in vitro and in vivo (Figure 52)151. Compound 95 has an
Ki of 5 µM against AKT1. The chlorine atom was removed, the pyridine was replaced with
an indazole and the methyl group was substituted with a 3-indole to give compound 96
that had a potency of 0.00016 µM and was 40-fold selective over PKA. Compound 96
displayed a dose dependent decrease in cell growth and lowered AKT mediated
phosphorylation of downstream targets. It displayed an IC 50 = 0.1 µM in MiaPaCa-2
human pancreatic cancer cells and decreased tumor growth in mouse xenograft models,
however this compound displayed poor pharmacokinetic properties and displayed QT
prolongation and hypotension152. Compound 96 was further modified to give 97, which
displayed a Ki = 0.0006 µM but with a lowered selectivity profile towards PKA. Despite a
lowered potency and selectivity towards AKT, compound 97 exhibited no statistically
significant hypotension when dosed orally in mice153.

Figure 52: Structures of Abbott’s 3,5-disubstituted pyridine analogues
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In 2008 GSK described a series of AKT inhibitors analogued from the oxadiazole leads
98 and 99154. Using molecular modeling and co-crystalization the preclinical candidate
100 (GSK690693) was identified (AKT1 IC50 = 0.002 µM, AKT2 IC50 = 0.013 µM, AKT3
IC50 = 0.009 µM, Figure 53). The compound 100 inhibited GSK3β phosphorylation in cells
and displayed a dose dependent reduction in tumor volume in BT474 breast carcinoma
xenograft mice155. The compound was withdrawn from phase-1 clinical trials while testing
an IV formulation of the agent for undisclosed reasons145.

Figure 53: Structures of ATP competitive inhibitors from GSK
3.1.6.3: Allosteric inhibitors
Compounds 101 and 102 were identified from high throughput screening (Figure 54).
Kinetic analyses indicated that neither compound competed with ATP nor the peptide
substrate, also they were not active against AKT3, mutants lacking the PH domain or
other closely related AGC kinases156.
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Figure 54: Allosteric inhibitors of AKT
Further work showed that these inhibitors prevented phosphorylation of Thr308157 by
PDK1. This led to a description of a model for this novel mode of inhibition wherein the
inhibitors only bind to a site that exists in presence of the PH domain, and stabilize AKT
in a closed conformation that is not capable of being activated by PDK1. This has been
proved by further studies that show the residue Trp80 in the PH domain forms a cavity in
AKT1, but is absent in AKT3. Also in vivo FRET data shows that compound 102 locks
AKT into its inactive conformation preventing its activation by phosphorylation.
Merck, in 2005, identified the compound 103 (Figure 55), a dual AKT1/2 allosteric
inhibitor from the lead 102158. Compound 103 displayed PH-domain dependent inhibition
and it inhibited AKT and AKT dependent phosphorylation in a mouse pharmacodynamics
assay. Due to the poor physical properties of compound 102, further work consisted of
replacing the 2,3-diphenyl-quinoxaline core with a quinoline core to give compound
104158. This analog displayed better physical properties, but to reduce molecular weight
and increase basicity, the quinoline core was truncated to a pyridine to give compound
105, a potent AKT1/AKT2 inhibitor with excellent aqueous solubility at pH 4.5159.
Furthermore, chemical manipulation of the scaffold followed trying to improve aqueous
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solubility, balancing biochemical and cell based activity and removing hERG liabilities,
leading to the compound [1,2,4]triazolo[3,4-f][1,6]napthypyridine 106160.

Figure 55: Allosteric inhibitors of AKT from Merck
Merck also disclosed their recent allosteric AKT inhibitor MK-2206 (Figure 56), which is
based on the triazolone-napthypyridine core. It also has an allosteric mode of action and
currently is in phase-2 studies161.

Figure 56: Structure of MK-2206
3.1.6.4: Covalent inhibitors
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A

high-throughput

screening

effort

in

2007

led

to

the

discovery

of

the

pyanonaphthquinone lactones 107 and 108 (Figure 57). These compounds were found
to be highly potent and selective inhibitors of AKT162.

Figure 57: Structure of PNQ lactones
The mechanism of inhibition was found to be irreversible, with an adduct being formed
with the pyanonaphthquinone and Cys310 and or Cys296 present in the T-loop of AKT1.
A bioreductive alkylation mechanism was proposed wherein the quinone gets reduced
under in vitro and in vivo conditions and forms a quinone methide 109’ that acts as a
Michael acceptor. This reacts with the nucleophilic cysteine 310 in the T-loop of AKT and
forms the adduct 110. The formation of this activated quinone methide 109’ by reduction
is essential for the activity of these compounds (Figure 58). Analogues that lack this
lactone ring are inactive as AKT inhibitors up to concentrations of 20 µM163.
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Figure 58: Bioreductive alkylation mechanism postulated for PNQ lactones
3.1.6.5: Substrate-Mimetic Inhibitors
These compounds are more selective than all the earlier mentioned classes of inhibitors
due to the natural selectivity filter of the kinase substrate binding pocket to recognize only
a limited number of substrates. The substrate binding site offers potential for a large
number of interactions for small molecules that can mimic a peptide.
Activated AKT2 has been crystallized with the GSK3β 10 residue substrate sequence
(3GRPRTTSFAE12) and a non-hydrolysable ATP analog (AMP-PMP)164. A similar
shortened sequence 111 (GRPRTSSF), was reported by Alessi et al. to have a Km of 8
µM110. This shortened sequence was used by Hamilton et al. to develop substratemimetic inhibitors of AKT165.
Initially, they substituted the serine, which can be phosphorylated, for a valine to give
compound 112. More rigidity was introduced into the sequence by substituting Thr-Thr
with para-aminobenzoic acid and a hydrophobic group; benzyl was added to the C89

terminal Phe to get compound 113 (Figure 59). This was followed by removal of the Nterminal GRP- sequence to obtain the compound 114. Compound 114 displayed a 3-fold
decrease in affinity compared to 113, but Hamilton et al. were able to shorten the chain
by 3 residues. Further optimization led to the extension of the linker between the paraaminobenzoic acid and the guanidine group and addition of an N-benzyl acetamide group
to fill the pocket that was occupied by threonine side chain to get compound 115.

Figure 59: Peptidomimetic analogues
Livnah et al. prepared the novel heptapeptide inhibitor 116 (Figure 60), which was found
to have more than 50-fold selectivity for AKT over PKA166. Peptide 116 selectivly killed
prostate cancer cells where in AKT was upregulated but not normal cells or cancer cells
in which AKT was not activated. Also, the compound was effective in two prostate cancer
mouse models.
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Figure 60: Livnah Heptapeptide inhibitor
Based on the structure of compound 115 and the 10 residue GSK3β peptide sequence
(3GRPRTTSFAE12), Hamilton et al. designed compound 117 using the docking software
GOLD (Figure 61)167. The compound was designed based on their observation that the
N-terminal Gly3, Arg4 and Pro5 are not needed, the Thr7 and Thr8 are replaced with a
p-aminobenzoic acid scaffold, and addition of a benzyl to the C-terminal Phe10 moiety
increased affinity. The C-terminal dibenzyl group mimics Phe10 and the benzyl group
from compound 115. Addition of a phenyl substituent to the 3-position of the paminobenzoic acid scaffold gave 118 with an IC50 = 84 µM. Further rounds of analoguing
led to the substitution of the C-terminal dibenzyl with a di-p-cyanobenzyl group, and gave
the compound 119 that displayed a fourfold increase in inhibition. Substitution of a
naphthyl group on the 3-position of the p-aminobenzoic acid gave compound 120, and
replacement of the ethylamine-linker with a glycine linker led to the compound 121 with
about an eightfold increase in inhibition as compared with the computationally designed
lead 117. This work provides the example that the substrate binding site of AKT can be
targeted with small molecule peptide mimetics.
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Figure 61: Structures of substrate-competitive peptidomimetics
Following the above mentioned work, Valle et al. reported synthesis of GSK3β peptide
small molecule mimetics168. They used the lead GSK3β peptide (3GRPRTTSFAE12) as a
lead and replaced the Thr7-Thr8 residues with a bicyclic-carbamate scaffold consisting
of a proline, a 6-membered carbamate ring as a dipeptide surrogate and removed the Nterminus 3GPR5 segment (Figure 62). Also they introduced the Val-Phe-NHBn fragment
at the C-terminus as reported earlier by Hamilton et al. Further optimization led to the
compound 122, which is ~5 fold more potent than compound 121.
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Figure 62: Peptidomimetic reported by Valle et al.168.
3.2 Rationale for the work
3.2.1 Utilizing the Substrate Binding Pocket of AKT
AKT is a widely expressed Ser/Thr kinase that phosphorylates various substrates in the
cell that are involved in regulation of cellular functions such as cell proliferation,
transcription, migration, apoptosis, cellular differentiation and metabolism. Persistent
activation of the AKT pathway leads to human oncogenesis. Disregulation of AKT kinase
activity is seen in many human cancers such as ovarian, breast, thyroid and colon
cancers129, 143. Suppression of this aberrant AKT signaling by using small molecules that
target AKT kinase has been shown to increase apoptosis and reduce cell proliferation in
tumor cells that in particular express high levels of activated AKT. The development of
small molecules that target AKT kinase is currently a highly active area of research with
many such compounds currently in clinical trials169.
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The majority of the small molecule AKT kinase inhibitors use the ATP binding site for
binding to the kinase. The problem with such an approach is achieving selectivity with
other homologous members in the AGC kinase family such as PKA and PKC. Selective
binding in the ATP pocket of kinases is challenging, as this pocket is highly conserved
among other kinases, and achieving specificity requires utilizing the subtle differences in
residues lining these pockets. Hence, these inhibitors tend to compete with other
enzymes that utilize ATP having similar binding regions and also with high cellular
concentrations of ATP. This competition with millimolar concentrations of ATP in the cell
explains why ATP mimetics require much higher concentrations for tumor growth
inhibition compared to recombinant enzyme assays170.
One significant problem with using kinase inhibitors that target the ATP pocket is the
development of drug resistance. This is because the mutations that accumulate in the
ATP binding site of the kinase, as was observed in patients with CML undergoing
treatment with Imitinib. The mutated residues found in the ATP binding site were highly
conserved among kinases, so use of the substrate binding pocket potentially may obviate
that problem. Such a strategy has already been used sucessfully for targeting
Extracellular signal Regulated Kinase (ERK), Polo-like Kinase 1, Abl kinase, Insulin-like
growth factor-receptor 1 (IGF-RI) and AKT170-172.
Substrate-mimetic inhibitors offer a new paradigm in the targeting of protein kinases by
blocking phosphorylation, and thus not competing with ATP. The enzyme substrate
binding site has evolved to recognize specific substrate sequences in contrast to the ATP
binding site. These sites are adapted individually for each kinase to recognize a particular
substrate sequence in the cell. Therefore, they offer a large number of specific potential
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interactions that could be used for designing a small molecule to target these sites,
compared to the corresponding ATP pocket. Hence, exploiting the substrate specificity of
these sites will allow the design of a more specific inhibitor for AKT kinase 170.
3.2.2: Utilizing a Covalent Mode of Inhibition
The problem with using the substrate binding site is the large binding pocket and the
extended binding conformation that many of the substrates use. This creates a problem
where a large binding space has to be targeted for the design of an effective and specific
inhibitor. Although the substrate peptides possess high selectivity and specificity in
binding to the kinase, these sequences are poor inhibitors due to their lack in potency.
The usual approaches used to increase potency with these peptides involve screening
combinatorial libraries of peptides173, incorporation of unnatural amino acids166, 174 and
bisubstrate approaches that link the peptide to an ATP pocket binder175. We chose to
develop a covalent substrate competitive binding approach to increase potency.
Covalent mechanisms of binding to proteins has been traditionally shunned in drug
development because these compounds were thought to form highly reactive metabolites
and cause drug allergies. But, about 30% of the drugs on the market that target an
enzyme do act through a covalent mechanism176. The risk of toxicity by covalent inhibitors
can be minimized by optimization of the non-covalent binding interactions and by
modulation of the reactivity of the electrophile. This would lead to more target specificity
and mitigate unwanted side reactions with nucleophiles in vivo177.
The advantages of a covalent mechanism of action include an improved biochemical
efficiency due to irreversible binding, less frequency of dosing due to longer duration of
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action, increased efficacy due to the lower concentrations required, and the potential to
avoid drug resistance due to continuous suppression of the target. Also, targets with
shallow binding sites could be inhibited. There has been a recent surge in the
identification of covalent inhibitors with compounds from the programs targeting EGFR,
BTK, FAAH and MetAP2 progressing to phase II and III clinical trials172, 176, 178.
3.2.3: Identification of a Nucleophilic Residue in AKT
The pyranonaphthoquinone (PNQ) lactone class of natural products potently and
selectively inhibits AKT by alkylating Cys310 in the activation loop. The PNQ lactones
have been shown to form a covalent adduct with Cys311 in AKT2 (Figure 59)162, 163.
Other non-selective cysteine alkylating electrophiles like N-ethylmaleimide179, iodoacetic
acid180 and 4-hydroxynonenal181 (4-HNE, a Michael acceptor) have been shown to
alkylate Cys310 in AKT. An iodoacetamidate activity-based probe has been shown to
alkylate Cys310 in AKT by Cravatt et al. by mass spectrometry182.
3.2.4: Identification of an appropriate Substrate Mimetic for AKT
The X-ray crystal structure of activated AKT2 with the GSK3β 10 residue substrate
sequence (3GRPRTTSFAE12) and a non-hydrolysable ATP analog (AMP-PMP) was
reported in 2002164. The peptide is phosphorylated by AKT on Ser9 and includes the
consensus sequence for AKT (RXRXXSF). The crystal structure shows the GSK3β
peptide to be bound in an extended conformation, with discrete sections of the β-strand
on either side of Ser9. According to the crystal structure, Phe10 of the GSK3β peptide
aligns adjacent to AKT Cys310 (Figure 63). The distance measure from the peptide
backbone of GSK3β to Cys310 is ~6.0 Å.
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Figure 63: Distance between Cys310 and peptide backbone of GSK3β peptide
Hamilton and coworkers identified the small molecule peptidomimetic 121 of AKT by
analoguing from the GSK3β peptide. In order to understand the spatial relationships of
compound 121 binding to AKT, we docked this compound using GOLD into the substrate
binding pocket of the AKT co-crystal structure (Figure 64)167. The docking pose we
obtained closely matches that reported by Hamilton. The docking model predicts that one
of the two p-cyanobenzyl rings on the C-terminal end of the molecule is located ~5.5 Å
from the thiol of Cys311 (AKT311 numbering).
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Figure 64: Docked Structure of compound 121
3.2.5: Initial Design of Compounds and Selection of the Electrophile
Based on our docking model that predicts the distance of ~5.5 Å from the nucleophile of
Cys310 in AKT to the p-cyanobenzyl group, we reasoned that we could replace this Cterminal moiety in 121 (Figure 65) with appropriate electrophiles that would react with the
sulphur of Cys310. To synthesize covalent inhibitors of this type, we needed to identify
electrophiles that can be installed on the aniline nitrogen and that could inhibit AKT. As
our initial screen we decided to screen α-haloacetamides, maleimides, epoxides,
acrylamides and vinyl ketones. These electrophiles have been reported to alkylate
cysteines, when used in various kinase inhibitors176-178. For the ease of synthesis and
quick screening for inhibition of AKT activity, we initially decided to use only the C-terminal
end or the right hand fragment of compound 121 to install the electrophiles. We reasoned
that from the most potent compound obtained from this set, we will elaborate by adding
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the N-terminal end of the Hamilton fragment to result in a potent and selective substrate
mimetic covalent inhibitor for AKT.

Figure 65: Design of the first set of compounds
3.3: Synthesis and Biological evaluation of the First Set of Compounds
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3.3.1: Synthesis of α-haloacetamides

Figure 66: Synthesis of α-haloacetamides
The α-haloacetamides were synthesized either starting from aniline 123 or from 4nitroaniline 124 as shown in Figure 66. The electrophiles were installed using either
chloroacetyl chloride or bromoacetyl chloride using standard acid chloride coupling
conditions with triethylamine as the acid-trap. Compound 131 was prepared by reductive
amination from 4-nitroanilline and 4-cyanobenzaldehyde using the acid stable sodium
triacetoxborohydride as the reductant. The iodo-acetamides 127, 128 and 133 were
prepared using a Finkelstein reaction by refluxing the chloro-acetamides 125, 126 and
132 with excess sodium iodide in acetone.
3.3.2: Synthesis of acrylamides
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Figure 67: Synthesis of the acrylamides
The acrylamides 135, 136 and 137 were prepared form aniline 123, 4-nitroaniline 124
and compound 131 using acryloyl chloride by acid coupling conditions using triethylamine
as the base (Figure 67). Acrolyl chloride was added at 0 0C to the reaction and they were
allowed to react overnight at room temperature.
3.3.3: Synthesis of Epoxide

Figure 68: Synthesis of compound 138
The compound 138 was synthesized from the acrylamide 135 by refluxing it with the
oxidant m-CPBA in dichloromethane (Figure 68).
3.3.4: Synthesis of Maleimides
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Figure 69: Synthesis of the maleimides 141, 144 and 145
The maleimides 141 and 145 were synthesized from the iodo-acetamides 127 and 133
according to Figure 69. Maleimide itself cannot be used in a base catalyzed reaction
because of its reactive Michael-acceptors. Hence it was protected using furan in a heteroDiels Alder cyclization to give compound 139. This compound was then reacted with
compounds 127 and 133 in an SN2 reaction with potassium carbonate as the base to
obtain the intermediates 140 and 145’. The furan protecting group was removed using a
retro Diels-Alder reaction by heating the compounds 140 and 145’ in anisole at 160 0C
for four hours to give the maleimides 141 and 145.
Compound 143 was prepared by a SNAr reaction using 2-aminoethanol as the nucleophile
and 142 as the electrophile. The primary alcohol was substituted with maleimide in a
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Mitsonobu reaction to give the compound 144. Mitsonobu reactions use much milder
conditions and allow the use of unprotected maleimide itself as the nucleophile.
3.3.5: Synthesis of Vinyl ketones

Figure 70: Synthesis of Vinyl ketones 148 and 151
The vinyl ketone 148 was prepared starting from Boc-Phe-OH 146, which was converted
to the Weinreb amide 147 using EDCI as the coupling reagent and HOBt to prevent
racemization (Figure 70). The Weinreb amide was reacted with the Grignard reagent
vinyl magnesium bromide to obtain the vinyl ketone 148. The vinyl ketone was found to
be both acid and base labile, hence the N-Boc protecting group was removed by first
reducing the ketone using sodium borohydride in methanol to obtain a diastereomeric
mixture of alcohols 149. From this compound 149, the N-Boc group was removed using
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a mixture of TMSOTf and 2,6-lutidine. The primary amine was coupled to p-nitrobenzoic
acid to give a diasteromeric mixture of alcohols 150. The secondary alcohol was oxidized
using Dess Martin reagent in dichloromethane to give the vinyl ketone 151.
3.3.6: Biochemical evaluation of the compounds
We evaluated the first set of compounds in a biochemical fluorescence assay (Z’-LYTE
kinase assay, Ser/Thr kit 6, Invitrogen) using commercially available recombinant AKT1
(Invitrogen, P2999). This assay uses a proprietary peptide substrate that contains the
AKT1 consensus sequence and is labeled with a coumarin on one end and fluorescein at
the other. During the kinase reaction, the peptide substrate is phosphorylated by AKT1.
After the reaction is stopped, the FRET signal between the coumarin and fluorescein is
detected only on the phosphorylated peptide. Unphosphorylated peptide is cleaved by a
site-specific protease when the reaction is developed, disrupting the FRET signal from
the unphosphorylated substrate. Addition of compounds to the assay that inhibit
phosphorylation of the substrate by AKT1 results in a decrease of the FRET signal. This
assay detects functional inhibitors of AKT1 independent of mechanism of action.
Compounds 125 to 151 were evaluated by this assay in triplicate over a concentration
range of 8 nM to 100 µM. The data we obtained is shown in Table 7.
Table 7: Evaluation of compounds against AKT1
AKT1 IC50
Compound

AKT1 IC50
Compound

(µM)
125

(µM)

>100

141

104

1.55

129

10.59

144

1.79

127

3.25

145

1.97

128

2.33

138

>100

133

1.11

148

0.58

135

>100

151

0.32

Based on the above IC50 data, the epoxide 138, acrylamide 135 and the α-chloro
acetamide 125 were inactive as AKT1 inhibitors with IC50 > 100 µM. The α-bromo 129
and α-iodo acetamides 127, 128, 133 and the maleimides 141, 144 and 145 were all
active in the low-micromolar range of concentrations. However, the vinyl ketones 148 and
151 inhibited AKT in the submicromolar range of concentration, with an IC 50 of 0.58 µM
and 0.32 µM.
Among the α-haloacetamides, the inhibition was dependent on the reactivity of the
electrophile. The α-chloro acetamides 125 were inactive, and the iodo-acetamides 127,
128, 133 were ~4 fold active, as compared to the bromo-acetamide 129. Among the iodoacetamides, compound 133 was twice as active as compared to 127 and 128. This can
be explained by the additional interactions made by the p-cyanobenzyl moiety.
Among the maleimides 141, 144 and 145, there were no differences in IC50s among the
compounds with these variations in structure. This suggests that the interactions were
mostly covalent binding and the addition of more binding elements did not make any
difference in the IC50.
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The most potent compounds in this series were the vinyl ketones 148 and 151. The most
potent compound 151 has the p-nitrobenzyl group instead of the N-Boc group. This is the
fragment present in the Hamilton compound 121, which can be elaborated on to add the
N-terminal end of the compound.
3.3.7: Synthesis and biochemical evaluation of the reduced analogues and with the
alkyne handle
Having identified the most potent compound in the series, we decided to confirm that the
mechanism of inhibition was covalent. We inactivated the vinyl ketone electrophile by
reducing it to the ethyl ketone using catalytic hydrogenation over palladium on charcoal
to give the compounds 152 and 153 (Figure 71).

Figure 71: Synthesis of 152 and 153
To determine the selectivity of the compounds in a cellular context, as compared with the
purified recombinant enzyme, we made the vinyl ketones with an alkyne handle attached
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to the N-terminal: 156 and 161 (Figure: 72 and Figure: 73). The alkyne handle can be
used to attach detection or purification tags to the compound in a biological sample. This
will allow the identification of the compound-protein adduct in the sample.

Figure 72: Synthesis of compound 156
The compound 156 was synthesized starting from phenylalanine 146, to which the
propargyl carbamate group was installed using propargyl chloroformate and sodium
hydroxide as the base. This compound was converted to the Weinreb amide using the
coupling reagent EDCI to give compound 155. This was reacted with the Grignard reagent
vinyl magnesium bromide in THF to give the compound 156.
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Figure 73: Synthesis of compound 161
Compound 161 was synthesized starting from the mixture of the diastereomeric alcohols
150. The nitro group was reduced to the amine using tin chloride dihydrate in refluxing
ethylacetate to give compound 157. The secondary alcohol was then protected as the
TBS ether using TBSOTf and 2,6-lutidine as the base to give 158. The propargyl group
was then installed onto the amine using propargyl chloroformate and triethylamine as the
base, followed by removal of the TBS ether using TBAF to give compound 160. The
secondary alcohol was oxidized using Dess-Martin periodane to give compound 161.
To confirm the covalent mechanism of action of compounds, the inactivated analogues
152 and 153 were screened for inhibition of AKT phosphorylation using the Z-LYTE assay
as described before. Also, to determine the selectivity of the compounds for AKT, we
screened the alkyne analogues 156 and 161 against c-AMP-dependent protein kinase A
(PKAα) (Table 8). PKAα is a member of the AGC kinases and is most identical to AKT,
sharing 43% sequence identity in its kinase catalytic domain183. Hence, the fold selectivity
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obtained for AKT over PKA is a probable measure of how selective the compound will be
in a cellular context.
Table 8: IC50 of compounds against AKT1 and PKAα
Compound

AKT1 IC50 (µM)

PKAα IC50 (µM)

152

>100

nd

153

>100

nd

148

0.58

52.6

151

0.32

>100

156

2.44

161

0.82

13.47

To confirm that the vinyl ketones 148 and 151 inhibit AKT by a covalent mechanism of
action, we tested the inhibition of AKT by the inactivated analogues 152 and 153. These
compounds have their electrophilic moiety removed by reduction of the vinyl ketone to
the ethyl ketone. As shown in Table 8, compounds 152 and 153 are inactive towards AKT
with IC50s > 100 µM. This confirms that the mechanism of action of these compounds is
by covalent inactivation of AKT.
The first step in determining the selectivity of these compounds towards AKT is by
screening them against c-AMP-dependent protein kinase A (PKAα), which is a member
of the AGC kinase family. As shown in Table 8, the Boc-Phe-vinyl ketone 148 inhibits
PKAα with an IC50 of 52.6 µM, hence is ~90 fold more selective for AKT1 than PKAα,
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whereas the p-nitrobenzoyl-Phe-vinyl ketone 151 was essentially inactive towards PKAα
(IC50 > 100 µM) displaying a selectivity of more than ~310 fold for AKT1.
To determine the selectivity of the compounds in a cellular context, we made the alkynetagged analogues 156 and 161. These compounds were selectively and potently active
towards AKT with 161 displaying a ~16 fold selectivity towards AKT1.
Now that we determined the mechanism of inhibition of these compounds to be covalent,
we wanted to determine the residue in AKT1 that is covalently modified by the vinyl
ketones. Hence, we made the fluorescein-labeled analog of 156 by azide-alkyne
cycloaddition as shown in Figure 74 to give the compound 165.

Figure 74: Synthesis of 165
This compound was incubated with AKT1, followed by gel electrophoresis and
confirmation of labeling by in-gel fluorescence scanning (Figure 75). Once the AKT1
band was confirmed to be labeled by 165, it was excised and subjected to trypsin
digestion. The mass-spectrum was obtained on a LTQ Orbitrap Velos instrument and an
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average 93% coverage was obtained. 165 was shown to modify the AKT fragment
Cys310 (Table 9). Modification of other cysteines was not observed.

Figure 75: Labeling of AKT1 with 165. a) Coomassie Blue Staining b) Fluorescence
image at 488/526 nm (Lane 1: AKT1 only, Lane 2: AKT1 incubated with 165)

Table 9: Mass Spectrometry Data for AKT1 Fragment Modified by 165
308TFCGTPEYLAPEVLEDNDYGR328

Mass Found

Mass Calculated

2389.04

2389.06

Modified with 165 3177.33

3177.32

Unmodified

To determine the selectivity of 165 in a cellular context, we incubated the compound with
cell lysates from the HCT-116 cell line. HCT-116 carries two mutations that constitutively
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activate the PI3K/AKT signaling pathway (one in the large subunit of PI3K and the other
that constitutively activates Ras). The cell lysates were treated with increasing
concentrations of 165 (0 – 100 µM final concentration) and incubated at room temperature
for 1 hour. Following this, the labeling reactions were separated by gel electrophoresis on
a 10% SDS-PAGE gel (Figure 76, A). Labeled proteins were visualized on an in-gel
fluorescence scanner. AKT alone was detected by Western Blot with biotin-conjugated
AKT (pan) antibody and streptavidin horseradish peroxidase (Figure 76, B). All proteins
in the cell lysates were visualized using Coomassie stain (Figure 76, C)

Figure 76: Labeling of AKT in HCT-116 cell lysates by compound 165
Figure 76 shows that the major band labeled by the probe 165 corresponds to the
molecular weight of AKT, as is shown by the western Blot (Figure 76, B). This shows that
additional bands are labeled, especially at higher concentrations and that non-specific
labeling occurs. The compound 148 displays non-specific labeling in cells lysates, hence,
despite the vinyl ketone electrophile being highly potent and selective for AKT over PKAα,
it cannot be used for further elaboration because of its non-selective binding to proteins.
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3.4: Synthesis and Biological Activity of the second set of compounds
Our approach to develop covalent inhibitors for AKT till now was to focus on identification
of an appropriate electrophile by structural elements from the C-terminal end of the
Hamilton compound 121. This led us to identify the vinyl ketones 148 and 151, which
were potent inhibitors of AKT and were highly selective for AKT against PKAα. However,
in a cellular context, we found that these compounds displayed non selective labeling of
other proteins in the cell. To address this issue of improving selectivity for AKT over other
proteins we chose to shift our focus from the electrophile and examine rest of the
substrate binding site. Our new approach was:


Dial down the reactivity of the electrophile so that it would not react indiscriminately
with other proteins in the cell.



Include additional binding elements from reported inhibitors, so that the noncovalent interactions from the inhibitor provide more selectivity for AKT.

We envisioned that using an electrophile that had moderate to low reactivity towards
Cys310 in AKT would make it less susceptible for indiscriminate labelling. Compound 133
has an IC50 of 1.11 µM towards AKT. Hence, we decided to use the α-iodoacetamide
electrophile and also prepare and screen the α-bromo and α-chloro electrophiles. TPCK
has been used traditionally as an active site label for serine proteases (Figure 77). It has
been shown by mass spectrometry to label Cys310 in AKT1 and no inhibition of AKT was
seen in vitro in concentrations up to 500 µM184,

185.

Thus, we decided to use the

phenylalanine chloromethyl ketone core as an electrophile.
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For additional binding elements, we included the N-terminal fragment of the Hamilton
inhibitor 121. We did not include the 3-naphthyl group from the p-amino benzoic acid
fragment in the α-haloacetamide compounds for the ease of synthesis, rationalizing that
this fragment can be included for later analogues if the compounds were active. For the
α-chloromethyl ketone analogues, we used a phenyl group at that position instead
(Figure 77).

Figure 77: Rationale for second set of compounds
As a control analog, we decided to prepare the compounds 198 and 203 (Figure 78).
Compound 198 would give us a qualitative estimate of electrophilicity of the αchloromethyl ketone against AKT. Compound 203 would give clues about the noncovalent interactions with AKT. It was designed as a hybrid, based on the GSK3β peptide
and Hamiltons peptidomimetic 121.
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Figure 78: Control compounds
3.4.1: Synthesis of the α-haloacetamide compounds

Figure 79: Synthesis of intermediate 172
Our synthetic routes to these compounds was designed such that the steps were linear
and more fragments were added from the C-terminal to the N-terminal end. This route
would be successful only if the electrophile that would be installed in the beginning would
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survive all the synthetic conditions leading to the product. Gratifyingly, the α-chloro
acetamide was stable enough to be installed from the start of the synthetic route and be
carried till the end. The more reactive α-bromo and α-iodo could be synthesized under
Finkelstein conditions at the penultimate step in the route. We started the synthesis of
the α-haloacetamides from the intermediate 132 that was previously prepared (Figure
79). The para-nitro group was reduced in refluxing tin chloride to give the aniline 166,
which was coupled with 4-nitrobenzoic acid by acid-chloride 167, coupling to give
compound 168. The newly introduced para-nitro group was reduced with tin chloride in
refluxing ethyl acetate to give the aniline 169. The aniline was coupled with Fmoc-Gly-Cl
using sodium bi-carbonate as the base in a mixture of water and chloroform to give the
Fmoc-protected compound 170. The protecting group Fmoc was removed using base
and the primary amine was coupled to the Diboc protected amidine reagent: N,N’-Di-Boc1H-pyrazole-1-carboxamidine in methanol, with triethylamine as the base to give the
compound 172. The Diboc-protecting group was removed under acidic conditions using
TFA to give the α-chloro acetamidate 173 (Figure 80). The α-chloro group was
exchanged either to a bromo or iodo under Finkelstein conditions by refluxing it with
sodium bromide or sodium iodide in acetone to give compounds 174 and 176. The Dibocprotecting group was removed under acidic conditions to give the final compounds 175
and 177.
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Figure 80: Synthesis of the α-haloacetamides 173, 175 and 177
3.4.2: Synthesis of the α-chloromethyl ketone compounds and control compounds
To synthesize the chloromethyl ketone compounds, we had to synthesize the N-terminal
fragment of the Hamilton’s compound 187 separately and then couple it with the Cterminal chloromethyl ketone fragment. We tried to prepare these compounds in an
analogous manner as that of the α-haloacetamides, but the α-chloromethyl ketone
electrophile was too reactive and did not survive the reaction conditions.
Our synthetic route starts with the preparation of the N-terminal binding fragment 187
(Figure 81). Starting from 3-bromo-4-nitrobenzoic acid 178, the carboxylic acid was
protected as a tert-butyl ester using tert-Butyl 2,2,2-trichloroacetamidate and the Lewis
acid boron trifluoride diethyl etherate to give compound 179. Other common reaction
conditions like tert-butanol and EDCI or tert-butyl bromide did not give any product.
Suzuki

reaction

with

phenylboronic
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acid

catalyzed

by

palladium-

tetrakistriphenylphosphine was carried out to give compound 180. The tert-butyl
protecting group was removed with acid to give compound 181. Using standard acid
chloride coupling the fragment benzyl 4-amino benzoate was coupled to the acid 181 to
give the amide 182. The nitro group was reduced with tin chloride in refluxing ethyl acetate
to give the aniline 183. To this intermediate N-Boc-2-aminoacetaldehyde was coupled by
reductive amination using sodium cyanoborohydride as the reductant to give compound
184. The N-Boc group was removed using acid and the amidine fragment was coupled
using the reagent N,N’-Di-Boc-1H-pyrazole-1-carboxamidine with triethylamine as the
base to give compound 186. The benzyl protecting group was removed using catalytic
hydrogenation using palladium on carbon to get the fragment 187.

Figure 81: Synthesis of the fragment 187.
We prepared the phenylalanine chloromethylketone 189 as described in Figure 82.
Starting from Boc-Phe-OH 146 was converted into the α-diazoketone 188 with
diazomethane. The intermediate mixed anhydride is initially formed with isobutyl
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chloroformate, which forms the α-diazoketone 188 in 95% on treatment with a
diazomethane solution in ether. Compound 188 is hydrolyzed by hydrochloric acid in
dioxane to give compound 189 in quantitative yield.

Figure 82: Preparation of the α-diazoketone 189
Much to our consternation, subsequent attempts to couple α-chloromethyl ketone 189
with the Hamilton fragment 187 under standard peptide coupling conditions led to
exhaustive degradation and no isolable product was detected on TLC. We tried various
peptide

coupling

reagents

like

carbodiimides,

mixed

anhydrides

and

phosphonium/uronium based salts, but no reaction condition tried gave product (Figure
83).

Figure 83: Attempted amide coupling of the α-chloromethyl ketone
We reasoned that peptide coupling reactions were not progressing because that the
compound 189 is not stable to base due of the presence of the electrophilic αchloromethyl ketone moiety. Also, we did not find any reports in literature where the
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phenylalanine chloromethylketone 189 was coupled to any small molecule carboxylic acid
substrates except in solid phase peptide coupling procedures where 6-10 equivalents of
189 was used. Therefore, we decided to reduce the ketone to the halohydrin, making the
primary alkyl chloride much less reactive, and then carrying out the oxidation of the
secondary alcohol to the ketone in the end stage to reveal the electrophile.
As described in Figure 84, we selectively hydrolyzed the α-diazoketone to α-chloromethyl
ketone in presence of the N-Boc group by addition of 1.5 equiv of HCl in dioxane at -200C,
giving compound 190 in quantitative yield. The secondary alcohol was reduced using
sodium borohydride in methanol and the N-Boc group was deprotected using
trifluoroacetic acid to give the halohydrin 192.

Figure 84: Synthesis of compound 192
In the next step, this compound was reacted with the Hamilton fragment 187 using the
peptide coupling reagent PyBOP and Hunigs base in dichloromethane overnight (Figure
85). Much to our surprise, the amide 193 was obtained as a diastereomeric mixture
epimeric at the secondary alcohol in 90% yield. The secondary alcohol was oxidized to
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the ketone using Dess-Martin periodane and the N-Boc protecting groups on the
guanidine were removed under acidic conditions to give 195 in quantitative yield.

Figure 85: Synthesis of the α-chloromethyl ketone 195
Bolstered by our above mentioned success in coupling the α-chloromethyl ketone, we
prepared the control compound 198 in a similar fashion (Figure 86). 4-methoxybenzoic
acid 196 was coupled to the halohydrin 192 using the peptide coupling reagent PyBOP
and Hunigs base to give the compound 197 in 91% yield. This secondary alcohol was
oxidized to the ketone using Dess-Martin periodane in dichloromethane to give 198 in
50% yield.
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Figure 86: Synthesis of the control compound 198
Next, we prepared the control analog 203, which is a hybrid between GSK3β and the
Hamilton’s compound 121 as described in Figure 87. Compound 200 was prepared by a
standard EDCI coupling between benzylamine 199 and Boc-Phe-OH 146 to give the
product in 75% yield. The N-Boc group was removed under acidic conditions and was
coupled to Hamilton’s fragment 187 using the peptide coupling reagent PyBOP and
Hunig’s base to give the amide 202 in 80% yield, following which the N-Boc protecting
groups on the guanidine were removed under acidic conditions to give 203 in quantitative
yield.

Figure 87: Synthesis of the control analog 203
3.4.3: Biochemical evaluation of full-length compounds and controls
We evaluated this second set of compounds by the Z-LYTE assay for AKT inhibition as
described earlier and the results are shown in Table 10.
Table 10: IC50 of second set of compounds
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Compound

AKT1 IC50 (µM)

173

>100

175

>100

177

>100

195

0.578

198

>25

203

>25

3.5: Results and discussion
Based on the second set of compounds that were prepared and evaluated, the most
active compound turned out to be 195 with an IC50 of 0.578 µM. This compound is derived
from the GSK3β peptide sequence (Phe10 from 3GRPRTTSFAE12) with the N-terminal
portion of the Hamilton non-covalent analog 121 and the chloromethyl ketone electrophile
appended to the C-terminal phenylalanine. The compound 198, which has the
phenylalanine chloromethyl ketone electrophile coupled with a p-methoxybenzoic acid
has an IC50 > 25 µM. This indicates that the phenylalanine chloromethyl ketone by itself
is not a potent inhibitor of AKT and our results are in line with the activity reported for
TPCK for inhibition of AKT184, 185. The non-covalent control analog 203 also has an IC50
> 25 µM, indicating that the chloromethyl ketone electrophile is necessary for inhibition.
The α-haloacetamides 173, 175, 177 were not active with IC50s > 100 µM. This indicates
that the 3-position phenyl substituent in the N-terminal portion is important for guiding the
compound into the substrate binding pocket of AKT or the sequence that we used to
attach the electrophile was not optimal.
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Our design and selection within the first set of compounds involved utilizing only the Cterminal portion of the Hamilton compound 121 and screening various electrophiles. This
led to the selection of the most potent electrophile that had only minimal fragments of the
Hamilton compound 121 to guide selectivity. The major downfall of this approach was,
that by including minimal binding elements of the Hamilton compound, we focused our
identification of compounds solely based on the reactivity of the electrophile, leading to a
compound that was potent for AKT but not selective in a cellular context. Our design
concept for the second set of compounds synthesized involved dialing down the reactivity
of the electrophile so that it would not display non-selective binding and including either
most of the binding elements of the Hamilton compound 121 or a hybrid between the
GSK3β peptide and the Hamilton compound 121. For this purpose, we used the αhaloacetamides and the α-chloromethyl ketone as electrophiles, which are much milder
in comparison with the vinyl-ketone, and inclusion of the whole N-terminal binding
fragment of Hamilton’s compound 121. This led to the identification of 195 as a potent
sub-micromolar inhibitor of AKT. Further experiments have to be done to discern the
selectivity of this compound for AKT, but we expect 195 to be selective towards AKT in a
cellular context because of the relatively milder reactivity of the chloromethyl ketone
electrophile in comparison to the vinyl-ketone and inclusion of additional binding elements
from Hamilton compound 121 and GSK3β peptide.
3.6: Future work
1. Compound 195 was identified as a potent sub-micromolar inhibitor of AKT. Before
we move on to optimizing the structure and analyzing reactivity and selectivity
patterns, we plan to confirm the mechanism of action of the compound. The IC50
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of the inactivated electrophile (204, Figure 88), where the methyl-ketone is used
instead, will confirm a covalent mechanism of action. Mass spectrometry with
labeled AKT will indicate the residue that is covalently modified by 195. We expect
Cys310 to be labeled based on the labeling of Cys310 by TPCK.
2. To test the selectivity of the compound among other kinases especially within the
AGC kinase family, 195 must be tested in a kinase selectivity screen assay. The
data from this kinase panel will determine whether 195 is selective as an AKT
inhibitor. To evaluate the cellular selectivity of 195 among other kinases we
propose to do a protein profiling experiment. Compound 205, which has an alkyne
functional handle substituted on the 3/4-position of the phenyl will be prepared.
Selection of this 3-position is based on the observation that a naphthyl group in
compound 121 increases affinity. We will incubate this compound with cell lysates
and subject the lysates to copper-promoted click conditions using a fluorescent
azide tag. Visualizing these lysates on a SDS-page gel will determine other
proteins labeled by compound 205.
3. Finally, optimizing the potency and selectivity of the compound towards AKT can
be done by further chemical manipulation. The reactivity of the electrophile can be
further dialed down if needed by using a fluoromethyl ketone. The affinity of the
compound can be increased by using further binding elements from Hamilton’s
compound 121, i.e., substituting the phenylalanine to 4-cyanophenylalanine,
phenyl for a naphthyl, and or changing the ethylamine linker to a glycine linker.
These optimizations are shown as compound 206, and are expected to yield a
compound that will be more potent/selective for AKT.
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Figure 88: Future analogues of Compound 195 to be prepared.
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CHAPTER 4: EXPERIMENTALS
4.1 Experimental for Flavone-based analogues inspired by the natural product
simocyclinone D8 as DNA gyrase inhibitors.
4.1.1 Chemistry Experimentals
Chemical reagents and solvents were purchased from Sigma-Aldrich (MO, USA), AlfaAesar (MA, USA), Fisher Scientific (PA, USA). Analytical Thin Layer Chromatography
(TLC) was performed using silica gel GHLF plates (Analtech Inc., DE, USA). Flash
chromatography was performed on TELEDYNE ISCO CombiFlash® Rf instrument using
RediSep Rf Normal-phase Flash Columns (4-gm, 12-gm, 24-gm or 40-gm). 1H NMR and
13C

NMR spectra were recorded on a Bruker TopSpin 400 MHz using deuterated

chloroform (CDCl3) or methanol (CD3OD). All chemical shifts are reported as δ in units of
parts per million (ppm) relative to chloroform and methanol residual peaks at 7.26 and
3.31 respectively (1H NMR spectra); 77.16 and 49.00 respectively (13C NMR spectra).
The data is reported as: chemical shifts (ppm), multiplicity (s = singlet, d = doublet, dd =
doublet of doublets, t = triplet, q = quartet, m = multiplet), coupling constant(s) (Hz) and
integral values. Electrospray ionization (ESI) mass spectra were obtained from Perkin
Elmer Flexar UPLC/AxION2 TOF Mass Spectrometer.
General procedures
A. Procedure for N-phthalylglycine acid chloride couplings with anilines and
deprotection
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a.

To a suspension of N-phthaloylglycine 5 (1.0 equiv) in chloroform (0.2 M) was added
thionyl chloride (1.5 equiv). The reaction mixture was refluxed for 4 hours, after which
the solution was concentrated in vacuo. The mixture was then taken in THF (0.4 M)
and cooled down to 0 °C in an ice bath. To this was added a solution of the suitably
functionalized aniline 11a-j (1.2 equiv) and triethylamine (2.0 M) in THF (0.4 M). The
reaction mixture was then refluxed overnight, following which it was diluted with ethyl
acetate and washed subsequently with 1 N HCl and saturated NaHCO3. The ethyl
acetate layer was concentrated in vacuo and the crude was used in the next step
without purification.

b.

To a solution of the crude from the previous step in ethanol (0.2 M) was added
hydrazine hydrate (2.0 equiv). The reaction mixture was refluxed for 2 hours and the
resulting thick suspension was filtered over celite and washed with ethyl acetate. The
filtrate was concentrated and was purified by column chromatography (silica gel,
methanol/dichloromethane, 10% v/v) to give the desired amine 12a-j.

B. Procedure for amide couplings
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To a solution of the acid 10 (1.0 equiv) in DMF (0.4 M) was added EDCI (1.3 equiv), HOBt
(1.1 equiv) and NMM (2.0 equiv). The reaction mixture was stirred for 30 minutes, followed
by addition of the amine 12a-j (1.0 equiv) in DMF (0.4 M). The mixture was stirred
overnight, after which it was diluted with ethyl acetate and washed with excess 1 N HCl
solution. The ethyl acetate layer was dried over sodium sulfate and concentrated in vacuo
and was purified by column chromatography (silica gel, methanol/dichloromethane, 5%
v/v) to give the desired amide 13a-j.

C. Procedure for removal of silyl protecting groups
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To a solution of the amide 13b, h in THF (0.1 M) was added a 1 M solution of TBAF in
THF (3.0 equiv). The reaction mixture was stirred at room temperature overnight and was
diluted with ethyl acetate and washed with saturated ammonium chloride solution. The
ethyl acetate layer was concentrated in vacuo and was purified by column
chromatography (silica gel, methanol/dichloromethane, 10% v/v) to give the desired
alcohol 14b and 14h.

D. Procedure for the removal of benzyl protecting groups
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To a solution of the amide 13a-j in ethanol:dioxane (3:1), was added 5% Pd/C (25% w/w).
The reaction mixture was stirred overnight in an atmosphere of hydrogen (balloon
pressure). The mixture was then filtered over celite and was purified by column
chromatography (silica gel, methanol/dichloromethane, 10% v/v) to give the desired
phenol 15a, 15d-g, 15j, 14b-c, 14h-i .

2-Amino-N-phenylacetamide (12a): Compound 12a was prepared according to general
procedure A and was obtained in 75% overall yield (0.113 g, 0.73 mmol). 1H NMR (400
MHz, CD3OD) δ 7.56 (d, J=7.8, 2H) 7.63 (t, 2H), 7.42 (t, 1H), 3.42 (s, 2H).
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2-Amino-N-(4-((tert-butyldiphenylsilyloxy)methyl)phenyl)acetamide (12b):
Compound 12b was prepared according to general procedure A and was obtained in
67% yield (0.42 g, 1.0 mmol). 1H NMR (400 MHz, CD3OD) δ 7.53 (d, J=8, 2H), 7.457.36 (m, 10H), 7.27 (d, J=8, 2H), 4.72 (s, 2H), 3.46 (s, 2H), 1.07 (s, 9H).

tert-butyl

2-(4-(2-aminoacetamido)phenyl)acetate

(12c):

Compound

12c

was

prepared according to general procedure A and was obtained in 72% yield (0.319 g, 1.2
mmol). 1H NMR (400 MHz, CD3OD) δ 7.53 (d, J=9, 1H), 7.38 (d, J=8, 1H), 7.19 (dd, J1=8,
J2=9, 2H), 3.59 (s, 2H), 3.49 (s, 1H), 3.43 (s, 1H), 1.44 (d, J=7, 9H).

2-amino-N-(p-tolyl)acetamide

(12d): Compound 12d was prepared according to

general procedure A and was obtained in 64% yield (0.35 g, 2.13 mmol). 1H NMR (400
MHz, CDCl3) δ 9.31 (br. s., 1H), 7.47 (d, J = 8.30 Hz, 2H), 7.12 (d, J = 8.30 Hz, 2H), 3.43
(s, 2H), 2.31 (s, 3H).
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2-amino-N-(4-ethylphenyl)acetamide (12e): Compound 12e was prepared according to
general procedure A and was obtained in 76 % yield (0.27 g, 1.51 mmol). 1H NMR (400
MHz, CDCl3) δ 6.66 (d, J = 8.53 Hz, 2H), 6.48 (d, J = 8.53 Hz, 2H), 3.06 (s, 2H), 2.08 (q,
J = 7.61 Hz, 2H), 0.66 (t, J = 7.53 Hz, 3H).

2-amino-N-(4-isopropylphenyl)acetamide

(12f):

Compound

12f

was

prepared

according to general procedure A and was obtained in 69% yield (0.31 g, 1.61 mmol). 1H
NMR (400 MHz, CDCl3) δ 7.21 (d, J = 8.30 Hz, 2H), 7.00 (d, J = 8.28 Hz, 2H), 3.58 (s,
2H), 2.86 (td, J = 6.93, 13.99 Hz, 1H), 1.18 (d, J = 7.03 Hz, 6H).

2-amino-N-(4-chlorophenyl)acetamide (12g): Compound 12g was prepared according
to general procedure A and was obtained in 73% yield (0.137 g, 0.74 mmol). 1H NMR
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(400 MHz, CDCl3) δ 9.42 (br. s., 1H), 7.53 (d, J = 8.78 Hz, 2H), 7.26 (d, J = 8.80 Hz, 2H),
3.44 (s, 2H).

2-Amino-N-(4-(tert-butyldiphenylsilyloxy)phenyl)acetamide (12h): Compound 12h
was prepared according to general procedure A and was obtained in 61% yield (0.3 g,
0.74mmol). 1H NMR (400 MHz, CDCl3) δ 7.43-7.34 (m, 10H), 6.87 (d, J=9, 2H), 6.78 (d,
J=9, 2H), 3.6 (s, 2H), 1.1 (s, 9H).

2-Amino-N-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)acetamide (12i): Compound
12i was prepared according to general procedure A and was obtained in 80% yield (0.289
g, 1.22 mmol). 1H NMR (400 MHz, CD3OD) δ 6.99 (dd, J1=2, J2=6, 1H), 6.89 (d, J=2,
1H), 6.86 (d, J=8, 1H), 4.87 (s, 2H), 3.57 (s, 2H), 1.52 (s, 6H).
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2-amino-N-(4-methoxyphenyl)acetamide

(12j):

Compound

12j

was

prepared

according to general procedure A and was obtained in 79% yield (0.175 g, 0.97 mmol).
1H

NMR (400 MHz, CDCl3) δ 9.24 (br. s., 1H), 7.52 (d, J = 9.00 Hz, 2H), 6.88 (d, J = 9.00

Hz, 2H), 3.80 (s, 3H), 3.47 (s, 2H), 1.89 (br. s., 2H).

7-(Benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl

7-

oxo-7-(2-oxo-2-(phenylamino)ethylamino)heptanoate (13a): Compound 13a was
prepared according to general procedure B and was obtained in 79% yield (0.45 g, 0.53
mmol). 1H NMR (400 MHz, CDCl3) δ 7.84 (dd, J1=2.3, J2=6, 1H), 7.81 (d, J=2, 1H), 7.64
(d, J=8, 2H), 7.42-7.24 (m, 17H), 7.1 (t, J=7.78, 1H), 7.02 (d, J=9, 1H), 6.5 (d, J=2, 1H),
6.44 (d, J=2, 1H), 5.14 (s, 2H), 5.13 (s, 2H), 5.04 (s, 2H), 4.08 (d, J=5, 2H), 2.55 (t, J=7,
2H), 2.2 (t, J=7, 2H), 1.75-1.61 (m, 4H), 1.43-1.35 (m, 2H).
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7-(Benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl 7-(2(4-((tert-butyldiphenylsilyloxy)methyl)phenylamino)-2-oxoethylamino)-7oxoheptanoate (13b): Compound 13b was prepared according to general procedure B
and was obtained in 82% yield (0.582 g, 0.53 mmol). 1H NMR (400 MHz, CDCl3) δ 7.68
(dd, J1=1, J2=7, 2H), 7.49 (d, J=8, 2H), 7.44-7.28 (m, 27H), 7.02 (d, J=9, 1H), 6.51 (d,
J=2, 1H), 6.45 (d, J=2, 1H), 5.15 (s, 2H), 5.13 (s, 2H), 5.04 (s, 2H), 4.72 (s, 2H), 4.07 (d,
J=6, 2H), 2.56 (t, J=7, 2H), 2.2 (t, J=8, 2H), 1.76-1.61 (m, 4H), 1.44-1.36 (m, 2H), 1.07 (s,
9H).

7-(Benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl 7-(2(4-(2-tert-butoxy-2-oxoethyl)phenylamino)-2-oxoethylamino)-7-oxoheptanoate
(13c): Compound 13c was prepared according to general procedure B and was obtained
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in 77% yield (0.48 g, 0.5 mmol). 1H NMR (400 MHz, CDCl3) δ 7.85 (dd, J1=2.05, J2=6.65,
1H), 7.8 (d, J=2, 1H), 7.48-7.2 (m, 19H), 7.02 (d, J=9, 1H), 6.5 (d, J=2, 1H), 6.44 (d, J=2,
1H), 5.15 (s, 2H), 5.13 (s, 2H), 5.06 (s, 2H), 4.07 (s, 2H), 3.47 (s, 2H), 2.54 (t, J=8, 2H),
2.26 (t, J=8, 2H), 1.7-1.61 (m, 4H), 1.42 (s, 9H), 1.33-1.21 (m, 2H).

7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl 7oxo-7-((2-oxo-2-(p-tolylamino)ethyl)amino)heptanoate (13d): Compound 13d was
prepared according to general procedure B and was obtained in 53% yield (0.044 g,
0.051 mmol).

7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl

7-

((2-((4-ethylphenyl)amino)-2-oxoethyl)amino)-7-oxoheptanoate (13e): Compound
13e was prepared according to general procedure B and was obtained in 83% yield
(0.057 g, 0.058 mmol). 1H NMR (400 MHz, CDCl3) δ 8.48 (br. s., 1H), 7.77 - 7.90 (m, 1H),
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7.23 - 7.51 (m, 17H), 7.14 (d, J = 8.28 Hz, 2H), 7.03 (d, J = 8.78 Hz, 1H), 6.51 (d, J = 2.30
Hz, 1H), 6.45 (d, J = 2.26 Hz, 1H), 5.15 (d, J = 10.79 Hz, 4H), 5.07 (s, 2H), 4.10 (br. s.,
2H), 2.47 - 2.68 (m, 4H), 2.28 (t, J = 7.50 Hz, 2H), 1.56 - 1.75 (m, 4H), 1.25 - 1.40 (m,
2H), 1.21 (t, J = 7.53 Hz, 3H).

7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl
((2-((4-isopropylphenyl)amino)-2-oxoethyl)amino)-7-oxoheptanoate

7(13f):

Compound 13f was prepared according to general procedure B and was obtained in 72%
yield (0.05 g, 0.087 mmol). 1H NMR (400 MHz, CDCl3) δ 8.36 (br. s., 1H), 7.76 - 7.90 (m,
1H), 7.25 - 7.49 (m, 17H), 7.15 - 7.24 (m, 2H), 6.98 - 7.11 (m, 1H), 6.48 - 6.54 (m, 1H),
6.45 (d, J = 2.26 Hz, 1H), 5.15 (d, J = 10.54 Hz, 4H), 5.07 (s, 2H), 4.08 (br. s., 2H), 2.81
- 2.95 (m, 1H), 2.55 (t, J = 7.53 Hz, 2H), 2.27 (t, J = 7.65 Hz, 2H), 1.58 - 1.79 (m, 4H),
1.26 - 1.32 (m, 2H), 1.20 - 1.25 (m, 6H).
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7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl

7-

((2-((4-chlorophenyl)amino)-2-oxoethyl)amino)-7-oxoheptanoate (13g): Compound
13g was prepared according to general procedure B and was obtained in 46% yield
(0.031 g, 0.035 mmol). 1H NMR (400 MHz, CDCl3) δ 12.61 (s, 1H), 8.69 (s, 1H), 7.76 7.87 (m, 2H), 7.21 - 7.51 (m, 19H), 7.03 (d, J = 8.80 Hz, 1H), 6.52 (d, J = 2.20 Hz, 1H),
6.46 (d, J = 2.20 Hz, 1H), 6.25 (t, J = 5.27 Hz, 1H), 5.06 - 5.20 (m, 4H), 5.03 (s, 2H), 4.06
(d, J = 5.27 Hz, 2H), 2.58 (t, J = 7.20 Hz, 2H), 2.20 (t, J = 7.40 Hz, 2H), 1.52 - 1.80 (m,
4H), 1.35 - 1.49 (m, 2H).

7-(Benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl 7-(2(4-(tert-butyldiphenylsilyloxy)phenylamino)-2-oxoethylamino)-7-oxoheptanoate
(13h): Compound 13h was prepared according to general procedure B and was obtained
in 67% yield (0.61 g, 0.55 mmol). 1H NMR (400 MHz, CDCl3) δ 7.7-7.68 (m, 2H), 7.427.21 (m, 29H), 6.7 (d, J=8, 1H), 6.5 (d, J=2, 1H), 6.44 (d, J=2, 1H), 5.14 (s, 2H), 5.13 (s,
2H), 5.03 (s, 2H), 3.98 (d, J=5, 2H), 2.54 (t, J=7, 2H), 2.17 (t, J=2, 2H), 1.73-1.58 (m, 4H),
1.39-1.35 (m, 2H), 1.08 (s, 9H).
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7-(Benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl 7-(2(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-ylamino)-2-oxoethylamino)-7oxoheptanoate (13i): Compound 13i was prepared according to general procedure B
and was obtained in 81% yield (0.512 g, 0.55 mmol). 1H NMR (400 MHz, CDCl3) δ 7.85
(dd, J1=2, J2=7, 1H), 7.8 (d, J=2, 1H), 7.42-7.3 (m, 17H), 7.12 (dd, J1=2, J2=6, 1H), 7.02
(d, J=9, 1H), 6.75 (d, J=8, 1H), 6.5 (d, J=2, 1H), 6.44 (d, J=2, 1H), 5.15 (s, 2H), 5.13 (s,
2H), 5.05 (s, 2H), 4.79 (s, 2H), 4.04 (d, J=5, 2H), 2.54 (t, J=8, 2H), 2.25 (t, J=8, 2H), 1.721.6 (m, 4H), 1.42-1.35 (m, 2H), 1.51 (s, 6H).

7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl
((2-((4-methoxyphenyl)amino)-2-oxoethyl)amino)-7-oxoheptanoate

7(13j):

Compound 13j was prepared according to general procedure B and was obtained in 55%
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yield (0.057 g, 0.065 mmol). 1H NMR (400 MHz, CDCl3) δ 12.64 (s, 1H), 8.74 (s, 1H),
7.75 - 7.91 (m, 2H), 7.22 - 7.48 (m, 18H), 7.06 - 7.14 (m, 2H), 7.02 (d, J = 8.78 Hz, 1H),
6.51 (d, J = 2.01 Hz, 1H), 6.45 (d, J = 2.26 Hz, 1H), 5.03 - 5.17 (m, 6H), 4.10 (d, J = 5.02
Hz, 2H), 2.55 (t, J = 7.40 Hz, 2H), 2.29 (s, 3H), 2.22 (t, J = 7.40 Hz, 2H), 1.59 - 1.78 (m,
4H), 1.33 - 1.47 (m, 2H).

7-(Benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl 7-(2(4-(hydroxymethyl)phenylamino)-2-oxoethylamino)-7-oxoheptanoate

(14b):

Compound 14b was prepared according to general procedure C and was obtained in
67% yield (0.363 g, 0.41 mmol). 1H NMR (400 MHz, CDCl3) δ 7.79 (dd, J1=2, J2=7, 1H),
7.73 (d, J=2, 1H), 7.43-7.18 (m, 19H), 6.96 (d, J=9, 1H), 6.44(d, J=2, 1H), 6.38 (d, J=2,
1H), 5.09 (s, 2H), 5.07 (s, 2H), 4.99 (s, 2H), 4.56 (s, 2H), 4.01 (d, J=6, 2H), 2.47 (t, J=7,
2H), 2.2 (t, J=8, 2H), 1.65-1.54 (m, 4H), 1.44-1.36 (m, 2H).
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7-(Benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl 7-(2(4-hydroxyphenylamino)-2-oxoethylamino)-7-oxoheptanoate (14h): Compound 14h
was prepared according to general procedure C and was obtained in 65% yield (0.317 g,
0.367 mmol). 1H NMR (400 MHz, CD3OD) δ 7.88 (dd, J1=2, J2=7, 1H), 7.79 (d, J=2, 1H),
7.53-7.2 (m, 20H), 6.71 (d, J=2, 1H), 6.43 (d, J=2, 1H), 3.98 (s, 2H), 2.56 (t, J=7, 2H),
2.27 (t, J=7, 2H), 1.72-1.6 (m, 4H), 1.44-1.42 (m, 2H).

2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl7-oxo-7-(2-oxo-2(phenylamino)ethylamino)heptanoate (15a): Compound 15a was prepared according
to general procedure D and was obtained in 43% yield (0.253 g, 0.44 mmol). 1H NMR
(400 MHz, CD3OD) δ 7.99-7.96 (m, 1H), 7.89 (s, 1H), 7.52 (d, J=8, 2H), 7.28 (t, J=7, 2H),
7.1 (t, J=7, 1H), 7.02 (d, J=9, 1H), 6.39 (s, 1H), 4.0 (s, 2H), 2.66 (t, J=7, 2H), 2.36 (t, J=7,
2H), 1.82-1.71 (m, 4H) 1.57-1.51 (m, 2H).

13C

NMR (100 MHz, CD3OD) δ 177.3, 176.6,

175.9, 169.7, 165.6, 162.5, 158.2, 148.7, 148.0, 146.2, 139.5, 137.2, 129.8, 125.3, 124.1,
121.6, 121.2, 116.2, 116.0, 104.5, 99.2, 94.4, 70.6, 56.1, 44.0, 36.6, 34.6, 32.1, 30.6,
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29.7, 29.5, 26.4, 25.6. HRMS (ESI) C30H28N2O10 m/z [M-H]- found 575.1686, expected
575.1665.

2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl7-(2-(4(hydroxymethyl)phenylamino)-2-oxoethylamino)-7-oxoheptanoate

(15b):

Compound 15b was prepared according to general procedure D and was obtained in
33% yield (0.241 g, 0.4 mmol). 1H NMR (400 MHz, CD3OD) δ 7.97 (dd, J1=2, J2=7, 1H),
7.88 (d, J=2, 1H), 7.38 (d, J=8, 2H), 7.07 (d, J=8, 2H), 7.01 (d, J=9, 1H), 6.37 (m, 1H),
6.17 (d, J=2, 1H), (3.98 (s, 2H), 2.64 (t, J=5, 2H), 2.35 (t, J=7, 2H), 1.81-1.71 (m, 4H),
1.54-1.5 (m, 2H).

13C

NMR (100MHz, DMSO-d6) δ 176.0, 172.5, 171.1, 164.0, 161.0,

167.6, 156.1, 150.8, 138.3, 138.2, 136.3, 136.2, 126.4, 122.7, 119.1, 116.8, 115.5, 98.2,
59.6, 54.8, 33.2, 33.1, 28.1, 28.0, 24.8, 24.2, 24.1, 20.3, 20.6. HRMS (ESI) C31H30N2O11
m/z [M-H]- found 605.1771, expected 605.1772.
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2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl7-(2-(4-(2-tertbutoxy-2-oxoethyl)phenylamino)-2-oxoethylamino)-7-oxoheptanoate

(14c):

Compound 14c was prepared according to general procedure D and was obtained in 52%
yield (0.248 g, 0.36 mmol). 1H NMR (400 MHz, CD3OD) δ 7.59 (d, J=9, 2H), 7.43 (d, J=2,
1H), 7.38 (dd, J1=2, J2=6, 1H), 7.29 (d, J=8, 2H), 7.01 (d, J=8, 1H), 6.53 (d, J=2, 1H),
6.339 (d, J=2, 1H), 4.09 (s, 2H), 3.58 (s, 2H), 2.76 (t, J=7, 2H), 2.4 (t, J=8, 2H), 1.86-1.76
(m, 4H), 1.55-1.52 (m, 2H), 1.52 (s, 9H).

2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl7-oxo-7-((2-oxo-2(p-tolylamino)ethyl)amino)heptanoate (15d): Compound 15d was prepared according
to general procedure D and was obtained in 31% yield (0.043 g, 0.073 mmol). 1H NMR
(400 MHz, CD3OD) δ 7.98 (dd, J = 1.63, 8.66 Hz, 1H), 7.81 - 7.91 (m, 1H), 7.32 - 7.44
(m, 2H), 6.95 - 7.15 (m, 3H), 6.39 (br. s., 1H), 6.12 - 6.22 (m, 1H), 3.99 (s, 2H), 2.66 (t, J
= 7.30 Hz, 2H), 2.35 (t, J = 7.50 Hz, 2H), 2.27 (s, 3H), 1.67 - 1.85 (m, 4H), 1.47 - 1.60 (m,
2H).
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2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl7-((2((4ethylphenyl)amino)-2-oxoethyl)amino)-7-oxoheptanoate (15e): Compound 15e
was prepared according to general procedure D and was obtained in 41% yield (0.07 g,
0.116 mmol). 1H NMR (400 MHz, DMSO-d6) δ 12.40 (s, 1H), 9.83 (s, 1H), 8.11 (t, J = 5.65
Hz, 1H), 7.93 (dd, J = 2.26, 8.78 Hz, 1H), 7.85 (d, J = 2.26 Hz, 1H), 7.40 - 7.51 (m, 2H),
7.00 - 7.14 (m, 3H), 6.39 - 6.46 (m, 1H), 6.13 - 6.22 (m, 1H), 3.84 (d, J = 5.77 Hz, 2H),
2.50 - 2.63 (m, 4H), 2.18 (t, J = 7.40 Hz, 2H), 1.50 - 1.71 (m, 4H), 1.33 - 1.44 (m, 2H),
1.13 (t, J = 7.53 Hz, 3H).

13C

NMR (101 MHz, DMSO-d6) δ 175.8, 172.6, 171.2, 167.6,

163.9, 160.5, 156.2, 150.8, 145.5, 138.6, 138.2, 136.5, 136.0, 127.9, 122.7, 122.1, 119.1,
116.8, 103.1, 98.2, 93.6, 42.5, 35.0, 30.6, 28.0, 27.6, 24.9, 24.1, 15.6, 15.1. HRMS (ESI)
C32H32N2O10 m/z [M+H]+ found 605.2038, expected 605.2135.
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2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl7-((2-((4isopropylphenyl)amino)-2-oxoethyl)amino)-7-oxoheptanoate (15f): Compound 15f
was prepared according to general procedure D and was obtained in 46 % yield (0.09 g,
0.145 mmol). 1H NMR (400 MHz, CD3OD) δ 7.96 (dd, J = 2.26, 8.53 Hz, 1H), 7.80 - 7.89
(m, 1H), 7.38 - 7.45 (m, 2H), 7.07 - 7.17 (m, 2H), 7.01 (d, J = 8.78 Hz, 1H), 6.37 (d, J =
2.01 Hz, 1H), 6.12 - 6.21 (m, 1H), 3.99 (s, 2H), 2.78 - 2.89 (m, 1H), 2.65 (t, J = 7.30 Hz,
2H), 2.35 (t, J = 7.53 Hz, 2H), 1.68 - 1.85 (m, 4H), 1.46 - 1.58 (m, 2H), 1.14 - 1.24 (m,
6H).

13C

NMR (101 MHz, DMSO-d6) δ 175.9, 172.5, 172.5, 172.5, 171.2, 171.0, 167.6,

164.0, 160.7, 160.7, 156.1, 150.8, 145.5, 145.2, 143.2, 138.2, 136.6, 136.0, 129.2, 126.3,
122.6, 122.0, 121.9, 119.2, 116.8, 103.0, 98.2, 93.5, 42.5, 34.9, 33.1, 33.1, 32.8, 28.0,
24.8, 24.1, 23.8. HRMS (ESI) C33H34N2O10 m/z

[M+H]+ found 619.2260, expected

619.2291.

2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl7-((2-((4chlorophenyl)amino)-2-oxoethyl)amino)-7-oxoheptanoate (15g): Compound 15g
was prepared according to general procedure D and was obtained in 15% yield (0.02 g,
0.033 mmol). 1H NMR (400 MHz, CD3OD) δ 7.93 – 8.01 (m, 1H), 7.77 – 7.93 (m, 1H),
7.44 – 7.58 (m, 2H), 7.18 – 7.33 (m, 2H), 6.96 – 7.15 (m, 2H), 6.32 – 6.43 (m, 1H), 6.11
– 6.22 (m, 1H), 4.00 (d, J = 5.77 Hz, 2H), 2.66 (t, J = 7.30 Hz, 2H), 2.35 (t, J = 7.30 Hz,
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2H), 1.64 – 1.87 (m, 4H), 1.54 (dt, J = 3.26, 7.53 Hz, 2H).

13C

NMR (101 MHz, CD3OD)

δ 177.5, 176.8, 176.8, 165.7, 162.6, 158.4, 148.9, 148.2, 146.4, 138.6, 137.4, 134.1,
130.0, 129.9, 129.9, 125.4, 124.3, 122.7, 121.9, 121.4, 116.4, 116.2, 104.7, 99.4, 94.6,
44.2, 36.7, 36.7, 34.8, 29.8, 29.8, 26.5, 25.8.

2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl7-(2-(4hydroxyphenylamino)-2-oxoethylamino)-7-oxoheptanoate (15h): Compound 15h
was prepared according to general procedure D and was obtained in 34% yield (0.258 g,
0.43 mmol). 1H NMR (400 MHz, CD3OD) δ 7.99 (dd, J1=2, J2=7, 1H), 7.89 (d, J=2, 1H),
7.3 (d, J=9, 2H), 7.03 (d, J=9, 1H), 6.72 (d, J=9, 2H), 6.41 (d, J=2, 1H), 6.18 (d, J=2, 1H),
3.97 (s, 2H), 2.67 (t, J=7, 2H), 2.35 (t, J=7, 2H), 1.82-1.72 (m, 4H), 1.55-1.51 (m, 2H). 13C
NMR (100MHz, CD3OD) δ 177.1, 172.0, 165.1, 163.0, 158.7, 158.3, 153.2, 150.3, 148.1,
146.6, 130.5, 125.3, 124.7, 123.3, 122.3, 121.4, 118.6, 116.2, 104.1, 100.5, 98.3, 96.0,
94.1, 44.2, 36.7, 34.6, 26.3, 25.7, 25.5. HRMS (ESI) C30H28N2O11 m/z [M-H]- found
591.1591, expected 591.1615.
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2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl7-(2-(2,2-dimethyl4H-benzo[d][1,3]dioxin-6-ylamino)-2-oxoethylamino)-7-oxoheptanoate

(14i):

Compound 14i was prepared according to general procedure D and was obtained in 57%
yield (0.193 g, 0.29 mmol). 1H NMR (400 MHz, CD3OD) δ 7.32 (d, J=2, 1H), 7.28 (dd,
J1=2, J2=6, 2H), 7.2 (dd, J1=2, J2=6, 1H), 6.91 (d, J=8, 1H), 6.7 (d, J=9, 1H), 6.42 (d,
J=2, 1H), 6.23 (d, J=2, 1H), 4.91 (s, 2H), 3.97 (s, 2H), 2.66 (t, J=7, 2H), 2.3 (t, J=8, 2H),
1.76-1.66 (m, 4H), 1.48 (s, 6H), 1.46-1.4 (m, 2H).

2-(4-(2-(7-(2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yloxy)-7oxoheptanamido)acetamido)phenyl)acetic acid (15c): Compound 14c (0.1 g, 0.145
mmol, 1.0 equiv) was dissolved in a mixture of triethylsilane (0.06 mL, 0.36 mmol, 2.5
equiv) and DCM (1.45 mL, 0.1 M). To this mixture was added TFA (0.145 mL, 1.9 mmol,
13.0 equiv) and was stirred overnight at room temperature. The reaction mixture was
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concentrated and dried in vacuo to obtain pure 15c (0.085 g, 0.13 mmol, 92%). 1H NMR
(400 MHz, CD3OD) δ 7.5 (d, J=8, 2H), 7.33 (d, J=2, 1H), 7.28 (dd, J1=2, J2=6, 1H), 7.22
(d, J=8, 2H), 6.9 (d, J=8, 1H), 6.43 (d, J1=2, 1H), 6.24 (d, J=2, 1H), 3.99 (s, 2H), 3.56 (s,
2H), 2.66 (t, J=7, 2H), 2.3 (t, J=7, 2H), 1.76-1.66 (m, 4H), 1.44-1.39 (m, 2H). 13C NMR
(100MHz, CD3OD) δ 177.2, 176.7, 175.5, 172.5, 169.7, 166.2, 163.1, 158.7, 158.5, 150.3,
146.6, 138.3, 132.0, 131.5, 122.2, 122.1, 116.6, 116.3, 105.4, 100.2, 95.1, 44.1, 41.3,
36.6, 34.5, 29.5, 26.3, 25.5. HRMS (ESI) C32H30N2O12 m/z [M+H]+ found 635.1866,
expected 635.1877.

2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl7-(2-(4-hydroxy-3(hydroxymethyl)phenylamino)-2-oxoethylamino)-7-oxoheptanoate (15i): Compound
14i (0.074 g, 0.111 mmol, 1.0 equiv) was dissolved in a mixture of 1 N HCl:THF (1:1, 0.6
mL, 0.2 M). The mixture was stirred for 90 minutes and was concentrated in vacuo to
obtain compound 15i (0.025 g, 0.04 mmol, 36% yield. 1H NMR (400 MHz, CD3OD) δ 7.397.37 (m, 1H), 7.33 (d, J=2, 1H), 7.28 (dd, J1=2, J2=6, 2H), 6.91 (d, J=8, 1H), 6.71 (d, J=9,
1H), 6.44 (d, J=2, 1H), 6.24 (d, J=2, 1H), 4.61 (s, 2H), 3.97 (s, 2H), 2.66 (t, J=7, 2H), 2.3
(t, J=8, 2H), 1.76-1.64 (m, 4H), 1.15-1.41 (m, 2H). 13C NMR (100MHz, CD3OD) δ 177.2,
172.6, 166.2, 163.1, 158.7, 158.5, 153.6, 150.3, 148.7, 146.6, 131.5, 125.7, 124.1, 123.3,
122.2, 121.7, 116.6, 116.3, 116.1, 105.4, 100.2, 99.3, 95.1, 94.4, 70.9, 58.4, 44.0, 36.6,
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34.6, 26.3, 25.7, 25.5. HRMS (ESI) C31H30N2O12 m/z [M-H]- found 621.1721, expected
621.1720.

2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl7-((2-((4methoxyphenyl)amino)-2-oxoethyl)amino)-7-oxoheptanoate (15j): Compound 15j
was prepared according to general procedure D and was obtained in 27% yield (0.034 g,
0.056 mmol). 1H NMR (400 MHz, CD3OD) δ 7.98 (dd, J = 2.13, 8.66 Hz, 1H), 7.85 – 7.92
(m, 2H), 7.74 (td, J = 1.00, 8.28 Hz, 1H), 7.46 – 7.58 (m, 2H), 7.37 – 7.44 (m, 2H), 7.02
(d, J = 8.53 Hz, 1H), 6.81 – 6.86 (m, 2H), 6.37 – 6.41 (m, 1H), 6.16 – 6.21 (m, 1H), 3.98
(s, 2H), 3.75 (s, 3H), 2.59 – 2.71 (m, 2H), 2.35 (t, J = 7.40 Hz, 2H), 1.67 – 1.87 (m, 4H),
1.46 – 1.59 (m, 2H).
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7-(benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-3,5-dihydroxy-4H-chromen-4-one

(6):

Quercetin (0.977 g, 3.23 mmol, 1.0 equiv) was dissolved in DMF (26 mL, 0.125M) and
was cooled to 0 °C. To this mixture was added potassium carbonate (1.43 g, 10.34 mmol,
3.2 equiv) and benzyl bromide (1.23 mL, 3.13 mmol, 3.5 equiv). The reaction mixture was
allowed to slowly warm to room temperature and stirred overnight. The reaction was
diluted with ethyl acetate and washed with copious amounts of 1N HCl. The ethyl acetate
layer was dried over sodium sulfate and concentrated in vacuo. The crude was purified
by column chromatography (silica gel, acetone/hexane, 20% v/v) to give the desired
compound 2 (0.925 g, 1.62 mmol, 50%). 1H NMR (400 MHz, DMSO-d6) δ 7.9 (d, J=2,
1H), 7.84 (dd, J1=2, J2=2, 1H), 7.51-7.32 (m, 15H), 7.25 (d, J=9, 1H), 6.85 (d, J=2, 1H),
6.44 (d, J=2, 1H), 5.24 (s, 4H), 5.2 (s, 2H).

1-(7-(Benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3-yl)
7-tert-butyl heptanedioate (9): 7-tert-butoxy-7-oxoheptanoic acid (0.036 g, 0.168 mmol,
1.2 equiv) was dissolved in THF (2.8 mL, 0.05M), after which was added EDCI (0.032 g,
0.168 mmol, 1.2 equiv), Hunig’s base (0.03 mL, 0.168 mmol, 1.2 equiv) and DMAP
(0.0017 g, 0.014 mmol, 0.1 equiv). To this solution was added compound 6 (0.08 g, 0.14
mmol, 1.0 equiv) and the mixture was stirred overnight. The reaction mixture was washed
with 1 N HCl and extracted into ethyl acetate. The ethyl acetate layer was dried over
sodium sulfate and was purified by column chromatography (silica gel, ethyl
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acetate/hexane, 25% v/v) to give the desired compound 9 (0.106 g, 0.13 mmol, 98%). 1H
NMR (400 MHz, CDCl3) δ 7.54-7.29 (m, 17H), 6.36 (d, J=2, 1H), 6.48 (d, J=2, 1H), 5.6
(dd, J1=2, J2=4, 1H), 5.21 (s, 2H), 5.19 (s, 2H), 5.11 (s, 2H), 2.54 (t, J=8, 2H), 2.34 (t,
J=8, 2H), 1.76-1.71 (m, 4H), 1.43 (s, 9H), 1.41-1.32 (m, 2H).

7-(7-(Benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3yloxy)-7-oxoheptanoic acid (10): To the solution of compound 9 (1.23 g, 1.6 mmol, 1.0
equiv) in DCM (16.0 mL, 0.1M) was added triethylsilane (0.64mL, 4.0 mmol, 2.5 equiv)
and trifluoroacetic acid (1.6 mL, 20.8 mmol, 13.0 equiv). The reaction mixture was stirred
overnight, concentrated in vacuo and purified by column chromatography (silica gel,
dichloromethane/methanol, 5% v/v) to give the desired compound 10 (0.876 g, 1.22
mmol, 76%). 1H NMR (400 MHz, CDCl3) δ 7.47-7.33 (m, 17H), 7.01 (d, J=9, 1H), 6.49 (d,
J=2, 1H), 6.45 (d, J=2, 1H), 5.24 (s, 2H), 5.2 (s, 2H), 5.13 (s, 2H), 2.54 (t, J=7, 2H), 2.36
(t, J=7, 2H), 1.77-1.62 (m, 4H), 1.46-1.38 (m, 2H).
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1-(7-(Benzyloxy)-2-(3,4-bis(benzyloxy)phenyl)-5-hydroxy-4-oxo-4H-chromen-3yl)10-methyl decanedioate (14k): 10-methoxy-10-oxodecanoic acid (87 mg, 0.4 mmol,
1.2 equiv) was dissolved in THF (8.0 mL 0.05M), after which was added EDCI (77 mg,
0.4 mmol, 1.2 equiv), Hunig’s base (0.07 mL, 0.4 mmol, 1.2 equiv) and DMAP (5 mg,
0.04 mmol, 0.1 equiv). To this solution was added compound 6 (0.193 g, 0.34 mmol, 1.0
equiv) and the mixture was stirred overnight. The reaction mixture was washed with 1N
HCl and extracted into ethyl acetate. The ethyl acetate layer was dried over sodium
sulfate and was purified by column chromatography (silica gel, ethyl acetate/hexane, 25%
v/v) to give the desired compound 14k (0.152 g, 0.2 mmol, 58%). 1H NMR (400MHz,
CDCl3) δ 7.5-7.32 (m, 17H), 6.48 (d, J=2, 1H), 6.44 (d, J=2, 1H), 5.59 (dd, J1=2, J2=4,
1H), 5.24 (s, 2H), 5.19 (s, 2H), 5.13 (s, 2H), 3.66 (s, 3H), 2.53 (t, J=8, 2H), 2.34 (t, J=8,
2H), 2.1-1.79 (m, 4H), 1.74-1.3 (m, 8H).

1-(2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl)

10-methyl

decanedioate (15k): Compound 15k was prepared from compound 14k according to
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general procedure D and was obtained in 27% yield (0.041 g, 0.08 mmol). 1H NMR (400
MHz, DMSO-d6) δ 7.3 (d, J=2, 1H), 7.25 (dd, J1=2, J2=6, 1H), 6.9 (d, J=9, 1H), 6.46 (d,
J=2, 1H), 6.24 (d, J=2,1H), 3.56 (s, 3H), 2.62 (t, J=7, 2H), 2.28 (t, J=7, 2H), 1.64-1.58 (m,
2H), 1.53-1.48 (m, 2H), 1.3-1.24 (m, 10H). 13C NMR (100 MHz, CD3OD) δ 177.2, 176.2,
172.6, 166.2, 163.1, 158.7, 158.5, 150.3, 146.6, 131.5, 122.2, 122.1, 116.5, 116.3, 105.3,
100.2, 95.1, 51.9, 34.8, 34.6, 30.1, 29.9, 25.9, 25.8. HRMS (ESI) C26H28O10 m/z [M-H]found 499.1593, expected 499.1604.
4.1.2: Biology Experimentals
Negatively supercoiled pBR322 DNA was purchased from New England Biolabs,
(Beverly, MA). Relaxed plasmid DNA was prepared by incubating pBR322 with calf
thymus Topo I (Life Technologies, Carlsbad, CA). Human Topo II and kinetoplast (kDNA)
were purchased from Topogen (Fort Orange, FL).
E. coli Gyr A and Gyr B were overexpressed using the pET expression system 186 and
purified by unpublished protocols similar to those described previously187, 188. Briefly, a
soluble fraction containing GyrA was precipitated with ammonium sulfate (60%
saturation), followed by chromatography on Q Sepharose FF, diethylaminoethyl cellulose
DE52, and Sephacryl S-200. A soluble fraction containing GyrB was also precipitated
with

ammonium

sulfate

(60%

saturation),

followed

by

chromatography

on

diethylaminoethyl cellulose DE52, Q Sepharose FF, and Sephacryl S-200. The final
preparations of GyrA and GyrB proteins were greater than 97% homogeneous for a single
band on an SDS-polyacrylamide gel (data not shown). Purified GyrA and GyrB were
mixed at a molar ratio of 1:1 to reconstitute active gyrase. All column resins were
purchased from GE Healthcare (Chalfont St. Giles, UK).
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Supercoiling assay
The effect of the compounds on the supercoiling activity of E. coli gyrase was assessed
as previously described189. Reaction mixtures (20 µL) contained 50 mM Tris-HCl (pH 8.0
at 23°C), 10 mM MgCl2, 100 mM potassium glutamate, 10 mM DTT, 50 µg/mL BSA, 1
mM ATP, 0.3 g of relaxed plasmid pBR322, 5 µg/mL tRNA, 10 fmoles of E. coli gyrase,
and various concentrations of the compounds (diluted in 50% DMSO from a 20 mM stock
solution in 100% DMSO). After incubating reaction mixtures at 37 °C for 15 minutes,
reactions were terminated by addition of EDTA to 25 mM and further incubation at 37°C
for 5 min. DNA products were analyzed by electrophoresis through vertical 1.2% agarose
gels at 2 V/cm for 15 hours in TAE buffer. Gels were stained with ethidium bromide prior
to being photographed and quantified using an Eagle Eye system. All reactions were
performed at least in duplicate.

Decatenation assays
The effect of the compounds on the catalytic activity of the  form of human Topo II was
assessed by a decatenation assay using kinetoplast DNA (kDNA) as the substrate as
previously described27. Reaction mixtures (20 µL) contained 50 mM Tris-HCl (pH 8.0 at
23°C), 10 mM MgCl2, 200 mM potassium glutamate, 10 mM DTT, 50 µg/mL BSA, 1 mM
ATP, 0.3 g of kDNA, 5 µg/mL tRNA, 2 units of Topo II, and various concentrations of the
compounds (diluted as described for the supercoiling assay). After incubating reaction
mixtures at 37 °C for 15 min, reactions were terminated by addition of EDTA to 25 mM
and further incubation at 37°C for 5 min. Reaction products were analyzed by agarose
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gel electrophoresis as described for the supercoiling assay. All reactions were performed
at least in duplicate.

DNA cleavage assays
DNA cleavage assays were performed as previously described190 to determine the ability
of the analogues to act as a topoisomerase poison. DNA cleavage reaction mixtures (20
µl) were as described for the supercoiling assay or decatenation assay, except that
potassium glutamate was omitted, relaxed plasmid pBR322 was used as the substrate,
and either 100 fmol of E. coli gyrase or 5 units of human Topo II was used. Reaction
mixtures were incubated for 10 minutes at 37°C, and then SDS was added to 1%, and
reactions were continued at 37 °C for 10 min. After addition of EDTA and proteinase K
to a final concentration of 40 mM and 100 µg/mL, respectively, the reaction mixtures were
further incubated at 37 C for 15 minutes (for E. coli gyrase) or 50 °C for one hour (human
Topo II). The DNA products were purified by extraction with phenol/chloroform/isoamyl
alcohol (25:24:1, v/v/v) and analyzed by electrophoresis through vertical 1.2% agarose
gels at 2 V/cm for 12 hours in TAE buffer. Ethidium bromide was present in both the
agarose gels and the TAE buffer at a concentration of 0.5 µg/mL. Gels were destained
in water and then photographed and quantified using an Eagle Eye system. All reactions
were performed at least in duplicate.

DNA unwinding assay
A DNA unwinding assay37 was performed as previously described189 to determine the
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ability of the compounds to intercalate into DNA. Reaction mixtures (20 µl) contained 50
mM Tris-HCl (pH 7.5 at 23°C), 1 mM MgCl2, 0.5 mM DTT, 50 μg/mL BSA, 0.3 g of
relaxed pBR322, 0.8 units of calf thymus Topo I and the indicated concentrations of the
compounds (diluted as described for the supercoiling assay). Ethidium bromide was used
as a positive control. Reaction mixtures were incubated at 37°C for 15 minutes. DNA
products were purified by extraction with phenol/chloroform/isoamyl alcohol (25:24:1,
v/v/v) and analyzed by electrophoresis through vertical 1.2% agarose gels at 2 V/cm for
15 hours in TAE buffer.

Gels were stained with ethidium bromide prior to being

photographed and quantified using a Stratagene Eagle Eye gel documentation system
(Agilent Technologies, Santa Clara, CA). All reactions were performed at least in
duplicate. Quercetin was purchased from Sigma-Aldrich (St. Louis, MO).

SPR Experimental Procedure
Linear, 5’ biotinylated DNA was dissolved in SPR buffer (10 mM HEPES pH 7.3, 3 mM
EDTA, 0.005% surfactant P20) to give a concentration of 600 nM. The DNA was
immobilized on the surface of flow cell two of a streptavidin-coated sensor chip by flowing
50 μL of the solution through at a rate of 10 μL per minute. Flow cells one and two were
then capped with 100 μL of a 1 mg/mL solution of biotin in SPR buffer. The BioCore T200
instrument was then primed with SPR buffer containing 1% (v/v) DMSO, and the flow rate
was increased to 50 μL/min. To test the compound’s ability to inhibit the DNA-DNA gyrase
binding interaction, a premixed solution of DNA gyrase (100 nM) with or without
compound (100 μM) was injected over flow cells one and two for 7 minutes. After allowing
four minutes for dissociation, the surface of the flow cell was regenerated using 1 M NaCl
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in 50 mM NaOH for 30 seconds (Figure 89).
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Figure 89: SPR Sensograms

4.2: Experimental for Studies toward Total Synthesis of SD8
Chemical reagents and solvents were purchased from Sigma-Aldrich (MO, USA), AlfaAesar (MA, USA), Fisher Scientific (PA, USA). Analytical Thin Layer Chromatography
(TLC) was performed using silica gel GHLF plates (Analtech Inc., DE, USA). Flash
chromatography was performed on a TELEDYNE ISCO CombiFlash® Rf instrument
using RediSep Rf Normal-phase Flash Columns (4-gm, 12-gm, 24-gm or 40-gm).

1H

NMR spectra were recorded on a Bruker TopSpin 400 MHz using deuterated chloroform
(CDCl3) or methanol (CD3OD). All chemical shifts are reported as δ in units of parts per
million (ppm) relative to chloroform and methanol residual peaks at 7.26 and 3.31
respectively (1H NMR spectra); 77.16 and 49.00 respectively (13C NMR spectra). The
data is reported as: chemical shifts (ppm), multiplicity (s = singlet, d = doublet, dd =
doublet of doublets, t = triplet, q = quartet, m = multiplet), coupling constant(s) (Hz) and
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integral values. Electrospray ionization (ESI) mass spectra were obtained from Perkin
Elmer Flexar UPLC/AxION2 TOF Mass Spectrometer.

(2E,4E)-hexa-2,4-dienedial
A

mixture

of

glyoxal trimer dihydrate (1.4

g,

6.7

mmol, 1.0 equiv) and

(triphenylphospharanylidene) acetaldehyde (12.16 g, 40.0 mmol, 6.0 equiv) was heated
to 80°C in DMF (80 mL, 0.08 M) for 12 hours. The reaction mixture was extracted into
ethyl acetate and washed with water and the ethyl acetate was purified over silica gel to
obtain the compound 46 (1.29 g, 11.7 mmol, 64%). 1H NMR (400 MHz, CDCl3) δ 9.73
(dd, J = 0.75, 7.78 Hz, 2H), 7.23 - 7.37 (m, 2H), 6.43 - 6.63 (m, 2H).

tert-butyl (2E,4E,6E)-8-oxoocta-2,4,6-trienoate
To a solution of mucodialdehyde (0.062 g, 0.56 mmol, 1.2 equiv) in THF, cooled to 0°C
was added a mixture of tert-Butyl diethylphosphonoacetate (0.118 g, 0.47 mmol, 1.0
equiv) and barium hydroxide (0.121 g, 0.705 mmol, 1.5 equiv) in THF:H2O (5.6 mL, 0.1
M, 40:1) over 30 minutes, after which the reaction was warmed up to room temperature
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and stirred for 90 minutes. The reaction mixture was purified over silica gel to obtain the
compound 48 (0.041 g, 0.197 mmol, 42%).

(2E,4E,6E,8E)-10-(tert-butoxy)-10-oxodeca-2,4,6,8-tetraenoic acid
To a solution of diethylphosphonoacetic acid (0.06 mL, 0.365 mmol, 1.1 equiv) in THF
(0.8 mL, 0.4 M) cooled to -60°C was added n-BuLi (2.5 M soln in hexanes, 0.316 mL, 0.8
mmol, 2.4 equiv) and the mixture was stirred for 30 minutes. To this solution was added
the aldehyde (0.069 g, 0.331 mmol, 1.0 equiv) dropwise and the solution was stirred for
30 minutes at -60°C and warmed to room temperature and stirred for 3 hours. The
reaction was quenched by addition of 1 N HCl and the compound was purified over silica
gel (0.075 g, 0.33 mmol, quant). 1H NMR (400 MHz, CDCl3) δ 7.40 (dd, J = 11.17, 15.18
Hz, 1H), 7.13 - 7.24 (m, 1H), 6.41 - 6.71 (m, 4H), 5.94 (dd, J = 15.06, 18.57 Hz, 2H), 1.51
(s, 9H).

(2E,4E,6E,8E)-deca-2,4,6,8-tetraenedioic acid
Fumagillin B (dicyclohexyammonium salt) from MEDIVET (0.021 g / 1.0 g, 5g, 0.229
mmol) was taken up into saturated sodium bicarbonate solution and was extracted into
DCM. The DCM layer was concentrated and was stirred with 1 N NaOH solution (excess)
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overnight, followed by addition of 6 N HCl to precipitate out the tetraene diacid which was
collected by flitration (0.04 g, 0.2 mmol, 90%). 1H NMR (400 MHz, DMSO-d6) δ 7.15 7.32 (m, 2H), 6.73 - 6.85 (m, 2H), 6.53 - 6.70 (m, 2H), 5.99 (d, J = 15.31 Hz, 2H).

1-(tert-butyl) 10-((3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl) (2E,4E,6E,8E)-deca-2,4,6,8tetraenedioate
Fumagillin (0.14 g, 0.3 mmol, 1.0 equiv), obtained from extraction of fumagillin B
(MEDIVET) with sodium bicarbonate was dissolved in DMF (3.0 mL, 0.1 M). To this
solution

was

added

cesium

carbonate

(2.58

g,

7.93

mmol,

26.0

equiv),

benzyltriethylammonium chloride (0.069 g, 0.305 g, 1.0 equiv) and tert-butyl bromide
(1.64 mL, 14.65 mmol, 48 equiv). The solution was heated at 60°C overnight and was
diluted with DCM and washed with saturated ammonium chloride solution. The DCM layer
was purified over silica gel to obtain the compound 52 (0.091 g, 0.177 mmol, 60%). 1H
NMR (400 MHz, CDCl3) δ 7.04 - 7.29 (m, 2H), 6.47 - 6.61 (m, 2H), 6.29 - 6.47 (m, 2H),
5.93 (d, J = 15.31 Hz, 1H), 5.83 (d, J = 15.31 Hz, 1H), 5.59 - 5.69 (m, 1H), 5.16 (t, J =
7.40 Hz, 1H), 3.62 (dd, J = 2.76, 11.04 Hz, 1H), 3.34 - 3.41 (m, 3H), 3.19 - 3.30 (m, 1H),
2.88 - 2.97 (m, 2H), 2.76 - 2.83 (m, 1H), 2.46 - 2.58 (m, 2H), 2.24 - 2.37 (m, 1H), 1.89 2.19 (m, 6H), 1.72 - 1.87 (m, 2H), 1.64 - 1.72 (m, 4H), 1.60 (s, 4H), 1.43 (s, 9H), 1.16 (s,
3H).
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(2E,4E,6E,8E)-10-(tert-butoxy)-10-oxodeca-2,4,6,8-tetraenoic acid
The above obtained fumagillin tert-butyl ester (0.091 g, 0.176 mmol, 1.0 equiv) was
dissolved in THF:EtOH (3:1, 1.76 mL, 0.1 M) and was added a solution of sodium
hydroxide (1N, 1.76 mmol, 10.0 equiv) and stirred for 3 hours. The solution was stirred
for 3 hours, followed by quenching with 1 N HCl and was purified over silica gel to obtain
the compound 50 (0.042 g, 0.17 mmol, quant). 1H NMR (400 MHz, CDCl3) δ 7.40 (dd, J
= 11.17, 15.18 Hz, 1H), 7.13 - 7.24 (m, 1H), 6.41 - 6.71 (m, 4H), 5.94 (dd, J = 15.06,
18.57 Hz, 2H), 1.51 (s, 9H).

(R)-1-(furan-2-yl)ethan-1-ol
To a solution of the furan ketone 53 (0.11 mg, 1.0 mmol) in H2O (0.5 mL), formic
acid/triethylamine (1:1, 0.5 mL) and Noyori asymmetric transfer hydrogenation catalyst
(R)-Ru(η6-mesitylene)-(R, R)-TsDPEN A (0.0095 g, 0.5 mol%). The resulting solution was
stirred at 40 °C for 8 hours. The reaction mixture was diluted with water and extracted
with diethyl ether. The combined organic layers were washed with saturated NaHCO 3,
dried over Na2SO4, and concentrated under reduced pressure. The crude product was
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purified by silica gel to give furan alcohol 54 (0.089 g, 0.79 mmol, 79%). 1H NMR (400
MHz, CDCl3) δ 7.34 (dd, J = 0.88, 1.88 Hz, 1H), 6.30 (dd, J = 1.76, 3.26 Hz, 1H), 6.20 (td,
J = 0.75, 3.26 Hz, 1H), 4.85 (q, J = 6.69 Hz, 1H), 1.51 (d, J = 6.53 Hz, 3H).

(2R)-6-hydroxy-2-methyl-2H-pyran-3(6H)-one
Compound furan alcohol 54 (0.5 g, 4.46 mmol), 9.9 mL of THF, and 5.0 mL of H2O were
added to a round bottom flask and cooled to 0 oC. Solid NaHCO3 (0.75 g, 8.9 mmol, 2.0
equiv), NaOAc•3H2O (0.61 g, 4.46 mmol, 1.0 equiv), and NBS (0.53 g, 4.46 mmol, 1.0
equiv) were added to the solution and the mixture was stirred for 1 hour at 0 oC. The
reaction was quenched with saturated NaHCO3, extracted with Et2O, dried (Na2SO4),
concentrated under reduced pressure and purified by silica gel chromatography to give
pyranone 55 (0.26 g, 2.01 mmol, 45%). 1H NMR (400 MHz, CDCl3) δ 6.73 (dd, J = 3.51,
10.04 Hz, 1H), 5.99 (d, J = 10.29 Hz, 1H), 5.18 (d, J = 3.51 Hz, 1H), 4.74 (d, J = 11.80
Hz, 1H), 4.59 (d, J = 11.80 Hz, 1H), 4.46 (q, J = 6.78 Hz, 1H), 1.27 (d, J = 6.78 Hz, 3H).

tert-butyl ((2S,6R)-6-methyl-5-oxo-5,6-dihydro-2H-pyran-2-yl) carbonate
To a benzene solution (21 mL) of pyranone 55 (1.281 g, 10.0 mmol, 1.0 equiv) and
(Boc)2O (3.5 g, 16.0 mmol) was added sodium acetate (0.985 g, 12.0 mmol). After stirring
at 80 ºC for 2 hours, the mixture was cooled down to room temperature and was quenched
by addition of saturated NaHCO3 solution, extracted with Et2O, dried (Na2SO4), and
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concentrated under reduced pressure. The crude product was purified by silica gel flash
chromatography to give two diastereomers of tert-butyl 5,6-dihydro-6-methyl-5-oxo-2Hpyran-2-yl carbonate; β (0.55 g, 2.4 mmol, 24%). 1H NMR (400 MHz, CDCl3) δ 6.81 - 6.95
(m, 1H), 6.36 (dd, J = 1.38, 2.64 Hz, 1H), 6.20 (dd, J = 1.25, 10.29 Hz, 1H), 4.37 (q, J =
7.03 Hz, 1H), 1.51 (s, 12H).

(2R,6R)-6-(benzyloxy)-2-methyl-2H-pyran-3(6H)-one
A DCM (2.3 mL) solution of Boc pyranone 56β (0.52 g, 2.28 mmol, 1.0 equiv) and benzyl
alcohol 0.48 mL, 4.56 mmol, 2.0 equiv) was cooled to 0° C. A DCM (1.4 mL) solution of
Pd2(DBA)3•CHCl3 (0.055 g, 0.06 mmol, 2.5 mol%) and PPh3 (0.06 g, 0.23 mmol, 10 mol%)
was added to the reaction mixture at 0°C. The reaction mixture was stirred at 0 °C for 2
hours and was quenched with saturated NaHCO3 solution, extracted with diethyl ether,
dried over sodium sulfate, and concentrated under reduced pressure. The crude product
was purified by silica gel flash chromatography to give 57 (340 mg, 2.17 mmol, 95%). 1H
NMR (400 MHz, CDCl3) δ 7.30 - 7.43 (m, 5H), 6.92 (dd, J = 2.01, 10.29 Hz, 1H), 6.15 (dd,
J = 1.51, 10.29 Hz, 1H), 5.33 - 5.46 (m, 1H), 4.96 (d, J = 11.80 Hz, 1H), 4.70 (d, J = 11.80
Hz, 1H), 4.25 (dq, J = 0.75, 6.86 Hz, 1H), 1.54 (d, J = 6.78 Hz, 3H).

(2R,6R)-6-(benzyloxy)-2-methyl-3,6-dihydro-2H-pyran-3-ol

165

A DCM (1.5 mL) solution of enone 57 (0.3 g, 1.37 mmol, 1.0 equiv) and CeCl3 in MeOH
solution (1.24 mL) was cooled to -78 °C. NaBH4 (0.052 g, 1.37 mmol) was added and the
reaction mixture was stirred at -78 °C for 3 hours. The reaction mixture was diluted with
diethyl ether and was quenched with saturated aqueous NaHCO 3, extracted with Et2O
and concentrated under reduced pressure. The crude product was purified by silica gel
flash chromatography to give allylic alcohols 58 (0.17 g, 1.08 mmol, 79%). 1H NMR (400
MHz, CDCl3) δ 7.14 - 7.33 (m, 5H), 5.67 - 5.80 (m, 1H), 5.00 - 5.12 (m, 1H), 4.80 (dd, J
= 11.80, 18.57 Hz, 1H), 4.49 - 4.62 (m, 1H), 3.58 (quin, J = 6.46 Hz, 1H), 1.79 (br. s., 1H),
1.23 - 1.33 (m, 3H).

(2R,6R)-2-(benzyloxy)-6-methyl-3,6-dihydro-2H-pyran
To a solution of dry N-methyl morpholine (NMM) (1.9 mL, 2.04 mmol, 3.0 equiv) triphenyl
phosphine (0.59 g, 2.25 mmol, 3.3 equiv) and was cooled to -30 °C under Ar atmosphere.
Diisopropylazodicarboxylate (0.41 mL, 2.04 mmol, 3.0 equiv) was added and the reaction
was stirred for 5 minutes, allylic alcohol 58 (0.15 g, 0.68 mmol, 1.0 equiv) was added in
a 1 M solution of NMM and the reaction mixture was stirred for 10 minutes, followed by
addition of o-nitrobenzenesulfonyl hydrazide (NBSH) (0.444 g, 2.04 mmol, 3.0 equiv).
The reaction was stirred at -30 °C for 2 hours and was monitored by TLC. Upon
consumption of starting material, the reaction was warmed up to room temperature and
stirred for another 2 hours. The reaction mixture was diluted with diethyl ether and was
quenched with saturated aqueous NaHCO3, extracted with diethyl ether and concentrated
under reduced pressure. The crude product was purified over silica gel to to give product
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59 (0.133 g, 0.65 mmol, 97%). 1H NMR (400 MHz, CDCl3) δ 7.15 - 7.33 (m, 5H), 5.55 5.66 (m, 1H), 5.52 (tdd, J = 1.38, 2.67, 10.13 Hz, 1H), 4.87 (d, J = 12.05 Hz, 1H), 4.67
(dd, J = 3.51, 7.78 Hz, 1H), 4.55 (d, J = 12.05 Hz, 1H), 4.21 - 4.31 (m, 1H), 2.04 - 2.26
(m, 2H), 1.25 (d, J = 6.78 Hz, 3H).

(2R,3S,4S,6R)-6-(benzyloxy)-2-methyltetrahydro-2H-pyran-3,4-diol
To a DCM (2.7 mL, 0.47 M) solution of olefin 17 (0.255g, 1.25 mmol, 1.0 equiv) at 0 °C
was added a solution of (50% w/v) of N-methyl morpholine N-oxide / water (0.57 mL).
Crystalline OsO4 (0.00318 g, 1 mol %) was added and the reaction was stirred for 3
hours. The reaction was quenched by adding EtOAc and saturated aqueous NaHCO 3.
The organic layer was separated and concentrated and was purified over silica gel to
obtain the diol 60 (0.24 g, 1.007 mmol, 80%). 1H NMR (400 MHz, CDCl3) δ 7.25 - 7.40
(m, 5H), 4.84 - 4.96 (m, 2H), 4.58 (d, J = 11.80 Hz, 1H), 4.08 - 4.17 (m, 1H), 3.76 (qd, J
= 6.27, 9.29 Hz, 1H), 3.35 (dd, J = 3.26, 9.29 Hz, 1H), 2.14 (ddd, J = 2.26, 3.64, 13.93
Hz, 1H), 1.80 (ddd, J = 3.01, 9.41, 13.93 Hz, 1H), 1.35 (d, J = 6.27 Hz, 3H).

(2R,3R,4R,6R)-6-(benzyloxy)-4-methoxy-2-methyltetrahydro-2H-pyran-3-ol
A THF (1.37 mL, 0.67M) solution of diol 60 (7.0 g, 29.4 mmol) at 0 °C were added PPh3
(0.495 g, 1.88 mmol, 2.05 equiv) and p-nitrobenzoic acid (0.309 g, 1.85 mmol, 2.0 equiv).
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DIAD (0.36 mL, 1.85 mmol, 2.0 equiv) in THF was added dropwise and the reaction
mixture was warmed up to room temperature and stirred overnight. The solution was
quenched with saturated aqueous NaHCO3, extracted with diethyl ether, and purified over
silica gel to give compound 61, which was used directly for the next step.

(((2R,3R,4R,6R)-6-(benzyloxy)-4-methoxy-2-methyltetrahydro-2H-pyran-3yl)oxy)(tert-butyl)dimethylsilane
To the above obtained alcohol 61 (0.242 g, 0.625 mmol, 1.0 equiv) in DCM (3.9 mL, 0.16
M) was added 2,6-lutidine (0.17 mL, 0.75 mmol, 1.2 equiv) and cooled to 0 °C. To this
solution was added TBSOTf (0.12 mL, 1.0 mmol, 1.6 equiv) and the reaction was allowed
to warm up to room temperature and stirred for 3 hours. The reaction mixture was
quenched by addition of 1N HCl and purified over silica gel to obtain the tri-protected
olivose sugar 62 (0.139 g, 0.38 mmol, 30% overall for 2 steps). 1H NMR (400 MHz, CDCl3)
δ 8.26 - 8.35 (m, 2H), 8.16 - 8.24 (m, 2H), 7.28 - 7.40 (m, 5H), 5.14 (ddd, J = 5.27, 8.60,
11.73 Hz, 1H), 4.91 (d, J = 12.05 Hz, 1H), 4.58 - 4.72 (m, 2H), 3.55 (t, J = 8.66 Hz, 1H),
3.41 (qd, J = 6.18, 8.82 Hz, 1H), 2.40 (ddd, J = 2.01, 5.27, 12.30 Hz, 1H), 1.80 (dt, J =
9.66, 12.11 Hz, 1H), 1.39 (d, J = 6.27 Hz, 3H), 0.77 (s, 9H), 0.09 (s, 3H), -0.13 (s, 3H).
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1-(2-hydroxy-4-((4-methoxybenzyl)oxy)phenyl)ethan-1-one
To a refluxing solution of 2’,4’-dihydroxyacetophenone (3 g, 19.72 mmol, 1.0 equiv) and
potassium carbonate (6 g, 43.39 mmol, 2.2 equiv) in acetonitrile (40 mL, 0.5 M) was
added PMBCl (2.67 mL, 19.72 mmol, 1.0 equiv) and the solution was refluxed for 16
hours, following which it was quenched by 1N HCl, extracted into ethyl acetate and
washed with 1N HCl solution. The ethyl acetate layer was dried and purified over silica
gel to obtain the compound 64 (2.45 g, 9.07mmol, 46% yield). 1H NMR (400 MHz, CDCl3)
δ 12.74 (s, 1H), 7.64 (d, J = 9.29 Hz, 1H), 7.35 (d, J = 8.80 Hz, 2H), 6.93 (d, J = 8.70 Hz,
2H), 6.51 (qd, J = 2.49, 4.83 Hz, 2H), 5.03 (s, 2H), 3.83 (s, 3H), 2.56 (s, 3H).

4-hydroxy-7-((4-methoxybenzyl)oxy)-2H-chromen-2-one
To a refluxing suspension of sodium hydride (60%, 1.09 g, 27.24 mmol, 2.0 equiv) in
toluene (91 mL, 0.1 M), was added a solution of compound 64 (2.47 g, 9.08 mmol, 1.0
equiv) in toluene dropwise, followed by dimethyl carbonate (1.15 mL, 13.63 mmol, 1.5
equiv) and the reaction was allowed to stir overnight under reflux. The following day, the
reaction was cooled to 0 °C and quenched with 1 N HCl and diluted with ethyl acetate.
The ethyl acetate layer was washed with 1 N HCl solution and concentrated. The product
was precipitated out using methanol to get the coumarin 65 (2.79 g, 9.08 mmol, quant).
1H

NMR (400 MHz, DMSO-d6) δ 12.32 (br. s., 1H), 7.70 (d, J = 8.78 Hz, 1H), 7.40 (d, J =
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8.80 Hz, 2H), 7.01 (d, J = 2.51 Hz, 1H), 6.93 - 6.99 (m, 3H), 5.45 (s, 1H), 5.11 (s, 2H),
3.75 (s, 3H).

bis(2,2,2-trichloroethyl) 1-(4-hydroxy-7-((4-methoxybenzyl)oxy)-2-oxo-2Hchromen-3-yl)hydrazine-1,2-dicarboxylate
To a solution of the coumarin 65 (0.1 g, 0.335 mmol, 1.0 equiv) in acetonitrile (0.67 mL,
0.5 M) was added ammonium acetate (0.00516 g, 0.067 mmol, 0.2 equiv) and bis(2,2,2trichloroethyl) azodicarboxylate (0.153 g, 0.4 mmol, 1.2 equiv). The reaction mixture was
stirred for 2 hours and the product was purified over silica gel to obtain the compound 67
(0.226 g, 0.335 mmol, quant). 1H NMR (400 MHz, CDCl3) δ 7.95 (br. s., 1H), 7.85 (d, J =
8.78 Hz, 1H), 7.37 (d, J = 8.53 Hz, 2H), 6.86 - 7.03 (m, 4H), 5.08 (s, 2H), 4.73 - 5.04 (m,
4H), 3.84 (s, 3H).

3-amino-4-hydroxy-7-((4-methoxybenzyl)oxy)-2H-chromen-2-one
To a solution of the coumarin 67 (0.226 g, 0.333 mmol, 1.0 equiv) in acetic acid (2.38 mL,
0.14 mL) was added acetone (238 µL) and zinc (0.68 g, 10.37 mmol, 31.0 equiv) and the
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reaction was stirred overnight. The following day, the reaction was filtered through celite,
basified with sodium bicarbonate solution and extracted into DCM. The DCM layer was
purified over silica to obtain the aminocoumarin 68 (0.048 g, 0.15 mmol, 46%). 1H NMR
(400 MHz, DMSO-d6) δ 7.75 (d, J = 8.53 Hz, 1H), 7.40 (d, J = 8.78 Hz, 2H), 6.79 - 7.00
(m, 4H), 5.08 (s, 2H), 3.76 (s, 3H).

4,7-dihydroxy-3-nitro-2H-chromen-2-one
To a solution of the coumarin 68 (0.5 g, 2.108 mmol, 1.0 equiv) in DMF (10.54 mL, 0.2
M), was added 1-dodecanethiol (3.54 mL, 14.76 mmol, 7.0 equiv) and potassium tertbutoxide (0.592 g, 5.27 mmol, 2.5 equiv). The reaction mixture was heated at 120 °C
overnight, followed by quenching the reaction with 1 N HCl and extracting the product
into ethyl acetate, which was purified over silica gel to obtain the compound 70 (0.416 g,
1.87 mmol, 88%). 1H NMR (400 MHz, DMSO-d6) δ 10.13 (br. s., 1H), 7.67 (d, J = 8.53
Hz, 1H), 6.62 (dd, J = 2.26, 8.53 Hz, 1H), 6.45 (d, J = 2.26 Hz, 1H).

8-chloro-4,7-dihydroxy-3-nitro-2H-chromen-2-one
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To a solution of the nitrocoumarin (0.055 g, 0.25 mmol, 1.0 equiv) in dioxane:water (1:1,
1.23 mL, 0.2 M) was added chloramine-T hydrate (0.07 g, 0.25 mmol, 1.0 equiv). The
reaction mixture was heated at reflux overnight and was extracted into ethyl acetate and
dried. Analysis of the crude mixture by 1H NMR indicated a 50% conversion into product
71. 1H NMR (400 MHz, DMSO-d6) δ 10.14 (s, 2H), 7.64 (d, J = 8.53 Hz, 1H), 6.83 (d, J =
8.53 Hz, 1H).

2-(hydroxymethyl)-6-methoxy-3,4-dihydronaphthalen-1(2H)-one
To a solution of n-butyllithium (0.7 mL, 1.7 mmol, 3.0 equiv) in THF (8.1 mL, 0.07M) was
added 2,2,6,6-tetramethylpiperidine (0.29 mL, 1.7 mmol, 3.0 equiv) at -10 °C. The
solution was stirred for 30 minutes and then cooled to -78 °C and compound 72 (0.1 g,
0.57 mmol, 1.0 equiv) was added in THF dropwise and stirred for an additional one hour.
To this, 1H-benzotriazole-methanol (0.17 g, 1.134 mmol, 2.0 equiv) was added dropwise
over a period of 30 minutes and kept at this temperature for 2 hours. The solution was
quenched with water and extracted into ethyl acetate and purified over silica gel to get
the compound 73 (0.076 g, 0.37 mmol, 65%). 1H NMR (400 MHz, CDCl3) δ 8.01 (d, J =
8.78 Hz, 1H), 6.79 - 6.87 (m, 1H), 6.71 (d, J = 2.51 Hz, 1H), 3.74 - 3.97 (m, 5H), 2.90 -
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3.15 (m, 2H), 2.68 (tdd, J = 4.49, 7.65, 13.24 Hz, 1H), 2.04 - 2.15 (m, 1H), 1.84 - 2.01 (m,
1H).

2-hydroxy-2-(hydroxymethyl)-6-methoxy-3,4-dihydronaphthalen-1(2H)-one
To a solution of the alcohol 73 (1.012 g, 4.91 mmol, 1.0 equiv) and triethylamine (1.71
mL, 12.27 mmol, 2.5 equiv) in DCM (9.82 mL, 0.5 M) was cooled to 0 °C was added
TBSOTf (2.48 mL, 10.8 mmol, 2.2 equiv). The reaction was allowed to warm up to room
temperature and stirred for 3 hours, following which the reaction was diluted with DCM
and washed with water and concentrated and used for the next step without any further
purification.
The above obtained crude was dissolved in DCE (15.0 mL, 0.2 M) and cooled to 0 °C. To
this solution was added 3-chloroperbenzoic acid (2.12 g, 12.27 mmol, 2.5 equiv) and was
allowed to warm up to room temperature. The reaction mixture was stirred for 2 hours
and was filtered over celite and washed with DCE. The mixture was diluted with DCM
and washed with half saturated sodium carbonate and the DCM layer was concentrated
and was used for the next step without purification.
The crude was dissolved in THF (10.0 mL, 0.5 M) and was added TBAF (1 M in THF,
14.7 mmol, 3.0 equiv) and was allowed to stir overnight. The following day, the reaction
mixture was diluted with ethyl acetate and washed with water and then brine. The ethyl
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acetate layer was concentrated and purified over silica gel to obtain the diol 74 (1.087 g,
3.19 mmol, 65%). 1H NMR (400 MHz, CDCl3) δ 7.99 (d, J = 8.78 Hz, 1H), 6.87 (dd, J =
2.51, 8.78 Hz, 1H), 6.71 (d, J = 2.51 Hz, 1H), 3.88 (s, 3H), 3.60 - 3.79 (m, 2H), 3.29 - 3.43
(m, 1H), 2.95 - 3.11 (m, 2H), 2.34 - 2.50 (m, 1H), 2.11 (ddd, J = 6.53, 11.04, 13.30 Hz,
2H), 1.62 - 1.75 (m, 1H), 1.41 - 1.53 (m, 1H), 1.02 (t, J = 7.40 Hz, 2H).

6-methoxy-3,4-dihydro-1H-spiro[naphthalene-2,2'-oxiran]-1-one
To a solution of the diol 74 (0.320 g, 1.44 mmol, 1.0 equiv) in DMF (14.4 mL, 0.1M) was
added DIAD (0.57 mL, 2.88 mmol, 2.0 equiv) and tributylphosphine (0.72 mL, 2.88 mmol,
2.0 equiv). The reaction mixture was allowed to stir overnight and purified over silica gel
to obtain the epoxide 75 (0.285 g, 1.39 mmol, 97%). 1H NMR (700 MHz, CDCl3) δ 8.07
(d, J = 8.80 Hz, 1H), 6.88 (dd, J = 2.64, 8.80 Hz, 1H), 6.76 (d, J = 2.64 Hz, 1H), 3.89 (s,
3H), 2.91 (d, J = 6.60 Hz, 1H), 2.44 - 2.59 (m, 1H), 1.95 - 2.10 (m, 2H).

2-hydroxy-2-(iodomethyl)-6-methoxy-3,4-dihydronaphthalen-1(2H)-one
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To a solution of the epoxide 75 (0.04 g, 0.196 mmol, 1.0 equiv) in THF (1.96 mL, 0.1 M)
was added TBAI (0.145 g, 0.4 mmol, 2.0 equiv) and boron trifluoride etherate (0.05 mL,
0.4 mmol, 2.0 equiv). The solution was stirred for one hour and was diluted by ethyl
acetate. The ethyl acetate layer was washed with water, brine and purified over silica gel
to obtain the compound 76 (0.042 g, 0.125 mmol, 64%). 1H NMR (700 MHz, CDCl3) δ
8.00 (d, J = 8.80 Hz, 1H), 6.88 (dd, J = 2.64, 8.80 Hz, 1H), 6.62 - 6.74 (m, 1H), 3.99 (s,
1H), 3.88 (s, 3H), 3.53 (d, J = 11.00 Hz, 1H), 3.30 (dd, J = 1.32, 11.00 Hz, 1H), 2.49 (ddd,
J = 2.42, 4.95, 13.75 Hz, 1H), 2.16 - 2.28 (m, 1H), 1.90 - 2.01 (m, 1H), 1.65 - 1.75 (m,
1H)

6-methoxy-2-((4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)methyl)-3,4dihydronaphthalen-1(2H)-one
Compound 72 (1.47 g, 8.34 mmol, 1.0 equiv) was dissolved in THF (42.0 mL, 0.2 M) and
cooled to -78°C. A solution of LiHMDS (1 M in THF, 12.5 mL, 1.5 equiv) was added
dropwise, and the solution was stirred for 30 minutes, following which iodomethylpinacol
boronate (12.5 mmol, 1.5 equiv) was added and the solution was stirred at the same
temperature for 30 minutes. Then the mixture was allowed to warm to room temperature
and was stirred for an additional 2 hours. The reaction mixture was quenched by addition
of water and extracted into ethyl acetate and purified on silica gel to get the compound
78 (1.423 g, 4.5 mmol, 55%). 1H NMR (700 MHz, CDCl3) δ 8.02 (d, J = 8.80 Hz, 1H), 6.83
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(dd, J = 2.42, 8.58 Hz, 1H), 6.69 - 6.74 (m, 1H), 3.87 (s, 3H), 2.94 (t, J = 5.94 Hz, 2H),
2.57 - 2.64 (m, 2H), 2.18 (s, 1H), 2.13 (td, J = 6.22, 12.65 Hz, 2H), 1.24 - 1.34 (m, 9H).

potassium trifluoro((6-methoxy-1-oxo-1,2,3,4-tetrahydronaphthalen-2yl)methyl)borate
The above obtained pinacol boronate (0.925 g, 2.925 mmol, 1.0 equiv) was dissolved in
acetonitrile (14.6 mL, 0.2 M) and cooled to 0 °C. To this was added saturated aqueous
KHF2 (4.5 M, 2.6 mL, 4.0 equiv) dropwise at 0 °C and the solution was stirred for 3 hours
at room temprature. The resulting suspension was concentrated in vacuo and was
purified by continuous Soxhlet extraction with acetone for 12 hours to provide the
compound 79 (0.864 g, 2.92 mmol, quant). 1H NMR (400 MHz, DMSO-d6) δ 7.77 (d, J =
8.78 Hz, 1H), 6.71 - 6.87 (m, 2H), 3.80 (s, 3H), 2.64 - 2.79 (m, 1H), 2.30 (tdd, J = 3.73,
7.69, 11.45 Hz, 1H), 2.03 - 2.14 (m, 1H), 1.79 - 1.92 (m, 1H), 0.44 (ddd, J = 2.89, 6.78,
13.43 Hz, 1H), -0.01 - 0.12 (m, 1H).

N,N-diethyl-3-hydroxybenzamide
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To a solution of 3-hydroxybenzoic acid (2.5 g, 18.1 mmol, 1.0 equiv) in DCM (30.0 mL,
0.6 M), cooled to 0 °C was added oxalyl chloride (1.84 mL, 22.0 mmol, 1.2 equiv) and
DMF (0.35 mL, catalytic). The reaction was allowed to warm up to room temperature and
stirred for 3 hours, followed by removal of all the solvents in vacuo. The crude was
dissolved in DCM (30 mL, 0.6 M) and was cooled to 0 °C. To this was added a solution
of diethylamine (2.81 mL, 26.89 mmol, 1.48 equiv) and triethylamine (5.04 mL, 36.2 equiv,
2.0 equiv) in DCM (60 mL). The reaction mixture was allowed to warm up to room
temperature and stirred overnight. The solution was concentrated in vacuo and the
product was purified out over silica gel (3.2 g, 16.6 mmol, 92%).

N,N-diethyl-3-methoxybenzamide
The above prepared phenol (3.48 g, 18.1 mmol, 1.0 equiv) was dissolved in acetone (60
mL, 0.3 M) and was added potassium carbonate (3.75 g, 27.15 mmol, 1.5 equiv) and was
refluxed. To this solution was added methyl iodide (1.69 mL, 27.15 mmol, 1.5 equiv) and
was allowed to react overnight. The crude mixture was allowed to cool down and
quenched with 1 N HCl and extracted into ethyl acetate. The ethyl acetate layer was
purified over silica gel to get compound 81’ (3.7 g, 18.0 mmol, quant).
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N,N-diethyl-2-formyl-3-methoxybenzamide
To a solution of the amide 81’ (1.7 g, 8.24 mmol, 1.0 equiv) in diethyl ether (22.0 mL, 0.4
M) was cooled to -78 °C was added TMEDA (1.23 mL, 8.24 mmol, 1.0 equiv) and
dropwise added s-BuLi (7.1 mL, 9.9 mmol, 1.2 equiv). The solution was allowed to stir for
one hour followed by the dropwise addition of DMF (0.77 mL, 9.9 mmol, 1.2 equiv). The
reaction was maintained for one hour at -78 °C followed by allowing it to warm up to room
temperature overnight. The reaction was quenched by addition of 1N HCl and followed
by extraction into ethyl acetate. The ethyl acetate layer was purified over silica gel to
obtain compound 82 (1.22 g, 5.52 mmol, 67%). 1H NMR (400 MHz, CDCl3) δ 10.49 (s,
1H), 7.55 (dd, J = 7.53, 8.53 Hz, 1H), 7.01 (dd, J = 0.75, 8.53 Hz, 1H), 6.85 (td, J = 0.75,
7.53 Hz, 1H), 3.95 (s, 3H), 3.59 (q, J = 7.19 Hz, 2H), 3.07 (q, J = 7.03 Hz, 2H), 1.33 (t, J
= 7.15 Hz, 3H), 1.01 (t, J = 7.15 Hz, 3H).

N,N-diethyl-2-formyl-3-hydroxybenzamide
To a solution of compound 82 (0.744 g, 3.162 mmol, 1.0 equiv) in DCM (16.0 mL, 0.2 M),
cooled to -78 °C was added boron tribromide (1M in DCM, 2.5 equiv). The reaction was
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allowed to warm to room temperature and kept overnight. Saturated solution of
ammonium chloride was added to quench the reaction and the product was extracted into
DCM and purified over silica gel to give compound 82’ (0.605 g, 2.73 mmol, 87%). 1H
NMR (400 MHz, CDCl3) δ 11.58 (s, 1H), 9.95 (d, J = 0.50 Hz, 1H), 7.53 (dd, J = 7.40,
8.41 Hz, 1H), 7.01 (td, J = 0.75, 8.53 Hz, 1H), 6.84 (dd, J = 1.00, 7.53 Hz, 1H), 3.62 (br.
s., 2H), 3.21 (q, J = 7.11 Hz, 2H), 1.29 (t, J = 7.00 Hz, 3H), 1.10 (t, J = 7.00 Hz, 3H).

3-(benzyloxy)-N,N-diethyl-2-formylbenzamide
Benzyl bromide (0.483 mL, 4.065 mmol, 1.5 equiv) was added to a solution of the
compound 81’ (0.6 g, 2.71 mmol, 1.0 equiv), sodium hydride (60%, 4.065 mmol, 1.5
equiv) in DMF (13.5 mL, 0.2 M) cooled to 0 °C. The solution was allowed to warm up to
room temperature over 4 hours and cooled to 0 °C again. The reaction was quenched by
addition of 1N HCl followed by extraction of the product into ethyl acetate and purification
over silica gel to obtain compound 83 (0.641 g, 2.05 mmol, 76%). 1H NMR (400 MHz,
CDCl3) δ 10.56 (d, J = 0.75 Hz, 1H), 7.51 (dd, J = 7.53, 8.28 Hz, 1H), 7.33 - 7.47 (m, 5H),
7.05 (dd, J = 0.88, 8.41 Hz, 1H), 6.78 - 6.90 (m, 1H), 5.21 (s, 2H), 3.59 (q, J = 7.11 Hz,
2H), 3.07 (q, J = 7.28 Hz, 2H), 1.32 (t, J = 7.15 Hz, 3H), 1.01 (t, J = 7.20 Hz, 3H).
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7-(benzyloxy)-3-oxo-1,3-dihydroisobenzofuran-1-carbonitrile
To a solution of the compound 83 (0.37 g, 1.19 mmol, 1.0 equiv) in DCM (6.0 mL, 0.2 M)
was added 18-crown-6 (0.063 g, 0.24 mmol, 0.2 equiv), potassium cyanide (0.016 g, 0.24
mmol, 0.2 equiv), TMSCN (0.221 mL, 1.67 mmol, 1.4 equiv) and cooled to 0°C. To this
solution, dropwise (CAUTION: EVOLUTION OF HCN GAS) was added glacial acetic acid
(3.0 mL, 0.4 M). The solution was stirred at 0 °C for 3 hours, followed by stirring at room
temperature overnight. The reaction was quenched by addition of 1 N HCl and extraction
into DCM. The DCM layer was purified over silica gel to obtain the compound 84 (0.214
g, 0.8 mmol, 68%). 1H NMR (400 MHz, CDCl3) δ 7.50 - 7.64 (m, 2H), 7.32 - 7.48 (m, 5H),
7.20 - 7.29 (m, 1H), 6.00 (s, 1H), 5.18 - 5.34 (m, 2H).

2-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2Hpyran-2-yl)naphthalen-1-ol
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To a solution of 2,3,4,6-Tetra-O-benzyl-D-glucopyranose 86 (0.3 g, 0.55 mmol, 1.0 equiv)
in DCM (12.0 mL, 0.023 M) was added trifluoroacetic anhydride (0.084 mL, 0.6 mmol,
1.09 equiv) and stirred for 1h at room temperature. The reaction was concentrated in
vacuo and dissolved in DCM (12.0 mL) and added 1-naphthol 85 (0.238 g, 1.65 mmol,
2.97 equiv) and cooled to 0 °C. To this solution was added trifluoromethanesulfonic acid
(0.09 mL, 1.021 mmol, 1.84 equiv) dropwise, and the solution was allowed to warm up to
room temperature and stirred for 3 hours. The reaction was quenched by addition of
water, extracted into DCM and purified over silica gel to obtain the product 87 (0.138 g,
0.2 mmol, 37%). 1H NMR (400 MHz, CDCl3) δ 7.99 - 8.26 (m, 2H), 7.87 - 7.99 (m, 1H),
7.65 - 7.87 (m, 1H), 7.38 - 7.51 (m, 3H), 7.06 - 7.36 (m, 18H), 5.15 (br. s., 1H), 5.03 - 5.12
(m, 1H), 4.28 - 4.47 (m, 2H), 4.00 - 4.23 (m, 4H), 3.86 - 4.00 (m, 1H).

2-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2Hpyran-2-yl)naphthalen-1-ol
To a solution of 1-naphthol 85 (0.029 g, 0.2 mmol, 2.0 equiv) and 2,3,4,6-Tetra-O-benzylD-glucopyranose 86 (0.054 g, 0.1 mmol, 1.0 equiv) and silver perchlorate (0.00415 g,
0.02 mmol, 20 mol%) in DCM (1.0 mL, 0.1 M was added TMSOTf (4.0 µL, 0.02 mmol, 20
mol%) at 0 °C. The reaction mixture was stirred for 2 hours, followed by quenching the
reaction with triethylamine and purification over silica gel to give the compound 87 (0.021
g, 0.032 mmol, 32% yield). 1H NMR (400 MHz, CDCl3) δ 7.99 - 8.26 (m, 2H), 7.87 - 7.99
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(m, 1H), 7.65 - 7.87 (m, 1H), 7.38 - 7.51 (m, 3H), 7.06 - 7.36 (m, 18H), 5.15 (br. s., 1H),
5.03 - 5.12 (m, 1H), 4.28 - 4.47 (m, 2H), 4.00 - 4.23 (m, 4H), 3.86 - 4.00 (m, 1H).

3-hydroxy-13-methyl-2-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)-6,7,8,9,11,12,13,14,15,16-decahydro17H-cyclopenta[a]phenanthren-17-one
To a solution of estrone 88 (0.029 g, 0.2 mmol, 2.0 equiv) and 2,3,4,6-Tetra-O-benzyl-Dglucopyranose 86 (0.054 g, 0.1 mmol, 1.0 equiv) and silver perchlorate (0.00415 g, 0.02
mmol, 20 mol%) in DCM (1.0 mL, 0.1 M was added TMSOTf (4.0 µL, 0.02 mmol, 20
mol%) at 0 °C. The reaction mixture was stirred for 2 hours, followed by quenching the
reaction with triethylamine and purification over silica gel to give the compound 89 (0.029
g, 0.037 mmol, 37% yield). 1H NMR (400 MHz, CDCl3) δ 6.91 - 7.19 (m, 15H), 6.82 - 6.90
(m, 1H), 6.71 - 6.79 (m, 1H), 3.98 - 4.03 (m, 1H), 3.69 - 3.97 (m, 6H), 2.47 - 2.75 (m, 2H),
2.24 - 2.47 (m, 2H), 1.91 - 2.10 (m, 6H), 1.73 - 1.90 (m, 3H), 1.23 - 1.49 (m, 7H), 1.11 1.22 (m, 3H), 0.75 - 0.81 (m, 2H), 0.71 - 0.75 (m, 3H).
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(2E,4E)-N-(2-oxo-2H-chromen-3-yl)hexa-2,4-dienamide
To a solution of 3-aminocoumarin 90 (0.1 g, 0.621 mmol, 1.0 equiv) in pyridine:DCM
(30%, 0.06 M) was added sorbic acid 91 (0.14 g, 1.241 mmol, 2.0 equiv) and EDCI (0.298
g, 1.55 mmol, 2.5 equiv) and the solution was let stir overnight. The following day, reaction
mixture was diluted with DCM, washed with copper sulfate solution, dried and purified
over silica gel to obtain the amide 92 (0.094 g, 0.37 mmol, 59%). 1H NMR (400 MHz,
CDCl3) δ 8.71 - 8.87 (m, 1H), 8.08 (br. s., 1H), 7.53 (dd, J = 1.51, 7.78 Hz, 1H), 7.42 7.48 (m, 1H), 7.28 - 7.40 (m, 3H), 6.18 - 6.29 (m, 2H), 5.94 (d, J = 15.06 Hz, 1H), 1.90 (d,
J = 5.27 Hz, 3H).

4-(benzyloxy)cyclohexyl (2E,4E)-hexa-2,4-dienoate
To a solution of sorbic acid 93 (0.163 g, 1.45 mmol, 1.5 equiv) in toluene (10.0 mL, 0.1
M) cooled to 0 °C was added triethylamine (0.54 mL, 3.9 mmol, 4.0 equiv) and 2,4,6trichlorobenzoyl chloride (0.26 mL, 1.65 mmol, 1.7 equiv). The reaction was stirred for 1
hour followed by addition of the alcohol 93 (0.2 g, 0.97 mmol, 1.0 equiv) and DMAP (0.24
g, 1.94 mmol, 2.0 equiv) and was stirred overnight at room temperature. The following
day, the reaction was quenched with sodium bicarbonate solution and extracted into
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diethyl ether. The ether layer was purified over silica gel to give the compound 94 (0.15g,
0.5 mmol, 51%). 1H NMR (400 MHz, CDCl3) δ 7.19 - 7.43 (m, 5H), 6.07 - 6.28 (m, 2H),
5.70 - 5.83 (m, 1H), 4.82 - 4.98 (m, 1H), 4.51 - 4.59 (m, 2H), 3.40 - 3.58 (m, 1H), 1.99 2.10 (m, 2H), 1.80 - 1.99 (m, 5H), 1.61 - 1.79 (m, 2H), 1.40 - 1.61 (m, 2H).
4.3: Experimental for Design and Synthesis of Substrate-Competitive Covalent
Inhibitors of AKT
4.3.1: Chemistry Experimentals
Chemical reagents and solvents were purchased from Sigma-Aldrich (MO, USA), AlfaAesar (MA, USA), Fisher Scientific (PA, USA). Analytical Thin Layer Chromatography
(TLC) was performed using silica gel GHLF plates (Analtech Inc., DE, USA). Flash
chromatography was performed on TELEDYNE ISCO CombiFlash® Rf instrument using
RediSep Rf Normal-phase Flash Columns (4-gm, 12-gm, 24-gm or 40-gm). 1H NMR and
13C

NMR spectra were recorded on a Bruker TopSpin 400 MHz using deuterated

chloroform (CDCl3) or methanol (CD3OD). All chemical shifts are reported as δ in units of
parts per million (ppm) relative to chloroform and methanol residual peaks at 7.26 and
3.31 respectively (1H NMR spectra); 77.16 and 49.00 respectively (13C NMR spectra).
The data is reported as: chemical shifts (ppm), multiplicity (s = singlet, d = doublet, dd =
doublet of doublets, t = triplet, q = quartet, m = multiplet), coupling constant(s) (Hz) and
integral values. Electrospray ionization (ESI) mass spectra were obtained from Perkin
Elmer Flexar UPLC/AxION2 TOF Mass Spectrometer.
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2-Chloro-N-phenylacetamide
To a stirred solution of aniline 123 (1.0 g, 10.74 mol, 1.0 equiv) and triethylamine (1.79
mL, 12.9 mmol, 1.2 equiv) in dichlomethane (11.0 mL, 1.0 M), cooled to 0 °C, was added
chloroacetyl chloride (1.03 mL, 12.9 mmol, 1.2 equiv) dropwise and the mixture was
allowed to warm up to room temperature overnight after which the mixture was washed
with 1 N HCl and dried over anhydrous sodium sulfate. The DCM layer was concentrated
in vacuo and purified over silica gel to get the desired compound 125 (1.821 g, 10.73
mmol, quant). 1H NMR (400 MHz, CDCl3) δ 8.24 (br. s., 1H), 7.56 (d, J = 8.53 Hz, 2H),
7.38 (t, J = 7.91 Hz, 2H), 7.13 - 7.23 (m, 1H), 4.21 (s, 2H). 13C NMR (101 MHz, CDCl3) δ
163.9, 136.6, 129.1, 125.3, 120.2, 42.9. HRMS (ESI) C8H9ClNO m/z [M+H]

+

found

170.0338, expected 170.0373.

2-bromo-N-phenylacetamide
To a stirred solution of aniline 123 (0.2 g, 2.15 mmol, 1.0 equiv and triethylamine (0.36
mL, 2.6 mmol, 1.2 equiv) in dichlomethane (2.5 mL, 1.0 M), cooled to 0 °C was added
bromoacetyl chloride (0.215 mL, 2.6 mmol, 1.2 equiv) dropwise and the mixture was
allowed to warm up to room temperature overnight after which the mixture was washed
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with 1 N HCl and dried over anhydrous sodium sulfate. The DCM layer was concentrated
in vacuo and purified over silica gel to get the desired compound 129 (0.45 g, 2.13 mmol,
quant). 1H NMR (400 MHz, CDCl3) δ 8.23 (br. s., 1H), 7.55 (t, J = 7.30 Hz, 2H), 7.37 (t, J
= 8.03 Hz, 2H), 7.14 - 7.22 (m, 1H), 4.21 (s, 2H).

13C

NMR (101 MHz, CDCl3) δ 163.8,

136.7, 129.1, 125.2, 120.1, 29.4. HRMS (ESI) C8H9BrNO m/z [M+H] + found 213.9827,
expected 213.9867.

2-iodo-N-phenylacetamide
To a solution of the aniline 123 (0.5 g, 2.95 mmol, 1.0 equiv) in acetone (15.0 mL, 0.2 M)
was added sodium iodide (1.76 g, 11.79 mmol, 4.0 equiv) and refluxed overnight,
following which the solution was allowed to cool to room temp and the acetone was
removed in vacuo. The crude was taken up in ethyl acetate and washed with sodium
thiosulphate solution and was dried over anhydrous sodium sulphate and was purified
over silica gel to get the compound 127 (0.645 g, 2.47 mmol, 84%). 1H NMR (400 MHz,
CDCl3) δ 7.70 (br. s., 1H), 7.51 (d, J = 7.53 Hz, 2H), 7.36 (t, J = 8.03 Hz, 2H), 7.12 - 7.20
(m, 1H), 3.87 (s, 2H).

13C

NMR (101 MHz, CDCl3) δ 164.9, 137.3, 129.1, 125.0, 120.0, -

0.1. HRMS (ESI) C8H9INO m/z [M+H] + found 261.9692, expected 261.9728.
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2-chloro-N-(4-nitrophenyl)acetamide
To a stirred solution of aniline 124 (1.5 g, 10.86 mmol, 1.0 equiv and triethylamine (1.81
mL, 13.03 mmol, 1.2 equiv) in dichlomethane (11.0 mL, 1.0 M), cooled to 0 °C was added
chloroacetyl chloride (1.04 mL, 13.03 mmol, 1.2 equiv) dropwise and the mixture was
allowed to warm up to room temperature overnight after which the mixture was washed
with 1 N HCl and dried over anhydrous sodium sulfate. The DCM layer was concentrated
in vacuo and purified over silica gel to get the desired compound 126 (0.586 g, 2.73 mmol,
25%). 1H NMR (400 MHz, CDCl3) δ 8.27 (d, J = 9.29 Hz, 2H), 8.06 (br. s., 1H), 7.78 (d, J
= 9.03 Hz, 2H), 4.25 (s, 2H).

13C

NMR (101 MHz, CDCl3) δ 167.5, 145.0, 143.7, 125.2,

119.6, 40.5.

2-bromo-N-(4-nitrophenyl)acetamide
To a stirred solution of aniline 124 (1.0 g, 7.24 mmol, 1.0 equiv and triethylamine (1.2
mL, 8.7 mmol, 1.2 equiv) in dichlomethane (2.5 mL, 1.0 M), cooled to 0 °C was added
bromoacetyl chloride (1.2 mL, 8.7 mmol, 1.2 equiv) dropwise and the mixture was allowed
to warm up to room temperature overnight after which the mixture was washed with 1 N
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HCl and dried over anhydrous sodium sulfate. The DCM layer was concentrated in vacuo
and purified over silica gel to get the desired compound 130 (0.882 g, 3.4 mmol, 47%).
1H

NMR (400 MHz, CDCl3) δ 8.49 (br. s., 1H), 8.27 (d, J = 9.00 Hz, 2H), 7.78 (d, J = 9.00

Hz, 2H), 4.25 (s, 2H).

13C

NMR (101 MHz, CDCl3) δ 164.2, 144.4, 142.3, 125.1, 119.5,

29.1

2-iodo-N-(4-nitrophenyl)acetamide
To a solution of the aniline 124 (0.586 g, 2.73 mmol, 1.0 equiv) in acetone (13.0 mL, 0.2
M) was added sodium iodide (1.64 g, 10.92 mmol, 4.0 equiv) and refluxed overnight,
following which the solution was allowed to cool to room temprature and the acetone was
removed in vacuo. The crude was taken up in ethyl acetate and washed with sodium
thiosulphate solution and was dried over anhydrous sodium sulphate and was purified
over silica gel to get the compound 128 (0.468 g, 1.53 mmol, 56%). 1H NMR (400 MHz,
CDCl3) δ 8.25 (d, J = 9.03 Hz, 2H), 7.72 (d, J = 9.29 Hz, 2H), 3.90 (s, 2H). 13C NMR (101
MHz, CD6CO) δ 168.1, 146.0, 125.8, 120.0, 0.0. HRMS (ESI) C8H6IN2O3 m/z [M-H] - found
304.9442, expected 304.9423.
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4-(((4-nitrophenyl)amino)methyl)benzonitrile
To a solution of the aniline 124 (0.1 g, 0.72 mmol, 1.0 equiv) and 4-formylbenzonitrile
(0.095 g, 0.72 mmol, 1.0 equiv) in dichloroethane (2.42 mL, 0.3 M) was added glacial
acetic acid (0.041 mL, 0.72 mmol, 1.0 equiv) and sodium triacetoxyborohydride (0.215 g,
1.01 mmol, 1.4 equiv). The mixture was stirred for 2.5 hours at room temperature,
following which DCE was removed in vacuo. The crude was taken in ethyl acetate and
washed with sat. sodium bicarbonate solution. The ethyl acetate layer was dried over
sodium sulphate and the product was crystallized from DCM to give 131 (0.096 g, 0.38
mmol, 52%). 1H NMR (400 MHz, CD6CO) δ 8.02 (d, J = 9.00 Hz, 2H), 7.76 (d, J = 8.50
Hz, 2H), 7.62 (d, J = 8.50 Hz, 2H), 6.75 (d, J = 9.00 Hz, 2H), 4.67 (s, 2H)

2-chloro-N-(4-cyanobenzyl)-N-(4-nitrophenyl)acetamide
To a stirred solution of aniline 131 (0.2 g, 0.79 mmol, 1.0 equiv and triethylamine (0.13
mL, 0.95 mmol, 1.2 equiv) in dichlomethane (4.0 mL, 0.2 M), cooled to 0 °C, was added
chloroacetyl chloride (0.075 mL, 0.95 mmol, 1.2 equiv) dropwise and the mixture was
allowed to warm up to room temperature overnight after which the mixture was washed
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with 1 N HCl and dried over anhydrous sodium sulfate. The DCM layer was concentrated
in vacuo and purified over silica gel to get the desired compound 132 (0.202 g, 0.61 mmol,
77%). 1H NMR (400 MHz, CDCl3) δ 8.29 (d, J = 9.03 Hz, 2H), 7.63 (d, J = 8.53 Hz, 2H),
7.34 (d, J = 8.53 Hz, 2H), 7.29 (d, J = 8.78 Hz, 2H), 5.00 (s, 2H), 3.89 (s, 2H)

2-bromo-N-(4-cyanobenzyl)-N-(4-nitrophenyl)acetamide
To a stirred solution of aniline 131 (0.2 g, 0.79 mmol, 1.0 equiv and triethylamine (0.13
mL, 0.95 mmol, 1.2 equiv) in dichlomethane (4.0 mL, 0.2 M), cooled to 0 °C, was added
bromoacetyl chloride (0.08 mL, 0.95 mmol, 1.2 equiv) dropwise and the mixture was
allowed to warm up to room temperature overnight after which the mixture was washed
with 1 N HCl and dried over anhydrous sodium sulfate. The DCM layer was concentrated
in vacuo and purified over silica gel to get the desired compound 134 (0.216 g, 0.58 mmol,
69%). 1H NMR (400 MHz, CDCl3) δ 8.28 (d, J = 8.78 Hz, 2H), 7.62 (d, J = 8.28 Hz, 2H),
7.34 (d, J = 8.03 Hz, 2H), 7.29 (d, J = 9.03 Hz, 2H), 5.00 (s, 2H), 3.89 (s, 2H).

13C

NMR

(101 MHz, CDCl3) δ 166.1, 146.2, 141.0, 132.7, 129.2, 128.9, 125.5, 118.2, 112.3, 53.4,
25.9.
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2-iodo-N-(4-cyanobenzyl)-N-(4-nitrophenyl)acetamide
To a solution of the aniline 132 (0.081 g, 0.246 mmol, 1.0 equiv) in acetone (13.0 mL, 0.2
M) was added sodium iodide (0.148 g, 0.989 mmol, 4.0 equiv) and refluxed overnight,
following which the solution was allowed to cool to room temprature and the acetone was
removed in vacuo. The crude was taken up in ethyl acetate and washed with sodium
thiosulphate solution, dried over anhydrous sodium sulphate, and was purified over silica
gel to get the compound 133 (0.118 g, 0.24 mmol, quant). 1H NMR (400 MHz, CD6CO) δ
8.30 (d, J = 9.03 Hz, 2H), 7.68 (d, J = 9.03 Hz, 2H), 7.73 (d, J = 8.53 Hz, 2H), 7.51 (d, J
= 8.50 Hz, 2H), 5.11 (s, 2H), 3.83 (s, 2H).

13C

NMR (101 MHz, CD6CO) δ 168.8, 149.2,

144.1, 133.9, 130.6, 126.5, 119.8, 112.9, 54.3, -1.1. HRMS (ESI) C16H13IN3O3 m/z [M+H]
+

found 421.9951, expected 422.0001.

N-phenylacrylamide
To a stirred solution of aniline 123 (1.0 g, 10.74 mmol, 1.0 equiv) and triethylamine (1.79
mL, 12.9 mmol, 1.2 equiv) in dichlomethane (11.0 mL, 1.0 M), cooled to 0 °C was added
acryloyl chloride (1.05 mL, 12.88 mmol, 1.2 equiv) dropwise and the mixture was allowed
to warm up to room temperature overnight after which the mixture was washed with 1N
HCl and dried over anhydrous sodium sulfate. The DCM layer was concentrated in vacuo
and purified over silica gel to get the desired compound 135 (1.182 g, 8.03 mmol, 75%).
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1H

NMR (400 MHz, CDCl3) δ 7.59 (d, J = 7.03 Hz, 2H), 7.31 - 7.40 (m, 2H), 7.09 - 7.18

(m, 1H), 6.45 (dd, J = 1.25, 16.81 Hz, 1H), 6.26 (dd, J = 10.16, 16.94 Hz, 1H), 5.78 (dd,
J = 1.25, 10.04 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 137.7, 131.2, 129.0, 127.7, 124.6,
120.0. HRMS (ESI) C9H10NO m/z [M+H] + found 148.0741, expected 148.0762.

N-(4-nitrophenyl)acrylamide
To a stirred solution of aniline 124 (1.5 g, 10.86 mmol, 1.0 equiv) and triethylamine (1.81
mL, 13.03 mmol, 1.2 equiv) in dichlomethane (11.0 mL, 1.0 M), cooled to 0° was added
acryloyl chloride (1.06 mL, 13.03 mmol, 1.2 equiv) dropwise and the mixture was allowed
to warm up to room temperature overnight after which the mixture was washed with 1 N
HCl and dried over anhydrous sodium sulfate. The DCM layer was concentrated in vacuo
and purified over silica gel to get the desired compound 136 (0.322 g, 1.68 mmol, 15%).
1H

NMR (400 MHz, CDCl3) δ 8.25 (d, J = 9.00 Hz, 2H), 7.79 (d, J = 9.00 Hz, 2H), 6.52

(dd, J = 1.00, 16.81 Hz, 1H), 6.28 (dd, J = 10.29, 16.81 Hz, 1H), 5.90 (dd, J = 1.13, 10.16
Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 143.5, 130.4, 129.6, 125.1, 119.3.

N-(4-cyanobenzyl)-N-(4-nitrophenyl)acrylamide
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To a stirred solution of aniline 131 (0.096 g, 0.38 mmol, 1.0 equiv) and triethylamine
(0.064 mL, 0.46 mmol, 1.2 equiv) in dichlomethane (2.0 mL, 0.2 M), cooled to 0 °C was
added acryloyl chloride (0.064 mL, 0.46 mmol, 1.2 equiv) dropwise and the mixture was
allowed to warm up to room temperature overnight after which the mixture was washed
with 1N HCl and dried over anhydrous sodium sulfate. The DCM layer was concentrated
in vacuo and purified over silica gel to get the desired compound 137 (0.076 g, 0.25 mmol,
65%). 1H NMR (400 MHz, CDCl3) δ 8.25 (d, J = 8.53 Hz, 2H), 7.61 (d, J = 8.28 Hz, 2H),
7.35 (d, J = 8.03 Hz, 2H), 7.23 (d, J = 8.78 Hz, 2H), 6.53 (dd, J = 1.38, 16.94 Hz, 1H),
6.06 (dd, J = 10.29, 16.56 Hz, 1H), 5.72 (dd, J = 1.51, 10.54 Hz, 1H), 5.09 (s, 2H).

13C

NMR (101 MHz, CDCl3) δ 165.3, 147.2, 141.8, 132.6, 132.4, 130.1, 128.8, 128.3, 127.6,
127.6, 127.0, 126.2, 125.9, 125.0, 118.3, 111.7, 111.4, 52.7. HRMS (ESI) C17H12N3O3
m/z [M-H] - found 306.0819, expected 306.0878.

N-phenyloxirane-2-carboxamide
To a solution of aniline 135 (0.1 g, 0.68 mmol, 1.0 equiv) in dichloromethane (4.0 mL, 0.2
M) was added m-CPBA (1.6 g, 6.8 mmol, 10.0 equiv). The mixture was refluxed overnight,
followed by extracting the crude into ethylacetate and washing with sat. sodium
bicarbonate solution. The ethylacetate layer was concentrated and purified on silica gel
to give the desired compound 138 (0.020 g, 0.13 mmol, 18%). 1H NMR (400 MHz, CDCl3)
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δ 7.79 (br. s., 1H), 7.49 - 7.56 (m, 2H), 7.35 (t, J = 8.00 Hz, 2H), 7.10 - 7.18 (m, 1H), 3.58
(dd, J = 2.64, 4.64 Hz, 1H), 3.11 (dd, J = 4.64, 5.40 Hz, 1H), 2.93 (dd, J = 2.60, 4.50 Hz,
1H). 13C NMR (101 MHz, CD6CO) δ 168.0, 130.1, 125.3, 125.1, 121.2, 120.9, 50.7, 47.6.
HRMS (ESI) C9H10NO2 m/z [M+H] + found 164.0684, expected 164.0711.

2-(1,3-dioxo-1,3,3a,4,7,7a-hexahydro-2H-4,7-epoxyisoindol-2-yl)-Nphenylacetamide
To a stirred solution of aniline 127 (0.24 g, 0.9 mmol, 1.2 equiv) and imide 139 191(0.127
g, 0.77 mmol, 1.0 equiv) in acetonitrile (8.0 mL, 0.1 M) was added potassium carbonate
(0.212 g, 1.54 mmol, 2.0 equiv) and refluxed overnight. The ethyl acetate solution was
cooled, washed with 1N HCl, dried over sodium sulphate and purified over silica gel to
obtain compound 140 (0.059 mg, 0.2 mmol, 26%). 1H NMR (400 MHz, CDCl3) δ 7.64 (br.
s., 1H), 7.49 (d, J = 7.53 Hz, 2H), 7.30 (d, J = 7.50 Hz, 2H), 7.11 (t, J = 7.53 Hz, 1H), 6.60
(s, 2H), 5.41 (s, 2H), 4.34 (s, 2H), 3.03 (s, 2H)
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2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-phenylacetamide
Maleimide 140 (0.059 g, 0.26 mmol) was heated in anisole (0.5 mL, 0.5 M) at 140 °C for
4 hours. The solution was purified over silica gel to obtain compound 141 (0.036 g, 0.16
mmol, 60%). 1H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 7.78 Hz, 2H), 7.40 (br. s., 1H),
7.33 (t, J = 7.65 Hz, 2H), 7.10 - 7.18 (m, 1H), 6.83 (s, 2H), 4.35 (s, 2H).

13C

NMR (101

MHz, CDCl3) δ 170.1, 134.6, 129.1, 124.9, 120.0, 41.3. HRMS (ESI) C12H11N2O3 m/z
[M+H] + found 231.0724, expected 231.0769.

2-((4-nitrophenyl)amino)ethan-1-ol
To a solution of 1-fluoro-4-nitrobenzene 142 (0.2 g, 1.42 mmol, 1.0 equiv) in DMSO (3.0
mL, 0.5 M) was added ethanolamine (0.096 g, 1.56 mmol, 1.1 equiv) and potassium
carbonate (294 mg, 2.13 mmol, 1.5 equiv). The mixture was warmed to 45 °C and kept
overnight. The crude solution in DMSO was taken up in ethyl acetate and washed with
water. The ethyl acetate layer was dried on sodium sulfate and purified over sodium
sulfate to give the compound 143 (0.225 g, 1.24 mmol, 87%). 1H NMR (400 MHz, CDCl3)
δ 8.11 (d, J = 9.00 Hz, 2H), 6.59 (d, J = 9.00 Hz, 2H), 3.92 (t, J = 5.00 Hz, 2H), 3.41 (t, J
= 5.00 Hz, 2H)
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1-(2-((4-nitrophenyl)amino)ethyl)-1H-pyrrole-2,5-dione
To a solution of compound 143 (0.1 g, 0.549 mmol, 1.1 equiv) in THF (5.5 mL, 0.15 M) at
-78 °C was added DEAD (0.087 g, 0.5 mmol, 1.0 equiv), triphenylphosphine (0.131 g, 0.5
mmol, 1.0 equiv) and tert-butanol (0.024 mL, 0.25 mmol, 0.5 equiv). The mixture was
stirred for 30 minutes followed by addition of maleimide (0.049 g, 0.5 mmol, 1.0 equiv)
and was raised to room temperature and stirred overnight. The crude mixture was taken
up in ethyl acetate and washed with water and the ethyl acetate layer dried over sodium
sulfate and purified over silica gel to obtain compound 144 (0.034 g, 0.13 mmol, 24%).
1H

NMR (400 MHz, CD6CO) δ 8.03 (d, J = 9.29 Hz, 2H), 6.87 (s, 2H), 6.73 (d, J = 9.29

Hz, 2H), 3.68 - 3.78 (m, 2H), 3.53 (q, J = 6.44 Hz, 2H).

13C

NMR (101 MHz, CD6CO) δ

172.3, 155.5, 139.0, 135.9, 127.4, 112.5, 42.4. HRMS (ESI) C12H12N3O4 m/z [M+H] +
found 262.0830, expected 262.0827.

N-(4-cyanobenzyl)-2-(1,3-dioxo-1,3,3a,4,7,7a-hexahydro-2H-4,7-epoxyisoindol-2yl)-N-(4-nitrophenyl)acetamide
To a solution of the compound 133 (0.036 g, 0.085 mmol, 1.0 equiv) in acetonitrile (0.85
mL, 0.1 M) was added compound 139 (0.027 g, 0.085 mmol, 1.0 equiv) and potassium
carbonate (0.012 g, 0.085 mmol, 1.0 equiv). The mixture was stirred at 50 °C for 2 hours,
followed by concentration of the solvent and washing the crude in ethyl acetate with 1 N
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HCl to obtain the product 145’, which was sufficiently pure to be used for the next step.
1H

NMR (400 MHz, CDCl3) δ 8.28 (d, J = 8.53 Hz, 2H), 7.62 (d, J = 8.28 Hz, 2H), 7.30 -

7.41 (m, 4H), 6.53 (s, 4H), 5.26 (s, 2H), 4.98 (s, 2H), 4.01 (s, 2H).

13C

NMR (101 MHz,

Acetone) δ 171.7, 167.5, 148.8, 148.2, 143.9, 136.3, 133.9, 130.9, 130.6, 126.7, 119.7,
112.9, 54.1, 40.9.

N-(4-cyanobenzyl)-2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-(4nitrophenyl)acetamide
The compound 145’ (0.066 g, 0.144 mmol, 1.0 equiv) was stirred in anisole (0.3 mL, 0.5
M) at 140 °C overnight, after which the compound 145 was isolated by purification on
silica gel (0.04 g, 0.1 mmol, 71%). 1H NMR (400 MHz, CDCl3) δ 8.31 (d, J = 8.78 Hz, 2H),
7.62 (d, J = 8.28 Hz, 2H), 7.38 (d, J = 8.78 Hz, 2H), 7.32 (d, J = 8.03 Hz, 2H), 6.80 (s,
2H), 4.97 (s, 2H), 4.06 (s, 2H). HRMS (ESI) C20H15N4O5 m/z [M+H] + found 391.1045,
expected 391.1042.
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tert-Butyl(S)-(1-(methoxy(methyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate: To
a mixture of EDCI (0.920 g, 4.8 mmol) and HOBt (0.595 g, 4.4 mmol) in anhydrous
dichloromethane (16.7 mL) was added 2-(tert-butoxycarbonylamino)-3-phenylpropanoic
acid 146 (1.061 g, 4 mmol) and stirred at 0 oC for 30 min. N,O-Dimethylhydroxylamine
hydrochloride (0.449 g, 4.6 mmol) and N-methylmorpholine (0.53 mL, 4.4 mmol) were
added to the mixture and the reaction was stirred at room temperature for 16 hours. The
reaction mixture was washed with 1 N HCl and then saturated NaHCO3. The organic
layer was dried over anhydrous sodium sulphate and concentrated in vacuo. The crude
product was purified by column chromatography (silica gel, ethyl acetate:hexane 1:4) to
give the desired product as colorless oil 147 (1.13 g, 96% yield). 1H NMR (400 MHz,
CDCl3) δ 7.28 (m, 2H) 7.22 (d, J=7.2, 1H), 7.17 (d, J=7.6, 2H), 5.14 (br, 1H), 4.95 (br,
1H), 3.65 (s, 3H), 3.16 (s, 3H), 3.05 (dd, J1=6.2, J2=13.5, 1H), 2.89 (m, 1H), 1.39 (s,
9H).

tert-Butyl 3-oxo-1-phenylpent-4-en-2-ylcarbamate
Weinreb amide 147 (0.13 g, 0.42 mmol) was dissolved in anhydrous THF (1.3 mL). The
reaction mixture was cooled to -40 oC in a dry ice/acetonitrile bath and purged with argon
before 1 M vinyl magnesium bromide in THF (1.26 mL, 1.26 mmol) was added dropwise.
After 3 hours stirring at -40 oC, the reaction mixture was poured into cold 3 N HCl, and
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extracted three times with ethyl acetate. The combined organic layers were dried over
anhydrous sodium sulphate and concentrated in vacuo. The crude product was purified
over silica gel chromatography to obtain the desired product as white solid 148 (0.081 g,
70% yield). 1H NMR (400MHz, CDCl3) δ 7.25 (m, 3H) 7.10 (d, J=7.4, 2H), 6.41 (m, 2H),
5.83 (d, J=10.4, 1H), 5.22 (m, 1H), 4.86 (q, J=9, 1H), 3.14 (dd, J1=6.4, J2=13.8, 1H), 2.98
(dd, J1=8.0, J2=15.4, 1H), 1.42 (s, 9H). 13C NMR (100MHz, CDCl3) δ 197.9, 155.2, 136.0,
133.5, 130.2, 129.6, 128.6, 127.1, 79.9, 58.3, 38.2, 28.4. HRMS (ESI) C16H21NO3 m/z
[M+Na]+ found 298.1415, expected 298.1419.

tert-butyl ((2S)-3-hydroxy-1-phenylpent-4-en-2-yl)carbamate
To the vinyl ketone 148 0.265 g, 0.962 mmol, 1.0 equiv) in methanol (3.21 mL, 0.3M)
cooled to 0 °C was added sodium bohydride (0.109 g, 2.9 mmol, 3.0 equiv). The mixture
was stirred for 2 hours, following which it was quenched with dilute acetic acid, taken up
in ethyl acetate and washed with saturated sodium bicarbonate solution. The ethyl
acetate layer was dried over anhydrous sodium sulfate and concentrated to get the
compound 149 (0.267 g, 0.96 mmol, quant), which was sufficiently pure to use for the
next step.
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N-((2S)-3-hydroxy-1-phenylpent-4-en-2-yl)-4-nitrobenzamide
The a solution of the alcohol 149 (0.117 g, 0.422 mmol, 1.0 equiv) in DCM (0.9 mL, 0.5
M), cooled to 0 °C was added 2,6-lutidine (0.16 mL, 1.5 M) and TMSOTf (0.163 mL, 1M).
The solution was warmed to room temperature and stirred for 3 hours, following which it
was concentrated in vacuo and was added into a solution of 4-nitrobenzoic acid (0.071 g,
0.422 mmol, 1.0 equiv), PyBOP (0.221 g, 0.422 mmol, 1.0 equiv), DIPEA (0.15 mL, 0.844
mmol, 2.0 equiv) in DCM (4.2 mL, 0.1 M). The mixture was stirred overnight and was
diluted with DCM and washed with 1 N HCl. The DCM layer was dried on sodium sulfate
and was purified over silica gel to get the alcohol 150 (0.103 g, 0.32 mmol, 75%). 1H NMR
(400 MHz, CDCl3) δ 8.17 - 8.38 (m, 2H), 7.77 - 7.93 (m, 1H), 7.63 - 7.77 (m, 1H), 7.13 7.40 (m, 5H), 5.84 - 6.11 (m, 1H), 5.46 (td, J = 1.47, 17.13 Hz, 1H), 5.28 - 5.39 (m, 1H),
4.35 - 4.59 (m, 1H), 2.99 - 3.15 (m, 1H), 2.93 (dd, J = 9.41, 14.43 Hz, 1H)

(S)-4-nitro-N-(3-oxo-1-phenylpent-4-en-2-yl)benzamide
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The alcohol 150 (0.030 g, 0.092 mmol, 1.0 equiv) was dissolved in DCM (1.0 mL, 0.1 M)
and Dess-Martin periodinane (0.039 g, 0.092 mmol, 1.0 equiv) was added. The mixture
was stirred at room temprature overnight, followed by dilution with DCM and washing with
sodium thiosulfate solution. The DCM layer was dried and purified over silica gel to get
the vinyl ketone 151 (0.029 g, 0.089 mmol, 97%). 1H NMR (400 MHz, CDCl3) δ 8.29 (d, J
= 9.00 Hz, 2H), 7.89 (d, J = 9.00 Hz, 2H), 7.20 - 7.37 (m, 5H), 7.03 - 7.18 (m, 2H), 6.94
(d, J = 6.27 Hz, 1H), 6.40 - 6.61 (m, 2H), 5.99 (dd, J = 1.63, 9.91 Hz, 1H), 5.38 (dt, J =
4.77, 6.90 Hz, 1H), 3.38 (dd, J = 6.78, 14.05 Hz, 1H), 3.14 - 3.30 (m, 1H). 13C NMR (101
MHz, CD6CO) δ 197.7, 165.7, 150.6, 140.9, 138.7, 138.4, 134.5, 130.2, 130.1, 129.7,
129.5, 129.2, 127.5, 124.4, 59.3, 36.9. HRMS (ESI) C18H17N2O4 m/z [M+H]

+

found

325.1198, expected 325.1188.

tert-butyl (S)-(3-oxo-1-phenylpentan-2-yl)carbamate
To a solution of the vinyl ketone 148 (0.009 g, 0.032 mmol) in ethyl acetate (1 mL) was
added 5% Pd/C (20% w/w). The reaction mixture was stirred under a hydrogen balloon
at room temperature overnight. The catalyst was removed by filtration, and the filtrate was
concentrated in vacuo to afford the desired product as white solid 152 (0.009 g,
quantitative yield). 1H NMR (400MHz, CDCl3) δ 7.28 (m, 3H), 7.14 (d, J=6.8, 2H), 5.12 (s,
1H), 4.54 (q, J=7.4, 1H), 3.00 (m, 2H), 2.38 (m, 2H), 1.41 (s, 9H), 1.00 (t, J= ,3H).
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13C

NMR (100MHz, CDCl3) δ 209.9, 155.3, 136.4, 129.4, 128.8, 127.1, 80.0, 60.0, 38.3, 34.3,
28.5, 7.5. HRMS (ESI) C16H23NO3 m/z [M+H]

+

found 278.1735, expected 278.1756;

[M+Na] + found 300.1566, expected 300.1575.

(S)-4-amino-N-(3-oxo-1-phenylpentan-2-yl)benzamide
To a solution of the vinyl ketone 151 (0.01 g, 0.03 mmol) in ethyl acetate (0.3 mL, 0.1 M)
was added 5% Pd/C (20% w/w). The reaction mixture was stirred under a hydrogen
balloon at room temperature overnight. The catalyst was removed by filtration, and the
filtrate was concentrated in vacuo to afford the desired product as white solid 153 (0.008
g, 0.025 mmol, quant). 1H NMR (400 MHz, CDCl3) δ 7.58 (d, J = 8.50 Hz, 2H), 7.20 - 7.33
(m, 3H), 7.12 - 7.19 (m, 2H), 6.65 (d, J = 8.50 Hz, 2H), 5.04 (q, J = 6.78 Hz, 1H), 3.98 (br.
s., 2H), 3.18 (dd, J = 3.26, 6.27 Hz, 2H), 2.37 - 2.55 (m, 2H), 1.04 (t, J = 7.28 Hz, 3H).
13C

NMR (101 MHz, CDCl3) δ 209.6, 166.5, 149.8, 136.2, 129.3, 128.8, 128.6, 127.1,

123.5, 114.1, 58.9, 37.9, 34.3, 7.4. HRMS (ESI) C18H21N2O2 m/z [M+H] + found 297.1590,
expected 297.1603.
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(Prop-2-yn-1-yloxy)carbonyl)-L-phenylalanine
To a solution of sodium hydroxide (0.467 g, 4 mmol) in water (8 mL) was added (L)phenylalanine 146, followed by propargyl chloroformate (0.39 mL, 4 mmol). The reaction
was stirred at room temperature for 16 hours. The reaction mixture was then acidified to
pH 4 with 2 N HCl, and extracted three times with ethyl acetate. The combined organic
fractions were pooled, dried over anhydrous sodium sulfate, concentrated in vacuo to
obtain compound 154 as white solid (0.438g, 44% yield). ). 1H NMR (400MHz, CD3OD) δ
7.23-7.28 (m, 5H), 4.89 (m, 1H), 4.61 (s, 2H), 3.05 (dd, J1=5.80, J2=13.9, 1H), 2.86 (m,
2H).

Prop-2-yn-1-yl (S)-(1-(methoxy(methyl)amino)-1-oxo-3-phenylpropan-2yl)carbamate
To a solution of 154 (0.438 g, 1.8 mmol) in anhydrous DCM (9 mL) in an ice-water bath
was added EDCI (0.479 g, 2.5 mmol) and HOBt (0.297 g, 2.2 mmol). After stirring at 0 oC
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for 1 hour, the reaction mixture was added N,O-dimethylhydroxylamine hydrochloride
(0.224 g, 2.3 mmol) and N-methylmorpholine (0.24 mL, 2.2 mmol). The reaction was
warmed up to room temperate and stirred for 16 hours. The reaction mixture was washed
with 1N HCl and then saturated NaHCO3 . The organic layer was dried over anhydrous
sodium sulphate and concentrated in vacuo. The crude product was purified by column
chromatography (silica gel, ethyl acetate:hexane 1:4) to give the desired product 155 as
yellow oil (0.312 g, 61% yield). 1H NMR (400 MHz, CD3OD) δ 7.23-7.29 (m, 5H), 4.89 (m,
1H), 4.60 (s, 2H), 3.73 (s, 3H), 3.17 (s, 3H), 3.04 (dd, J1=5.9, J2=13.3, 1H), 2.86 (m, 2H).

Prop-2-yn-1-yl (S)-(3-oxo-1-phenylpent-4-en-2-yl)carbamate (36). A reaction mixture
containing 155 (0.312 g, 1.1 mmol) in anhydrous THF (5.5 mL) was cooled to -40 oC in a
dry ice/acetonitrile bath and purged with argon before 1 M vinyl magnesium bromide in
THF (3.3 mL, 3.3 mmol) was added dropwise. After 3 hours stirring at -40 oC, the reaction
mixture was poured into cold 3 N HCl, and extracted three times with ethyl acetate. The
combined organic layers were dried over anhydrous sodium sulphate and concentrated
in vacuo. The crude product was purified over silica gel chromatography to obtain the
desired product as white solid 156 (0.136 g, 53% yield). 1H NMR (400 MHz, CD3OD) δ
7.22-7.28 (m, 5H), 6.61 (dd, J1=10.1, J2=12.4, 1H), 6.36 (d, J=17.4, 1H), 5.87 (d, J=11.4,
1H), 4.72 (m, 1H), 4.60 (s, 2H), 3.24 (dd, J1=5.5, J2=13.9, H), 2.87 (m, 2H).
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4-(3-(5-azidopentyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid
To a solution of fluorescein 5-isothiocynate 162 (0.050 g, 0.128 mmol, 1.13 equiv) and
Hunigs base (0.073 mL, 0.42 mmol, 3.5 equiv) in DMF (1.2 mL, 0.1 M) was added 163
(17 mg, 0.12 mmol, 1.0 equiv). The reaction mixture was stirred for 3 hours at room
temperature, followed by dilution with ethyl acetate and washing with 1N HCl solution.
The ethyl acetate layer was purified over silica to obtain compound 164 (43 mg, 0.088
mmol, 69%). 1H NMR (400 MHz, CD3OD) δ 7.98 (s, 1H), 7.76 (dd, J = 1.63, 8.16 Hz, 1H),
7.16 (d, J = 8.03 Hz, 1H), 6.69 (s, 4H), 6.56 (dd, J = 1.63, 9.41 Hz, 2H), 1.56 - 1.74 (m,
4H), 1.39 - 1.53 (m, 4H), 1.26 - 1.33 (m, 2H)

(S)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-4-(3-(4-(4-((((3-oxo-1-phenylpent-4-en-2yl)carbamoyl)oxy)methyl)-1H-1,2,3-triazol-1-yl)butyl)thioureido)benzoic acid
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To a solution of CuSO4 (8 mg, 0.039 mmol) and sodium ascorbate (catalytic amount) in
a mixture of 1:1 THF:water (1 mL) was added 156 (10 mg, 0.039 mmol) and Fluorescein
Azide 145 (21 mg, 0.039 mmol). The reaction was stirred at room temperature for 1 hour.
The reaction mixture then evaporated to dryness in vacuo and purified over silica gel
chromatography to obtain the product as dark pink solid 165 (12 mg, 40% yield). MS (ESI)
C94H97N11O21S m/z [M+H]+ 789.44.

4-amino-N-((2S)-3-hydroxy-1-phenylpent-4-en-2-yl)benzamide
To a solution of the alcohol 150 (0.11 g, 0.34 mmol, 1.0 equiv) in ethyl acetate (2.0 mL,
0.1 M) was added tin chloride dehydrate (0.228 g, 1.0 mmol, 3.0 equiv) and was refluxed
for 3 hours. The reaction mixture was diluted with ethyl acetate and was washed with
saturated sodium bicarbonate solution, following which it was dried over sodium sulfate
and was concentrated in vacuo. The crude was sufficiently pure to be used in the next
step without purification. 1H NMR (400 MHz, CDCl3) δ 7.48 - 7.55 (m, 1H), 7.40 - 7.46 (m,
1H), 7.19 - 7.34 (m, 5H), 6.55 - 6.69 (m, 2H), 5.85 - 6.04 (m, 1H), 5.41 (td, J = 1.60, 17.13
Hz, 1H), 5.23 - 5.36 (m, 1H), 4.21 - 4.48 (m, 2H), 2.82 - 3.09 (m, 2H).
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4-amino-N-((2S)-3-((tert-butyldimethylsilyl)oxy)-1-phenylpent-4-en-2-yl)benzamide
To the solution of the aniline from the previous step (0.1 g, 0.34 mmol, 1.0 equiv) in DCM
(1.7 mL, 0.2 M) was added 2,6-lutidine (0.06 mL, 0.45 mmol, 1.5 equiv) and the solution
was cooled to 0° C. To this mixture was added TBSOTf (0.086 mL, 0.37 mmol, 1.1 equiv)
dropwise, the mixture was allowed to warm to room temperature and stirred overnight,
following which the DCM layer was diluted and washed with 1 N HCl and purified over
silica gel to get the compound 158 (0.063 g, 0.153 mmol, 45% overall yield for 2 steps).
1H

NMR (400 MHz, CDCl3) δ 7.54 (d, J = 8.53 Hz, 1H), 7.45 (d, J = 8.78 Hz, 1H), 7.12 -

7.32 (m, 5H), 6.55 - 6.70 (m, 2H), 5.78 - 6.05 (m, 2H), 5.38 (td, J = 1.73, 17.13 Hz, 1H),
5.24 (td, J = 1.69, 10.42 Hz, 1H), 5.06 - 5.20 (m, 1H), 4.34 - 4.52 (m, 1H), 3.90 (d, J =
3.26 Hz, 1H), 2.79 - 3.08 (m, 2H), 1.00 (s, 3H), 0.88 - 0.96 (m, 6H), 0.15 (s, 1H), 0.08 (s,
2H), -0.02 (d, J = 19.32 Hz, 3H)
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prop-2-yn-1-yl (4-(((2S)-3-((tert-butyldimethylsilyl)oxy)-1-phenylpent-4-en-2yl)carbamoyl)phenyl)carbamate
To the solution of the aniline 158 (0.035 mg, 0.085 mmol, 1.0 equiv) in DCM (0.8 mL, 0.1
M) was added triethylamine (0.013 mL, 0.09 mmol, 1.1 equiv) and the solution was cooled
to 0 °C. To this solution was added propargyl chloroformate (0.01 mL, 0.09 mmol, 1.1
equiv) and the mixture was allowed to warm to room temperature and kept overnight,
followed which it was diluted with DCM and washed with 1 N HCl and concentrated in
vacuo. The crude was sufficiently pure to be used for the next step without purification.

prop-2-yn-1-yl (4-(((2S)-3-hydroxy-1-phenylpent-4-en-2yl)carbamoyl)phenyl)carbamate
The above reaction crude (0.085 mmol, 1.0 equiv) was dissolved in THF (0.85 mL, 0.1
M) and TBAF (1 M in THF, 1.5 equiv) was added. The mixture was stirred at room
temperature overnight and was diluted with ethyl acetate and washed with 1 N HCl
solution. The ethyl acetate layer was dried over sodium sulfate and purified over silica gel
to obtain compound 160 (0.010 g, 0.026 mmol, 31% overall for 2 steps). 1H NMR (400
MHz, CD6CO) δ 9.01 (br. s., 1H), 7.69 - 7.82 (m, 2H), 7.51 - 7.64 (m, 2H), 7.08 - 7.37 (m,
5H), 5.88 - 6.13 (m, 1H), 5.23 - 5.41 (m, 2H), 5.03 - 5.20 (m, 1H), 4.74 - 4.82 (m, 2H),
4.49 - 4.58 (m, 1H), 4.24 - 4.43 (m, 3H), 2.77 (br. s., 1H).
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prop-2-yn-1-yl (S)-(4-((3-oxo-1-phenylpent-4-en-2-yl)carbamoyl)phenyl)carbamate
To a solution of the above alcohol 160 (0.01 g, 0.026 mmol, 1.0 equiv) in DCM (0.3 mL,
0.1 M) was added Dess – Martin periodinane (0.011 g, 0.026 mmol, 1.0 equiv) and the
mixture was stirred at room temperature overnight, following which it was diluted with
DCM and was washed with sodium thiosulfate solution. The DCM layer was dried over
sodium sulfate and purified over silica gel to obtain compound 161 (0.007 g, 0.0186 mmol,
71%). 1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 8.53 Hz, 2H), 7.39 (d, J = 8.78 Hz, 2H),
7.11 - 7.25 (m, 3H), 6.97 - 7.05 (m, 2H), 6.89 (s, 1H), 6.75 (d, J = 7.03 Hz, 1H), 6.28 6.51 (m, 2H), 5.85 (dd, J = 1.51, 10.04 Hz, 1H), 5.29 (dt, J = 5.02, 6.90 Hz, 1H), 4.72 (d,
J = 2.26 Hz, 2H), 3.25 (dd, J = 6.65, 13.93 Hz, 1H), 3.12 (dd, J = 4.89, 13.93 Hz, 1H),
2.45 (t, J = 2.38 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 197.3, 166.0, 152.1, 140.7, 135.6,
133.3, 130.6, 129.5, 129.2, 129.0, 128.7, 128.5, 128.3, 127.1, 118.1, 75.2, 57.4, 53.0,
37.7.
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N-(4-aminophenyl)-2-chloro-N-(4-cyanobenzyl)acetamide
A solution of the compound 132 (0.115 g, 0.348 mmol, 1.0 equiv) in ethyl acetate (4.0
mL, 0.1 M) was refluxed with tin chloride dihydrate (0.4 g, 1.745 mmol, 5.0 equiv)
overnight, followed which the mixture was diluted with ethyl acetate, washed with
saturated sodium bicarbonate solution and the ethyl acetate layer was purified over silica
gel to obtain compound 166 (0.072 mg, 0.24 mmol, 69%). 1H NMR (400 MHz, CDCl3) δ
7.58 (d, J = 8.50 Hz, 2H), 7.34 (d, J = 8.50 Hz, 2H), 6.76 (d, J = 8.50 Hz, 2H), 6.61 (d, J
= 8.50 Hz, 2H), 4.87 (s, 2H), 3.89 (s, 2H).

N-(4-(2-chloro-N-(4-cyanobenzyl)acetamido)phenyl)-4-nitrobenzamide
To a solution of 4-nitrobenzoic acid (0.033 g, 0.192 mmol, 1.2 equiv) in DCM (0.2 mL, 0.1
M) was added oxalyl chloride (0.06 mL, 0.64 mmol, 4.0 equiv). To this solution was added
one drop of DMF (catalytic) and was stirred for an hour. The solution was concentrated
in vacuo to get a white solid 167. The solid was dissolved in DCM (0.1 mL, 0.2 M) and
was cooled to 0 °C. A solution of the aniline 166 (0.048 g, 0.16 mmol, 1.0 equiv) and
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triethylamine (0.05 mL, 0.32 mmol, 2.0 equiv) in DCM (0.1 mL, 0.2 M) was slowly added
to the acid chloride and the mixture was brought up to room temperature overnight. The
reaction mixture was diluted with DCM and washed subsequently with 1 N HCl and 1 N
NaOH solutions and dried over sodium sulfate. The DCM layer was concentrated in vacuo
and purified over silica gel to obtain compound 168 (0.069 g, 0.154 mmol, 96%). 1H NMR
(400 MHz, CDCl3) δ 8.38 (d, J = 8.78 Hz, 2H), 8.05 (d, J = 9.03 Hz, 2H), 7.71 (d, J = 8.80
Hz, 2H), 7.61 (d, J = 8.28 Hz, 2H), 7.36 (d, J = 8.50 Hz, 2H), 7.09 (d, J = 8.78 Hz, 2H),
4.95 (s, 2H), 3.90 (s, 2H).

4-amino-N-(4-(2-chloro-N-(4-cyanobenzyl)acetamido)phenyl)benzamide
The above prepared amide 168 (0.069 mg, 0.154 mmol, 1.0 equiv) was dissolved in ethyl
acetate (1.6 mL, 0.1 M) and was refluxed overnight with tin chloride dihydrate (0.174 mg,
0.77 mmol, 5.0 equiv), after which the mixture was diluted with ethyl acetate, washed with
saturated sodium bicarbonate solution, dried with sodium sulfate and purified over silica
gel to get compound 169 (0.041 mg, 0.094 mmol, 64%). 1H NMR (400 MHz, CDCl3) δ
7.71 (d, J = 8.50 Hz, 2H), 7.66 (d, J = 8.80 Hz, 2H), 7.60 (d, J = 8.28 Hz, 2H), 7.35 (d, J
= 8.30 Hz, 2H), 7.02 (d, J = 8.80 Hz, 2H), 6.72 (d, J = 8.53 Hz, 2H), 4.93 (s, 2H), 4.09 (br.
s., 2H), 3.89 (s, 2H).
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(9H-fluoren-9-yl)methyl (2-((4-((4-(2-chloro-N-(4cyanobenzyl)acetamido)phenyl)carbamoyl)phenyl)amino)-2-oxoethyl)carbamate
To a solution of the aniline 169 (0.031 mg, 0.074 mmol, 1.0 equiv) in chloroform (0.6 mL,
0.1 M) was added Fmoc glycyl chloride (0.035 g, 0.11 mmol, 1.5 equiv) and a solution of
NaHCO3 in water (10%, 10.0 equiv) and the mixture was stirred vigorously for 90 minutes.
The mixture was diluted with DCM and washed with 1N HCl and purified over silica gel to
obtain the title compound 170 (0.05 g, 0.07 mmol, 97%). 1H NMR (400 MHz, CDCl3) δ
8.37 (br. s., 1H), 8.07 (s, 1H), 7.77 (d, J = 7.53 Hz, 2H), 7.80 (d, J = 8.53 Hz, 2H), 7.70
(d, J = 8.80 Hz, 2H), 7.51 - 7.63 (m, 6H), 7.25 - 7.44 (m, 6H), 7.03 (d, J = 8.50 Hz, 2H),
5.57 (br. s., 1H), 4.93 (s, 2H), 4.52 (d, J = 6.80 Hz, 2H), 4.24 (t, J = 6.78 Hz, 1H), 4.00 (d,
J = 5.27 Hz, 2H), 3.88 (s, 2H).

4-(2-aminoacetamido)-N-(4-(2-chloro-N-(4cyanobenzyl)acetamido)phenyl)benzamide

212

To a solution of the above Fmoc protected amide 170 (0.05 g, 0.072 mmol, 1.0 equiv) in
DMF (0.3 mL, 0.33 M) was added DBU:piperidine (0.012 mL, 1:1, 4% v/v) and the mixture
was stirred for 30 minutes. The mixture was passed over a short plug of silica to obtain
the compound 171 (0.034 mg, 0.07 mmol, quant) and was used for the next step without
any further purification.

N-(4-(N-(4-cyanobenzyl)-2-chloroacetamido)phenyl)-4-(2-(N,N-Di-Boc-1Hguanidino)acetamido))benzamide
To a solution of the primary amine 171 (0.036 g, 0.076 mmol, 1.0 equiv) and triethylamine
(0.042 mL, 0.3 mmol, 4.0 equiv) in methanol (0.8 mL, 0.1 M) was added N,N’-Di-Boc-1Hpyrazole-1-carboxamidine (0.036 g, 0.113 mmol, 1.5 equiv). The reaction mixture was
stirred at room temperature overnight and was purified over silica gel to obtain compound
172 (0.046 g, 0.064 mmol, 84%). 1H NMR (400 MHz, CDCl3) δ 11.38 (s, 1H), 10.34 (s,
1H), 8.99 (t, J = 5.90 Hz, 1H), 8.31 (s, 1H), 7.71 (d, J = 8.78 Hz, 2H), 7.74 (d, J = 8.53
Hz, 2H), 7.49 - 7.65 (m, 4H), 7.34 (d, J = 8.03 Hz, 2H), 6.99 (d, J = 8.78 Hz, 2H), 4.90 (s,
2H), 4.17 (d, J = 6.02 Hz, 2H), 2.92 (s, 2H), 2.38 (br. s., 2H), 1.51 (s, 18H).
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1-(2-((4-((4-(2-chloro-N-(4cyanobenzyl)acetamido)phenyl)carbamoyl)phenyl)amino)-2-oxoethyl)guanidinium
2,2,2-trifluoroacetate
To a solution of the above compound 172 (0.02 g, 0.027 mmol, 1.0 equiv) in DCM (0.15
mL, 0.2 M) was added TFA (0.15 mL, 0.2 M) and stirred overnight. The reaction mixture
was dried in vacuo to obtain the title compound 173. (0.016 mg, 0.027 mmol, quant). 1H
NMR (400 MHz, CD3OD) δ 7.93 (d, J = 8.78 Hz, 2H), 7.76 (d, J = 8.78 Hz, 2H), 7.80 (d,
J = 8.78 Hz, 2H), 7.68 (d, J = 8.30 Hz, 2H), 7.44 (d, J = 8.30 Hz, 2H), 7.18 (d, J = 8.78
Hz, 2H), 5.04 (s, 2H), 3.87 (s, 2H), 3.51 - 3.66 (m, 3H).

13C

NMR (101 MHz, CD3OD) δ

173.2, 168.3, 168.2, 165.7, 159.8, 143.4, 143.2, 141.3, 135.9, 133.7, 131.2, 131.0, 130.0,
129.9, 123.6, 120.5, 119.6, 112.9, 61.7, 21.0, 14.6.

N-(4-(N-(4-cyanobenzyl)-2-bromoacetamido)phenyl)-4-(2-(N,N-Di-Boc-1Hguanidino)acetamido))benzamide
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The acetamide 172 (0.048 g, 0.0067 mmol, 1.0 equiv) was dissolved in acetone (1.0 mL,
0.1 M) and refluxed with sodium bromide (0.207 g, 2.0 mmol, 30.0 equiv) overnight. The
reaction mixture was concentrated and taken up in ethyl acetate, washed with sodium
thiosulfate solution and purified over silica gel to obtain the compound 174 (0.026 mg,
0.034 mmol, 51%). 1H NMR (400 MHz, CDCl3) δ 11.37 (s, 1H), 10.37 (br. s., 1H), 8.99
(br. s., 1H), 8.26 (br. s., 1H), 7.70 (d, J = 7.53 Hz, 2H), 7.75 (d, J = 8.03 Hz, 2H), 7.44 7.65 (m, 4H), 7.34 (d, J = 7.78 Hz, 2H), 6.99 (d, J = 8.03 Hz, 2H), 5.30 (s, 1H), 4.90 (br.
s., 2H), 4.17 (d, J = 5.27 Hz, 2H), 2.92 (br. s., 2H), 2.38 (br. s., 2H), 1.51 (br. s., 18H).

1-(2-((4-((4-(2-bromo-N-(4cyanobenzyl)acetamido)phenyl)carbamoyl)phenyl)amino)-2-oxoethyl)guanidinium
2,2,2-trifluoroacetate
To a solution of the above compound 174 (0.026 g, 0.034 mmol, 1.0 equiv) in DCM (0.17
mL, 0.2 M) was added TFA (0.17 mL, 0.2 M) and stirred overnight. The reaction mixture
was dried in vacuo to obtain the title compound 175. (0.019 mg, 0.03 mmol, quant). 1H
NMR (700 MHz, CD3OD) δ 7.93 (d, J = 8.36 Hz, 2H), 7.80 (d, J = 8.40 Hz, 2H), 7.76 (d,
J = 8.80 Hz, 2H), 7.67 (d, J = 7.90 Hz, 2H), 7.44 (d, J = 7.90 Hz, 2H), 7.18 (d, J = 8.80
Hz, 2H), 5.03 (s, 2H), 4.14 (s, 2H), 3.87 (s, 2H), 3.57 (d, J = 11.88 Hz, 2H). 13C NMR (101
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MHz, CD3OD) δ 168.3, 168.1, 165.7, 154.4, 153.2, 151.7, 151.3, 147.1, 143.4, 141.3,
135.9, 133.7, 130.9, 130.7, 130.0, 129.9, 123.6, 120.5, 115.5, 112.9, 92.9, 89.0, 85.9,
85.6, 63.5, 55.6, 45.5, 28.1.

N-(4-(N-(4-cyanobenzyl)-2-iodoacetamido)phenyl)-4-(2-(N,N-Di-Boc-1Hguanidino)acetamido))benzamide
The acetamide 172 (0.043 g, 0.006 mmol, 1.0 equiv) was dissolved in acetone (1.0 mL,
0.1 M) and refluxed with sodium iodide (0.3 g, 0.6 mmol, 30.0 equiv) overnight. The
reaction mixture was concentrated and taken up in ethyl acetate, washed with sodium
thiosulfate solution and purified over silica gel to obtain the compound 176 (0.041 mg,
0.05 mmol, 84%). 1H NMR (400 MHz, CDCl3) δ 12.30 (br. s., 1H), 9.12 (br. s., 1H), 8.59
(br. s., 1H), 8.24 (br. s., 1H), 7.79 (d, J = 6.78 Hz, 2H), 7.53 - 7.69 (m, 3H), 7.41 - 7.53
(m, 2H), 7.29 (br. s., 2H), 7.21 (d, J = 2.26 Hz, 1H), 6.92 (d, J = 6.78 Hz, 2H), 4.83 (br. s.,
2H), 4.08 (d, J = 3.51 Hz, 2H), 3.61 (br. s., 2H), 3.44 (br. s., 2H), 2.88 (br. s., 2H), 2.34
(br. s., 2H), 1.19 (s, 18H).
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1-(2-((4-((4-(N-(4-cyanobenzyl)-2-iodoacetamido)phenyl)carbamoyl)phenyl)amino)2-oxoethyl)guanidinium 2,2,2-trifluoroacetate
To a solution of the above compound 176 (0.041 g, 0.05 mmol, 1.0 equiv) in DCM (0.25
mL, 0.2 M) was added TFA (0.25 mL, 0.2 M) and stirred overnight. The reaction mixture
was dried in vacuo to obtain the title compound 177. (0.03 mg, 0.05 mmol, quant). 1H
NMR (700 MHz, CD3OD) δ 7.93 (d, J = 8.80 Hz, 2H), 7.81 (d, J = 8.80 Hz, 2H), 7.76 (d,
J = 8.80 Hz, 2H), 7.67 (d, J = 8.36 Hz, 2H), 7.43 (d, J = 8.36 Hz, 2H), 7.18 (d, J = 8.80
Hz, 2H), 4.29 (s, 2H), 3.88 (s, 2H), 3.57 (d, J = 11.88 Hz, 2H).

13C

NMR (101 MHz,

CD3OD) δ 168.3, 165.8, 159.4, 158.9, 154.1, 143.5, 141.3, 136.0, 133.7, 130.9, 130.0,
129.9, 129.3, 127.9, 123.6, 120.6, 119.6, 117.6, 114.8, 112.9, 58.6, 55.6, 45.9, 0.1

tert-butyl 3-bromo-4-nitrobenzoate
To a solution of 3-bromo-4-nitrobenzoic acid 178 (0.435 g, 1.77 mmol, 1.0 equiv) and tertbutyl 2,2,2-trichloroacetamidate (0.38 mL, 2.122 mmol, 1.2 equiv) in diethyl ether (9.0 mL,
0.2 M) cooled to 0°C, was slowly added boron trifluoride diethyl etherate (0.022 mL, 0.177
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mmol, 0.1 equiv). The reaction was slowly allowed to warm up to room temperature
overnight, followed which it was washed with saturated sodium bicarbonate solution and
the ether layer was purified over silica gel to obtain the compound 179 (0.373 g, 1.23
mmol, 70%). 1H NMR (400 MHz, CDCl3) δ 8.32 (d, J = 1.76 Hz, 1H), 8.04 (dd, J = 1.76,
8.28 Hz, 1H), 7.83 (d, J = 8.53 Hz, 1H), 1.62 (s, 9H).

tert-butyl 6-nitro-[1,1'-biphenyl]-3-carboxylate
A solution of the ester 179 (0.03 g, 0.1 mmol, 1.0 equiv), phenylboronic acid (0.013 g, 0.1
mmol, 1.0 equiv), tetrakis(triphenylphosphine)palladium(0) (0.006 g, 0.005 mmol, 5
mol%), sodium carbonate (0.027 g, 0.25 mmol, 2.5 equiv) in DME:H 2O (0.5 mL, 3:1, 0.2
M) was stirred vigorously overnight at 95 °C. The following day, the reaction mixture was
diluted with diethyl ether and washed with 1 N HCl and purified over silica gel to get the
compound 180 (0.028 g, 0.095 mmol, 96%). 1H NMR (400 MHz, CDCl3) δ 8.00 - 8.14 (m,
2H), 7.85 (d, J = 8.28 Hz, 1H), 7.40 - 7.50 (m, 3H), 7.28 - 7.40 (m, 2H), 1.62 (s, 9H)

6-nitro-[1,1'-biphenyl]-3-carboxylic acid
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The above prepared ester 180 (0.02 g, 0.067 mmol, 1.0 equiv) was dissolved in DCM
(0.35 mL, 0.2 M) and was added TFA (0.35 mL, 0.2 M). The reaction mixture was stirred
for 4 hours followed by removal of the excess TFA by vacuum to yield the compound 181
(0.016 mg, 0.066 mmol, quant). 1H NMR (400 MHz, CD3OD) δ 8.17 (dd, J = 1.88, 8.41
Hz, 1H), 8.09 (d, J = 1.51 Hz, 1H), 7.93 (d, J = 8.28 Hz, 1H), 7.40 - 7.49 (m, 3H), 7.30 7.37 (m, 2H)

benzyl 4-(6-nitro-[1,1'-biphenyl]-3-carboxamido)benzoate
To a solution of the acid 181 (0.07 g, 0.29 mmol, 1.0 equiv) in DCM (3.0 mL, 0.2 M) was
added thionyl chloride (0.21 mL, 2.9 mmol, 10.0 equiv) and was refluxed for 4 hours, after
which the excess thionyl chloride was removed under vacuum to obtain the acid chloride
.The acyl chloride was taken in DCM (1.5 mL, 0.4 M) and cooled to 0 °C. To this solution
was added a solution of benzyl 4-amino benzoate (0.066 g, 0.288 mmol, 1.0 equiv),
triethylamine (0.06 mL, 0.432 mL, 1.5 equiv) in DCM (1.5 mL, 0.4 M). The reaction mixture
was allowed to warm up to room temperature and stirred overnight, after which the
reaction was diluted by DCM, washed subsequently with 1 N HCl and 1 N NaOH and
purified on silica gel to obtain the compound 182. (0.118 g, 0.26 mmol, 90%). 1H NMR
(400 MHz, CDCl3) δ 8.27 (s, 1H), 8.10 (d, J = 8.80 Hz, 2H), 7.85 - 8.02 (m, 3H), 7.75 (d,
J = 8.80 Hz, 2H), 7.28 - 7.51 (m, 10H), 5.37 (s, 2H).
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benzyl 4-(6-amino-[1,1'-biphenyl]-3-carboxamido)benzoate
To a solution of the benzyl ester 182 (0.182 g, 0.4 mmol, 1.0 equiv) in ethyl acetate (4.0
mL, 0.1 M) was added tin chloride dehydrate (0.273 g, 1.21 mmol, 3.0 equiv) and refluxed
for 90 minutes. The reaction mixture was diluted with ethyl acetate and washed with
saturated sodium bicarbonate solution and the ethyl acetate layer was purified over silica
gel to obtain the compound 183 (0.119 g, 0.281 mmol, 69%). 1H NMR (400 MHz, CDCl3)
δ 8.07 (d, J = 8.70 Hz, 2H), 7.96 (s, 1H), 7.68 - 7.77 (m, 3H), 7.66 (d, J = 2.26 Hz, 1H),
7.31 - 7.51 (m, 10H), 6.79 (d, J = 8.53 Hz, 1H), 5.36 (s, 2H), 4.18 (s, 2H).

benzyl 4-(6-((2-((tert-butoxycarbonyl)amino)ethyl)amino)-[1,1'-biphenyl]-3carboxamido)benzoate
To the solution of the above prepared aniline 183 (0.086 g, 0.203 mmol, 1.0 equiv) in
methanol (2.0 mL, 0.1 M) with molecular seives was added N-Boc-2-aminoacetaldehyde
(0.012 mg, 0.203 mmol, 1.0 equiv), glacial acetic acid (0.21 mL, 0.203 mmol, 1.0 equiv)
and was stirred for one hour. To this solution was added sodium cyanoborohydride (0.013
g, 0.203 mmol, 1.0 equiv) and the mixture was stirred overnight. The reaction mixture was
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concentrated under vacuum and was taken into DCM and washed with saturated sodium
bicarbonate solution. The DCM layer was concentrated and used for the next step without
purification. 1H NMR (400 MHz, CDCl3) δ 8.03 - 8.12 (m, 2H), 7.89 (s, 1H), 7.82 (dd, J =
2.26, 8.53 Hz, 1H), 7.72 (d, J = 8.78 Hz, 2H), 7.57 - 7.68 (m, 1H), 7.30 - 7.54 (m, 10H),
6.79 (dd, J = 8.41, 19.20 Hz, 1H), 5.36 (s, 2H), 3.72 (t, J = 5.02 Hz, 1H), 3.32 (s, 3H),
1.47 (d, J = 6.02 Hz, 9H).

2-((5-((4-((benzyloxy)carbonyl)phenyl)carbamoyl)-[1,1'-biphenyl]-2-yl)amino)ethan1-aminium
The compound from the above step (0.108 g, 0.191 mmol, 1.0 equiv) was dissolved in
DCM (1.0 mL, 0.2 M) and TFA (1.0 mL, 0.2 M) was added and the mixture was stirred for
3 hours, followed by purification of the compound on silica gel to obtain compound 185
(0.099 g, 0.171 mmol, 84% for 2 steps). 1H NMR (400 MHz, CD6CO) δ 7.93 - 8.05 (m,
5H), 7.75 (d, J = 2.26 Hz, 1H), 7.31 - 7.54 (m, 10H), 7.04 (d, J = 8.78 Hz, 1H), 5.36 (s,
2H), 4.02 (t, J = 5.90 Hz, 2H), 3.81 (t, J = 5.90 Hz, 2H).

221

benzyl (Z)-4-(6-((2-(2,3-bis(tert-butoxycarbonyl)guanidino)ethyl)amino)-[1,1'biphenyl]-3-carboxamido)benzoate
To a solution of the primary amine TFA salt 185 (0.099 g, 0.071 mmol, 1.0 equiv) and
triethylamine (0.1 mL, 0.684 mmol, 4.0 equiv) in methanol (2.0 mL, 0.1 M) was added
N,N’-Di-Boc-1H-pyrazole-1-carboxamidine (0.08 g, 0.26 mmol, 1.5 equiv). The reaction
mixture was stirred at room temperature overnight and was purified over silica gel to
obtain compound 186 (0.051 g, 0.071 mmol, quant). 1H NMR (400 MHz, CD6CO) δ 11.61
(s, 1H), 9.58 (s, 1H), 8.46 (d, J = 5.52 Hz, 1H), 7.84 - 8.07 (m, 5H), 7.72 (d, J = 2.51 Hz,
1H), 7.27 - 7.55 (m, 10H), 7.17 (d, J = 8.78 Hz, 1H), 5.36 (s, 2H), 3.60 - 3.71 (m, 2H),
3.45 - 3.57 (m, 2H), 2.78 (br. s., 1H), 1.53 (s, 9H), 1.47 (s, 9H).

(Z)-4-(6-((2-(2,3-bis(tert-butoxycarbonyl)guanidino)ethyl)amino)-[1,1'-biphenyl]-3carboxamido)benzoic acid
To the solution of the above prepared guanidine 186 (0.051 g, 0.072 mmol, 1.0 equiv) in
ethyl acetate (1.0 mL, 0.1 M) was added 5% Pd/C (25% w/w). The reaction mixture was
stirred under a hydrogen balloon at room temperature overnight. The product was eluted
by filtration using copious amounts of acetone, and the filtrate was concentrated in vacuo
to afford the desired product as white solid 187 (0.045 g, 0.072 mmol, quant). 1H NMR
(400 MHz, CD6CO) δ 11.61 (br. s., 1H), 9.55 (br. s., 1H), 8.47 (br. s., 1H), 7.81 - 8.07 (m,
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5H), 7.73 (s, 1H), 7.43 - 7.52 (m, 3H), 7.27 - 7.43 (m, 2H), 7.16 (d, J = 6.78 Hz, 1H), 5.19
(t, J = 4.89 Hz, 1H), 3.58 - 3.70 (m, 2H), 3.52 (d, J = 6.02 Hz, 2H), 1.53 (s, 9H), 1.47 (s,
9H).

(S)-(3-((tert-butoxycarbonyl)amino)-2-oxo-4-phenylbutyl)diazen-1-ide
To a solution of Boc-Phe-OH 146 (1.326 g, 5.0 mmol, 1.0 equiv) and 4-methyl morpholine
(0.58 mL, 5.25 mmol, 1.05 equiv) in THF (7.14 mL, 0.7 M) cooled to 0 °C was slowly
added isobutyl chloroformate (0.68 mL, 5.25 mmol, 1.05 equiv). The reaction was stirred
for one hour followed by the addition of a solution of diazomethane in diethyl ether. The
reaction was allowed to warm to room temperature and stirred overnight, followed by
purification of the product over silica gel to obtain brown crystals of 188. (1.378 g, 4.74
mmol, 95%). 1H NMR (400 MHz, CDCl3) δ 7.15 - 7.35 (m, 5H), 5.22 (br. s., 1H), 5.09 (br.
s., 1H), 4.42 (br. s., 1H), 3.03 (d, J = 6.78 Hz, 2H), 1.42 (s, 9H).

tert-butyl (S)-(4-chloro-3-oxo-1-phenylbutan-2-yl)carbamate
The above prepared diazo ketone 188 (0.1 g. 0.35 mmol, 1.0 equiv) was dissolved in
diethyl ether (4.0 mL, 0.1 M) and cooled to -20 °C. To this solution was added HCl in
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dioxane (4 N, 0.13 mL, 1.5 equiv) slowly and the reaction was allowed to stir for 4 hours,
after which the pH of the solution was adjusted to 7.0 using triethyl amine and the reaction
was diluted with ether. The ether layer was washed with 1 N HCl, dried and purified over
silica gel to obtain the product 190. (0.102 mg, 0.34 mmol, quant). 1H NMR (400 MHz,
CDCl3) δ 7.24 - 7.38 (m, 3H), 7.13 - 7.21 (m, 2H), 5.02 (br. s., 1H), 4.68 (d, J = 7.28 Hz,
1H), 4.17 (d, J = 16.31 Hz, 1H), 3.99 (d, J = 16.31 Hz, 1H), 2.95 - 3.16 (m, 2H), 1.42 (s,
9H).

tert-butyl ((2S)-4-chloro-3-hydroxy-1-phenylbutan-2-yl)carbamate
To a solution of the α-chloro ketone 190 (0.043 g, 0.144 mmol, 1.0 equiv) in methanol
(0.8 mL, 0.2 M) cooled to 0 °C, was added sodium borohydride (0.011 g, 0.29 mmol, 2.0
equiv). The reaction mixture was stirred for 2 hours at 0 °C, followed by quenching the
mixture with dilute acetic acid. The reaction was taken up in ethyl acetate, washed with 1
N HCl and dried in vacuo to obtain the product 191 (0.043 g, 0.14 mmol, quant).

(2S)-4-chloro-3-hydroxy-1-phenylbutan-2-aminium 2,2,2-trifluoroacetate
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To the solution of the above compound 191 (0.043 g, 0.14 mmol, 1.0 equiv) in DCM (0.7
mL, 0.2 M) was added TFA (0.7 mL, 0.2 M). The reaction was stirred at room temperature
for 3 hours, after which the solvents were removed vacuo to obtain the compound 192.
(0.044 g, 0.14 mmol, quant). 1H NMR (400 MHz, CD6CO) δ 7.83 (br. s., 2H), 7.11 - 7.39
(m, 5H), 4.22 - 4.41 (m, 1H), 4.01 - 4.17 (m, 1H), 3.60 - 3.87 (m, 2H), 2.99 - 3.28 (m, 2H).

To a solution of the acid 187 (0.053 g, 0.86 mmol, 1.0 equiv) in DCM (1.0 mL, 0.1 M) was
added PyBOP (0.045 g, 0.86 mmol, 1.0 equiv), DIPEA (0.03 mL, 0.17 mmol, 2.0 equiv)
and stirred for 30 minutes, followed by the addition of the amine 192 (0.034 g, 0.086
mmol, 1.0 equiv). The reaction was stirred overnight, after which it was washed with 1 N
HCl and the DCM layer was purified over silica gel to get the compound 193 (0.062 g,
0.078 mmol, 90%). 1H NMR (400 MHz, CDCl3) δ 11.47 (br. s., 1H), 8.50 (t, J = 5.40 Hz,
1H), 8.25 (s, 1H), 7.77 - 7.85 (m, 1H), 7.61 - 7.73 (m, 6H), 7.51 - 7.60 (m, 3H), 7.33 - 7.50
(m, 8H), 7.15 - 7.33 (m, 7H), 6.78 (d, J = 8.53 Hz, 1H), 6.37 (d, J = 8.03 Hz, 1H), 4.32 4.53 (m, 2H), 3.93 - 4.18 (m, 2H), 3.49 - 3.69 (m, 4H), 3.37 (t, J = 6.53 Hz, 2H), 3.01 3.16 (m, 2H), 1.49 (s, 9H), 1.52 (s, 9H)
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To the above prepared alcohol 193 (0.062 g, 0.078 mmol, 1.0 equiv) in DCM (1.0 mL, 0.1
M) was added Dess Martin periodinane (0.04 g, 0.093 mmol, 1.2 equiv). The reaction
mixture was stirred for one hour at room temperature, followed by dilution of the reaction
with DCM, washing with sodium thiosulfate solution and purification of the DCM layer over
silica gel to obtain the α-chloro ketone 194 (0.022 g, 0.028 mmol, 67%). 1H NMR (400
MHz, CDCl3) δ 8.50 (t, J = 5.40 Hz, 1H), 8.18 (s, 1H), 7.81 (dd, J = 2.26, 8.53 Hz, 1H),
7.59 - 7.76 (m, 5H), 7.25 - 7.48 (m, 10H), 7.15 - 7.23 (m, 3H), 6.80 (d, J = 8.53 Hz, 1H),
6.70 (d, J = 7.03 Hz, 1H), 5.12 (q, J = 7.03 Hz, 1H), 4.24 (d, J = 16.06 Hz, 1H), 4.05 (d, J
= 16.06 Hz, 1H), 3.60 (q, J = 6.11 Hz, 2H), 3.38 (t, J = 6.30 Hz, 2H), 3.21 (tt, J = 6.93,
14.40 Hz, 2H), 1.49 (s, 9H), 1.52 (s, 9H).

To a solution of the α-chloro ketone 194 (0.022 g, 0.028 mmol, 1.0 equiv) in dioxane (0.3
mL, 0.1M) was added HCl in dioxane (4 N, 0.07 mL, 10.0 equiv). The solution was stirred
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overnight and the solvents were removed in vacuo to obtain the compound 195 (0.017 g,
0.026 mmol, 95%). 1H NMR (400 MHz, CD3OD) δ 7.88 (d, J = 6.78 Hz, 1H), 7.65 - 7.80
(m, 5H), 7.30 - 7.53 (m, 7H), 7.23 (s, 4H), 7.17 (br. s., 2H), 6.87 (d, J = 7.78 Hz, 1H), 4.45
(d, J = 16.31 Hz, 1H), 4.23 (d, J = 16.31 Hz, 1H), 3.58 - 3.77 (m, 2H), 3.34 - 3.57 (m, 6H),
2.97 - 3.11 (m, 1H).

13C

NMR (101 MHz, CD3OD) δ 170.2, 168.7, 159.0, 149.2, 144.1,

139.8, 138.5, 131.6, 130.6, 130.4, 130.4, 130.4, 129.8, 129.5, 129.5, 129.3, 129.2, 129.1,
128.0, 123.9, 121.4, 111.2, 60.3, 43.4, 41.8, 37.0. HRMS (ESI) C33H35ClN6O3 m/z [M+H]
+

found 598.2388, expected 598.2459.

N-((2S)-4-chloro-3-hydroxy-1-phenylbutan-2-yl)-4-methoxybenzamide
To a solution of the acid 196 (0.048 g, 0.154 mmol, 1.0 equiv) in DCM (1.0 mL, 0.1 M)
was added PyBOP (0.08 g, 0.154 mmol, 1.0 equiv), DIPEA (0.06 mL, 0.154 mmol, 2.0
equiv) and stirred for 30 minutes, followed by the addition of the amine 192 (0.024 g,
0.154 mmol, 1.0 equiv). The reaction was stirred overnight, after which it was washed
with 1 N HCl and the DCM layer was purified over silica gel to get the compound 197
(0.047 g, 0.14 mmol, 91%). 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 8.78 Hz, 2H), 7.18
- 7.38 (m, 5H), 6.89 (d, J = 8.80 Hz, 2H), 6.12 (d, J = 7.78 Hz, 1H), 4.34 - 4.47 (m, 1H),
3.98 - 4.06 (m, 1H), 3.79 - 3.91 (m, 5H), 3.61 - 3.69 (m, 2H), 3.01 - 3.22 (m, 3H).
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(S)-N-(4-chloro-3-oxo-1-phenylbutan-2-yl)-4-methoxybenzamide
To the above prepared alcohol 197 (0.020 g, 0.06 mmol, 1.0 equiv) in DCM (1.0 mL, 0.1
M) was added Dess Martin periodinane (0.031 g, 0.072 mmol, 1.2 equiv). The reaction
mixture was stirred for one hour at room temperature, followed by dilution of the reaction
with DCM, washing with sodium thiosulfate solution and purification of the DCM layer over
silica gel to obtain the α-chloro ketone 198 (0.01 g, 0.03 mmol, 50%). 1H NMR (400 MHz,
CDCl3) δ 7.68 (d, J = 9.00 Hz, 2H), 7.25 - 7.39 (m, 3H), 7.18 - 7.25 (m, 2H), 6.92 (d, J =
9.00 Hz, 2H), 6.55 (d, J = 6.02 Hz, 1H), 5.14 (q, J = 7.03 Hz, 1H), 4.24 (d, J = 16.06 Hz,
1H), 4.06 (d, J = 16.06 Hz, 1H), 3.86 (s, 3H), 3.14 - 3.28 (m, 2H).

13C

NMR (101 MHz,

CD6CO) δ 200.9, 167.4, 163.4, 142.1, 138.5, 133.5, 132.5, 131.6, 130.1, 130.1, 129.3,
127.5, 114.4, 59.4, 55.8, 48.6, 36.5. HRMS (ESI) C18H19ClNO3 m/z [M+H]
332.1063, expected 332.1053.

tert-butyl (S)-(1-(benzylamino)-1-oxo-3-phenylpropan-2-yl)carbamate
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+

found

To a solution of Boc-Phe-OH 146 (0.5g, 1.9 mmol, 1.0 equiv) in DCM (9.0 mL, 0.2 M) was
added 1-hydroxybenzotriazole hydrate (0.306 g, 2.26 mmol, 1.2 equiv), EDCI (0.362 g,
1.89 mmol, 1.0 equiv) and NMM (0.25 mL, 2.26 mmol, 1.2 equiv). The solution was stirred
for 30 minutes, followed by addition of benzylamine 199 (0.2 mL, 1.89 mmol, 1.0 equiv)
and the reaction was allowed to stir overnight. The following day, the solution was diluted
with DCM and washed with 1 N HCl. The DCM layer was purified over silica gel to obtain
the compound 200 (0.502 g, 1.42 mmol, 75%). 1H NMR (400 MHz, CDCl3) δ 7.17 - 7.34
(m, 7H), 7.11 (d, J = 6.27 Hz, 2H), 6.05 (br. s., 1H), 5.04 (br. s., 1H), 4.37 (d, J = 6.00 Hz,
2H), 2.98 - 3.18 (m, 3H), 1.40 (s, 9H).

(S)-1-(benzylamino)-1-oxo-3-phenylpropan-2-aminium
To the solution of the amide 200 (0.1 g, 0.282 mmol, 1.0 equiv) in DCM (0.7 mL, 0.4 M)
was added TFA (0.7 mL, 0.4 M) and the solution was stirred overnight. The following day,
solvents were removed in vacuo to obtain compound 201 that was sufficiently pure to use
for the next step.

229

To the solution of the acid 187 (0.027 g, 0.044 mmol, 1.0 equiv) in DCM (1.0 mL, 0.1 M)
was added PyBOP (0.023 g, 0.044 mmol, 1.0 equiv) and DIPEA (0.015 mL, 0.084 mmol,
2.0 equiv). The mixture was stirred for 30 minutes, followed by addition of the amine 201
(0.023 g, 0.044 mmol, 1.0 equiv). The solution was stirred overnight, followed by dilution
with DCM, washing with 1 N HCl and purification over silica gel to obtain compound 202
(0.035 g, 0.041 mmol, 80%). 1H NMR (400 MHz, CDCl3) δ 11.47 (s, 1H), 8.50 (t, J = 5.52
Hz, 1H), 8.20 (s, 1H), 7.83 (dd, J = 2.13, 8.66 Hz, 1H), 7.62 - 7.74 (m, 5H), 7.35 - 7.50
(m, 5H), 7.16 - 7.32 (m, 10H), 7.02 - 7.12 (m, 2H), 6.92 (d, J = 7.78 Hz, 1H), 6.81 (d, J =
8.53 Hz, 1H), 6.34 (t, J = 5.65 Hz, 1H), 4.81 - 4.92 (m, 1H), 4.47 (br. s., 1H), 4.39 (dd, J
= 6.15, 14.93 Hz, 1H), 4.28 (dd, J = 5.52, 14.81 Hz, 1H), 3.60 (q, J = 6.11 Hz, 2H), 3.34
- 3.44 (m, 2H), 3.26 (dd, J = 6.02, 13.55 Hz, 1H), 3.14 (dd, J = 8.03, 13.55 Hz, 1H), 1.51
(d, J = 8.78 Hz, 18H).
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(S)-1-(2-((5-((4-((1-(benzylamino)-1-oxo-3-phenylpropan-2yl)carbamoyl)phenyl)carbamoyl)-[1,1'-biphenyl]-2-yl)amino)ethyl)guanidinium
chloride
To a solution of the above prepared amide 202 (0.035 g, 0.041 mmol, 1.0 equiv) in
dioxane (0.4 mL, 0.1 M) was added HCl in dioxane (4 N, 0.1 mL, 10.0 equiv). The solution
was stirred overnight and the solvents were removed in vacuo to obtain the compound
203 (0.026 g, 0.04 mmol, quant). 1H NMR (400 MHz, CD3OD) δ 7.92 (br. s., 1H), 7.65 7.85 (m, 5H), 7.34 - 7.55 (m, 6H), 7.07 - 7.33 (m, 12H), 6.95 (br. s., 1H), 4.74 - 4.88 (m,
2H), 4.25 - 4.43 (m, 2H), 3.69 - 3.76 (m, 1H), 3.59 (s, 2H), 3.37 - 3.48 (m, 4H), 3.23 (dd,
J = 6.15, 13.43 Hz, 1H), 3.03 - 3.14 (m, 1H). 13C NMR (101 MHz, CD3OD) δ 169.4, 168.3,
158.7, 148.2, 143.6, 139.3, 138.3, 131.4, 130.3, 130.3, 130.2, 130.1, 129.9, 129.5, 129.4,
129.3, 129.1, 128.9, 128.4, 128.0, 127.7, 124.5, 121.1, 111.8, 56.8, 44.1, 41.6, 38.9.
HRMS (ESI) C39H41N7O3 m/z [M+H] + found 655.3187, expected 655.3270.

4.3.2: Biological Experimentals
Assays of AKT1 were performed using Z’-LYTE Kinase Assay Kit – Ser/Thr 6 peptide
(Invitrogen, NY, USA) in non-binding low-volume 384-well plates (Cat. No 3676, Corning,
NY, USA). All the reagents were diluted in kinase buffer (50 mM HEPES pH 7.5, 0.01%
BRIJ-35, 10 mM MgCl2, 1 mM EDTA). All compounds were prepared as 10 mM soulutions
in DMSO and diluted to 0.8% final DMSO concentrations in the assay. A typical 10 µL
assay contained 6 ng of AKT1, 75 µM ATP and 2 µM peptide substrate in kinase buffer
in the presence/absence of tested compounds. The assays were incubated at room

231

temperature for 1 h, following by the addition of 5 µL of development reagent and further
incubation at room temperature for another hour. The kinase reaction was terminated by
the addition of 5 µL of stop reagent. The FRET signal was measured using Flexstation 3
microplate reader (molecular Devices, CA, USA) with an excitation wavelength of 410 nm
and emission wavelengths of 458 nm and 522 nm. The percent inhibition was calculated
according to the kit guidelines. Staurosporine (CalBiochem) was used as the control
compound. Data analysis, curve fitting and calculation of error was performed using Prism
software from GraphPad. The IC50s (Table 11) were calculated from the graphs obtained
below (Figure 90);
Table 11: IC50s (µM) of compounds
Compound

IC50 (µM)

95% Confidence
Interval

125

>100

129

10.59

7.53 – 14.89

127

3.25

2.32 – 4.55

141

1.55

1.35 – 1.79

135

>100

138

>100

128

2.33

1.84 – 2.96

133

1.11

1.00 – 1.24

144

1.79

1.53 – 2.09

145

1.97

1.44 – 4.11
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151

0.32

152

>100

156

2.44

153

> 100

161

0.82

173

> 100

175

> 100

177

> 100

198

>25

195

0.578

203

>25

233

0.26 – 0.40

1.23 – 2.76

0.68 – 0.98

0.314 – 1.065

234

235

236

Figure 90: Graphs used to calculate IC50s for compounds

The assays of PKAα were performed using Z′-LYTE Kinase Assay Kit – Ser/Thr 1 Peptide
(Invitrogen, NY, USA) in non-binding low-volume 384-well plates (Cat. No 3676, Corning,
NY,USA). All the reagents were diluted in kinase buffer (50 mM HEPES pH 7.5, 0.01%
BRIJ-35, 10mM MgCl2, 1 mM EDTA). The compounds were prepared as 10 mM solutions
in DMSO and diluted to 0.8% final DMSO concentration in the assay. A typical 10 μL
assay contained 0.3 ng of PKAα, 4 μM ATP and 2 μM peptide substrate in kinase buffer
in the presence/absence of tested compounds. The assays were incubated at room
temperature for 1 h. 5 μL of development reagent was then added and the assay mixture
was incubated at room temperature for further 1 h. The kinase reaction was terminated
by the addition of 5 μL of stop reagent. The FRET signal was measured using a
Flexstation 3 microplate reader (Molecular Devices, CA, USA) using an excitation
wavelength of 410 nm and emission wavelengths of 458 nm and 522 nm. The percent
inhibition was calculated according to the kit guidelines. Staurosporine (CalBiochem) was
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used as a control compound. The IC50s (Table 12) were calculated from the graphs
obtained below (Figure 91)
Table 12: IC50 of compounds against PKAα
Compound

IC50 (µM)

151

>100

161

13.47

Confidence interval

11.75 – 15.43

Figure 91: Graphs used to calculate IC50s for PKAα
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